

proteoglycan, used for, e.g. obtaining compounds for
reducing **atherosclerosis**.

DERWENT CLASS: B04 D16 S03
INVENTOR(S): BOREN, J O S; INNERARITY, T L; BOREN, J; INNERARITY, T
PATENT ASSIGNEE(S): (REGC) UNIV CALIFORNIA; (BORE-I) BOREN J; (INNE-I)
INNERARITY T
COUNTRY COUNT: 85
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9946598	A1	19990916	(199946)*	EN	69
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD					
GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV					
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT					
UA UG UZ VN YU ZW					
AU 9929842	A	19990927	(200006)		
EP 1062512	A1	20001227	(200102)	EN	
R: AT BE CH DE FR GB IE IT LI NL					
US 2001024797	A1	20010927	(200159)		
US 2001029027	A1	20011011	(200162)		
AU 760794	B	20030522	(200338)		
US 6579682	B1	20030617	(200341)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9946598	A1	WO 1999-US4805	19990305
AU 9929842	A	AU 1999-29842	19990305
EP 1062512	A1	EP 1999-911123	19990305
		WO 1999-US4805	19990305
US 2001024797	A1 Provisional	US 1998-77618P	19980310
	Div ex	US 1999-265222	19990305
		US 2001-823418	20010329
US 2001029027	A1 Provisional	US 1998-77618P	19980310
	Div ex	US 1999-265222	19990305
		US 2001-822965	20010329
AU 760794	B	AU 1999-29842	19990305
US 6579682	B1 Provisional	US 1998-77618P	19980310
		US 1999-265222	19990305

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9929842	A Based on	WO 9946598
EP 1062512	A1 Based on	WO 9946598
AU 760794	B Previous Publ.	AU 9929842
	Based on	WO 9946598

PRIORITY APPLN. INFO: US 1998-77618P 19980310; US 1999-265222
19990305; US 2001-823418 20010329; US
2001-822965 20010329

AB WO 9946598 A UPAB: 19991110

DETAILED DESCRIPTION - A novel method for identifying compounds that affect a **low density** lipoprotein (**LDL**) - proteoglycan (PG) binding comprises:

- (a) incubating a mixture by:
- (i) PG;
 - (ii) **LDL**, and
 - (iii) a candidate compound, where **LDL** binds to PG to form an **LDL**-PG complex in the absence of the candidate compound, and
- (b) determining any difference between the amount of **LDL**-PG complex present in:
- (i) the mixture as prepared in (a), and
 - (ii) an assay mixture comprising the PG and the **LDL** in the absence of the candidate compound.

INDEPENDENT CLAIMS are also included for the following:

- (1) an apo-B100 protein comprising a PG receptor mutation in Site B;
- (2) an **LDL** particle comprising an apo-B100 protein as in (1);
- (3) an antibody composition which binds to an antigenic determinant in an apo-B100 protein as in (1), where the antigenic determinant is not present in the wild-type human apo-B100 protein;
- (4) a polynucleotide (PN) encoding an apo-B100 protein as in (1), and
- (5) a cell comprising a PN as in (4), and
- (6) a non-human animal comprising a PN as in (4).

USE - The method can be used for identifying compounds which disrupt **LDL**-PG binding without inhibiting **LDL** receptor binding. Such compounds can be used to reduce or prevent the formation of atherosclerotic lesions and prevent atherosclerosis. The transgenic non-human animals and mammals which express human apo-B100 can be used as an in vivo model system for the study of atherosclerosis, and in vivo assay methods for identifying compounds which modulate atherosclerosis and/or **LDL**-PG binding. They can also be used to identify compounds which result in an increase in atherosclerotic regions. Thus the assays may be used to determine whether a particular food or drug composition tends to stimulate or inhibit the formation of atherosclerotic lesions. The PNs can also be used in gene therapy for preventing or reducing the severity of atherosclerosis in an animal or mammal.

ADVANTAGE - None given.

Dwg.0/6

L91 ANSWER 40 OF 42 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: 1999-602336 [52] WPIDS
DOC. NO. CPI: C1999-175415
TITLE: New phosphorylated forms of sterol regulatory element
binding proteins useful for treating or preventing **arteriosclerosis**, stroke and diabetes mellitus.
DERWENT CLASS: B04 D16
INVENTOR(S): KRONE, W; MUELLER-WIELAND, D
PATENT ASSIGNEE(S): (KRON-I) KRONE W; (MUEL-I) MUELLER-WIELAND D
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
DE 19816902	A1	19991028	(199952)*		26
WO 9954352	A2	19991028	(199953)	GE	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					

MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
 UA UG US UZ VN YU ZA ZW
 AU 9943580 A 19991108 (200014)
 EP 1071713 A2 20010131 (200108) GE
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 19816902	A1	DE 1998-19816902	19980416
WO 9954352	A2	WO 1999-DE1137	19990415
AU 9943580	A	AU 1999-43580	19990415
EP 1071713	A2	EP 1999-926248	19990415
		WO 1999-DE1137	19990415

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9943580	A Based on	WO 9954352
EP 1071713	A2 Based on	WO 9954352

PRIORITY APPLN. INFO: DE 1998-19816902 19980416

AB DE 19816902 A UPAB: 19991210

NOVELTY - Phosphorylated polypeptides, SREBP1 (sterol regulatory element binding proteins) (I) and SREBP2 (II), comprising 1146 and 1141 amino acid sequences, respectively, both fully defined in the specification and their allelic variants or derivatives with transcription factor activity, are new.

ACTIVITY - Anti-arteriosclerosis; cerebroprotective; cardiant; antidiabetic; antihypertensive; anorectic; nootropic; neuroprotective; hepatotrophic; antineurodegeneration.

MECHANISM OF ACTION - **Low density** lipoprotein (LDL) receptor stimulator, by binding to the sterol-regulatory cis-element in the **LDL** gene promoter, in a cholesterol-independent manner. The activity of (I) and (II) is regulated not only by the cholesterol content of cells but also by post-translational modification (phosphorylation).

USE - (I) and (II) are used to prevent or treat arteriosclerosis, stroke, coronary heart disease, peripheral arterial occlusive disease, glucose intolerance, diabetes mellitus, arterial hypertension, adiposity, disorders of fat metabolism, genetic hypertriglyceridemia (associated with lack of ApoC2), Alzheimer's disease, neurodegeneration and genetic liver disease which are modulated by SREBP responsive genes.

ADVANTAGE - Phosphorylation significantly increases transcriptional activity of SREBP-1 or -2.

Dwg.0/5

L91 ANSWER 41 OF 42 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: 1996-039954 [04] WPIDS

DOC. NO. CPI: C1996-013405

TITLE: Compsn. containing oligosaccharide(s) that **bind** to **lipoprotein** lipase - to prevent its interaction with receptors that would cause cellular uptake of lipoprotein, especially to treat or prevent **atherosclerosis**.

COUNTRY COUNT: 64
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9533468	A1	19951214	(199604)*	EN	32
RW: AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ UG					
W: AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR					
LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US					
UZ VN					
AU 9525609	A	19960104	(199613)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9533468	A1	WO 1995-DK217	19950602
AU 9525609	A	AU 1995-25609	19950602

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9525609	A Based on	WO 9533468

PRIORITY APPLN. INFO: DK 1994-637 19940606
AB WO 9533468 A UPAB: 19960129

Compsn. comprises, apart from carrier or diluent, an oligosaccharide of formula (I): dUAp2S(1=>4)-[alpha-DGlcNp2R16R2(1=>4)-X(1=>4)]n-alpha-D-GlcNp2R16R2, where dUAp2S = 4-deoxy-alpha-L-threo-hex-4-eno-pyranosyl-uronic acid, 2-sulphate; alpha-D-GlcNp = alpha-D-2-deoxy-2-amino-glucopyranose; X= Idoap2R2(alpha-L-ido-pyranosyl-uronic acid) or beta-D-GlcAp (beta-D-glucopyranosyl-uronic acid); R1=H, sulphate or acetyl; R2= H or sulphate, and n is an integer of 3-16. (I) can bind to lipoprotein lipase (LPL) to inhibit interaction between the alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2-MR/LRP) and LPL (or its complex with lipoprotein). Such as interaction would result in uptake of lipoprotein by mammalian cells.

USE - (I) are used to treat or prevent diseases involving interaction between alpha2-MR/LRP (especially when expressed on smooth muscle cells or macrophages) and LPL (or its complex with lipoprotein), specifically atherosclerosis. (I) is administered at 1-100 mg/kg, given by injection, orally, nasally or rectally.

ADVANTAGE - (I) lock the anticoagulant activity of heparin.
Dwg.0/3

L91 ANSWER 42 OF 42 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
ACCESSION NUMBER: 1991-353525 [48] WPIDS
CROSS REFERENCE: 1989-356359 [48]; 1998-192802 [17]; 1999-539543 [45];
1999-632641 [52]
DOC. NO. CPI: C1991-152440
TITLE: Synthetic peptide(s) comprising amphiphilic domain of apoA-I - used to diagnose vascular injury or disease or inhibit binding of low density lipoprotein to vascular walls in treating atherosclerosis.

PATENT ASSIGNEE(S): (NEWE-N) NEW ENGLAND DEACONESS HOSPITAL
COUNTRY COUNT: 16
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9116919	A	19911114	(199148)*		70
RW: AT BE CH DE DK ES FR GB GR IT LU NL SE					
W: AU CA JP					

PRIORITY APPLN. INFO: US 1990-518215 19900503; US 1990-518142
19900503

AB WO 9116919 A UPAB: 19991221

Peptides and their analogues which comprise the following amino acid sequences are new.

Tyr-Lys-Leu-Ala-Leu -Glu-Ala-Ala-Arg-Leu-Leu-Ala -Asp-Ala-Glu-Gly-Ala-Lys; Tyr-Lys-Leu-Ala-Glu-Ala -Ala-Arg-Leu-Leu-Ala-Asn-Ala -Glu-Gly-Ala-Lys; Tyr-Arg-Ala-Leu-Val-Asp -Tyr-Leu-Lys-Phe-Val-Thr-Gln-Leu; Tyr-Arg-Ala-Leu -Val-Asp-Thr-Leu-Lys; Tyr-Ala-Lys-Phe-Arg-Glu-Thr -Leu-Glu-Asp-Thr-Arg-Asp-Arg-Met-Tyr; Tyr-Ala-Ala-Leu-Asp -Leu-Asn-Ala-Val-Ala-Asn-Lys-Ile -Ala-Asp-Phe-Glu-Leu; Tyr-Arg-Ala-Leu-Val-Asp -Thr-Leu-Lys-Phe-Val-Thr-Glu -Gln-Ala-Lys-Gly-Ala; and Tyr-Arg-Ala-Leu -Val-Asp-Thr-Glu-Phe-Lys-Val-Lys-Gln -Glu-Ala-Gly-Ala-Lys

The peptides may comprise an amphiphillic domain of apolipoprotein A-I and have a net charge of -2 or greater; they are soluble in water and plasma. Also claimed are peptides (again with a net charge of at least -2), which are derived from a vascular-associated protein such as elastin. The peptide may also contain a radioactive label which can be ¹³¹I, ¹²⁵I, ¹¹¹In, ^{99m}Tc, ²⁰³Pb, ¹⁹⁸Hg, ⁹⁷Ru or ²⁰¹Tc. Alternatively the label is a paramagnetic contrast agent.

USE/ADVANTAGE - (I) have an affinity for and a tendency to accumulate at a site of vascular injury. They can be used to diagnose vascular injury or disease or to inhibit the binding of **LDL** to vascular walls in the treatment of atherosclerosis. Administration may be oral or by arterial or venous injection. For diagnostic purposes, dosage is 0.5-1 mg/i.v. or 5-100 mg orally. For treatment of vascular disease, dosage is 5-100 mg i.v. or i.m.

Dwg.0/8

=> file home

FILE 'HOME' ENTERED AT 15:58:38 ON 15 MAR 2004

=>

GenCore version 5.1.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

leic search, using frame_plus_p2n model

March 12, 2004, 19:55:37 ; Search time 8134.53 Seconds
(without alignments)
1975.018 Million cell updates/sec

US-09-976-740-43
2850
1 MAGPPALPPETAAATTA.....HIKVLQGHFEDDDPDGFLG 538

BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

27513289 seqs, 14931090276 residues

hits satisfying chosen parameters: 55026578

length: 0
length: 2000000000
Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

ameters:
a.model -DEV-xlp
_spool_p/US09976740/runat_10032004_094548_19551/app_query.fasta_1.1898
step -SUFFIX=rst -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
RT=1 -END=-1 -MATRIX=blosum62 -TRANS-human40.cdi -LIST=45
W SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
M=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
@CGN 1 1 10332@runat_10032004_094548_19551 -NCPU=6 -ICPU=3
JERY -NEG SCORES=0 -WAIT -DSPELOCK=100 -LONGLOG
-WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
CP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

EST.*
1: em_estba.*
2: em_esthum.*
3: em_estin.*
4: em_estmu.*
5: em_estov.*
6: em_estpl.*
7: em_estro.*
8: em_hcc.*
9: gb_est1.*
10: gb_est2.*
11: gb_hcc.*
12: gb_est3.*
13: gb_est4.*
14: gb_est5.*
15: em_estfun.*
16: em_estom.*
17: em_gss_hum.*
18: em_gss_inv.*
19: em_gss_pln.*
20: em_gss_vrt.*
21: em_gss_fun.*
22: em_gss_mam.*
23: em_gss_mus.*
24: em_gss_pro.*
25: em_gss_rod.*
26: em_gss_pbg.*
27: em_gss_vrl.*
28: gb_gss1.*

29: gb_gss2.*

Pred. No. is the number of results predicted by chance to have
score greater than or equal to the score of the result being f
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Descripti
1	1309	45.9	996	13	BUI74966	BUI74966
2	1270	44.6	921	13	BQ671165	BQ671165
3	1241.5	43.6	828	10	BE794500	BE794500
4	1229	43.1	1109	10	BE270805	BE270805
5	1224	42.9	704	10	BF058975	BF058975
6	1217	42.7	707	10	BE748961	BE748961
7	1211	42.5	743	10	BF058118	BF058118
8	1194	41.9	680	10	BE675122	BE675122
9	1189	41.7	683	10	BE857956	BE857956
10	1181	41.4	785	12	B1226646	B1226646
11	1166	40.9	774	10	BE891267	BE891267
12	1154.5	40.5	858	10	BE561424	BE561424
13	1119.5	39.3	1057	12	BM554748	BM554748
14	1103.5	38.7	906	12	BG116718	BG116718
15	1080	37.9	686	10	BE513784	BE513784
16	1052	36.9	593	9	AI928488	AI928488
17	1044	36.6	756	12	BM013469	BM013469
18	1043	36.6	590	9	AI123580	AI123580
19	1037	36.4	583	9	AI660679	AI660679
20	1026	36.0	590	10	BE621115	BE621115
21	1022.5	35.9	1022	13	BUS38115	BUS38115
22	1022	35.9	568	12	BM792162	BM792162
23	1007	35.3	1056	12	BG298788	BG298788
24	991	34.8	580	10	BE257093	BE257093
25	988	34.7	600	12	B1987692	B1987692
26	987	34.6	829	10	BE270987	BE270987
27	967	33.9	600	12	B1985158	B1985158
28	947.5	33.2	694	14	CA451506	CA451506
29	933	32.7	518	10	BE269536	BE269536
30	929	32.6	864	12	BG704736	BG704736
31	913	32.0	554	10	AW743445	AW743445
32	911	31.3	533	10	BF190027	BF190027
33	891	31.3	512	10	AW515766	AW515766
34	888	31.2	509	9	AI632586	AI632586
35	869	30.5	495	9	AI199022	AI199022
36	868	30.5	572	12	BM697252	BM697252
37	866	30.4	487	9	AI186705	AI186705
38	862	30.2	501	9	AI796089	AI796089
39	858	30.1	531	13	BX527955	BX527955
40	846	29.7	481	12	BG284882	BG284882
41	846	29.7	483	9	AI569682	AI569682
42	843	29.6	572	9	AA543367	AA543367
43	827	29.0	466	10	BF061129	BF061129
44	827	29.0	600	12	B1987677	B1987677
45	816	28.6	538	12	BG144461	BG144461

ALIGNMENTS

RESULT 1
BUI74966
LOCUS
DEFINITION AGENCOURT_8073899 NIH_MGC_102 Homo sapiens cDNA clone IV
5', mRNA sequence.
ACCESSION BUI74966
VERSION BUI74966.1 GI:22688950
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eute
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Hom
REFERENCE 1 (bases 1 to 996)

415	GGGGGAACAGCTTCTGTTGCCACCGGGCCAGACTCCCGCTGCCCGTGCCTTTGG	
434	GLyLysProAlaLeuProGlyAlaAspGlyThrProPheGlyCysProProGlyA	
475	GGCAAAACACAGCCCTACTCGTGGGGCCGACGGGACCCCTTTTGGTGTCTCTCCCGGGC	
454	GLuLysProSerAspProValGluTrpThrValMetAspValValGluLysrPheT	
535	GAGAAAGCCATCTGATCCGTCGAGTGGACCGTGATGGATGTGTCCATATATTTTA	
474	AlaGlyPheProGluGlnAlaThrAlaPheGlnGlnGlnAlaAspGlyLysS	
595	GCTGATTCCCGAGCAAGCGACAGCTTTTCCAGAAACAGGAAATTGATGCGCAAT	
493	uLeuLeuMetGlnArgThrAspValLeuThrGlyLeuSerIleAtrqLeuGlyPro	
655	GCTGCTCATGACGGCGCAAAATGTGTCCACGGCCCTGTCCATCCGCTCGGGCCA	
513	uLysIleTyrGLuHisIleLysValLeuGlnGlnGlyHisPheGluAspA	
715	GAAATCTAGAGACACCCCATCAAGGTGCTTCAGCAAGGGCCCTTTGCGGATGAT	
533	oAspGlyPheLeu 537	
775	CGATGGCCTTCT 787	
RESULT 2		
BQ671165		
LOCUS	BQ671165	
DEFINITION	BQ671165	
ACCESSION	BQ671165	
VERSION	BQ671165.1	
KEYWORDS	EST.	
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	BQ671165	
AUTHORS	BQ671165	
TITLE	BQ671165.1	
JOURNAL	BQ671165.1	
COMMENT	BQ671165.1	
FEATURES		
source		
1..921		
/organism="Homo sapiens"		
/mol_type="mRNA"		
/db_xref="taxon:9606"		
/clone="IMAGE:6213736"		
/tissue_type="epidermoid carcinoma, cell line"		
/lab_host="DH10B (phage-resistant)"		
/clone_lib="NIH_MGC 102"		
/note="Organ: salivary gland; Vector: pOTB7; Site 2: EcoRI; CDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using following 5' adaptor: GGCACGAG(G). Library cons by Ling Hong in the laboratory of Gerald M. Rubi (University of California, Berkeley) using ZAP-synthesis kit (Stratagene) and Superscript II RT Technologies). Note: this is a NIH_MGC Library."		
Site 2: EcoRI; CDNA made by oligo-dT priming		
Directionally cloned into EcoRI/XhoI sites using following 5' adaptor: GGCACGAG(G). Library cons by Ling Hong in the laboratory of Gerald M. Rubi (University of California, Berkeley) using ZAP-synthesis kit (Stratagene) and Superscript II RT Technologies). Note: this is a NIH_MGC Library."		
ORIGIN		
Alignment Scores:		

5.59e-28 Length: 921
 1270.00 Matches: 247
 ty: 93.98% Conservatives: 3
 arity: 92.86% Mismatches: 12
 44.56% Indels: 4
 13 Gaps: 1
 (1-538) x BQ671165 (1-921)
 nGlyLeuLeuGluGluAlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGly 293
 GGGGCTCTGGAGAGAGGGGGGGCTCGAGGGCGCTCGAGGGCGACCGCTCGGA 60
 leuAlaLeuProArgGlyAspArgProGlyArgAlaProProAlaAlaSerAlaArg 313
 GCTTGGCTGCGCGCGGAGACAGCGCCGAGCGGGCGCGCGCGCGCGCGCGCG 120
 oSerArgSerIysArgGlyGlyGluArgValLeuGluLysGluGluGluAsp 333
 GTCTCCGAGCAAGAGAGGTGAGAGAGCGAGTACTTGGAGAAAGAGAGAGAGAT 180
 pAspGluAspGluAspGluAspAspValSerGluGlySerGluValProGluSer 353
 T-----GATGAAGATGAAGAGATGATGTGTGAGAGGGCTCTGAGTGGCCGAGAT 234
 pArgProAlaGlyAlaGlnHisGlnLeuAsnGlyGluArgGlyProGlnSerAla 373
 CCGTCTCTGAGTCCCGAGCAGCACCAGCTTAAAGCGGAGCGCGGAGCTCAGAGTGC 294
 sGluArgValLysGluThrProCysGlyProHisGlnGlyGlnAspGluGlyArg 393
 GGAGGGGTCAAGAGAGTGGACCCCTCGGAGCCGACAGCGGCGAGGATGAAGGGCG 354
 yProAlaProGlySerGlyThrArgGlnValPheSerMetAlaAlaMetAsnLysGlu 413
 CCCAGCCCCGGGAGCGGCGCCCGCAGGTGTCTCCATGCGACGCCATGACAGGAA 414
 yGlyThrAlaSerValAlaThrGlyProAspSerProSerProValProLeuProPro 433
 GGGAAAGCTTCTGTGCGACCGGGCGAGACTCCCGCTCCCGCTGCTTTGCCCGCA 474
 yLysProAlaLeuProGlyAlaAspGlyThrProPheGlyCysProProGlyArgLys 453
 CAACACGAGCCCTACTCGGGCGGAGCGGACCCCTTTGGCTGTCTCCCGGGCGCAAA 534
 uLysProSerAspProValGluTyrThrValMetAspValValGluTyrPheThrGlu 473
 GAAGCCATCTGATCCCGTCAAGTGGACCGTGTGATGTGCTCGAATATTTTACTGAG 594
 aGlyPheProGluGlnAlaThrAlaPheGlnGluGlnGluLeuAspGlyLysSerLeu 493
 TGGATTCCCGAGCAGCGACAGCTTTCCAGAGCAGGAAATTCATGCGAAATCTTTG 654
 uLeuMetGlnArgThrAspValLeuThrGlyLeuSerIleArgLeuGlyProAlaLeu 513
 GCTCATGAGCGCGGATGTGCTTCCCGGGCTGTTCATCGCCCTCGGGCGCAACCTTG 714
 sIleTyrGluHisHisIleLysValLeuGln-GlnGlyHisPheGlu-AspAspAsp 533
 ATTTACGATCACCAGATCAAGGGGCTTTCCGAGAGGGCCCTTTTGGGGGTGATGACC 774
 AspGlyPheLeu 537
 : : : : :
 GAGGGCTTCTTA 788

4500 828 bp mRNA linear EST 20-SEP-2000
 90248F1 NIH_MGC_7 Homo sapiens cDNA clone IMAGE:3944674 5',
 sequence.
 4500
 4500.1 GI:10215698

SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eute-
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Hom
 1 (bases 1 to 828)
 NIH-MGC http://mgs.nci.nih.gov/
 National Institutes of Health, Mammalian Gene Collection
 Unpublished (1999)
 Contact: Robert Strausberg, Ph.D.
 Email: cgapbs@mail.nih.gov
 Tissue Procurement: DCTD/DTP
 cDNA Library Preparation: Ling Hong/Rubin Laboratory
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone Distribution: MGC clone distribution information
 found through the I.M.A.G.E. Consortium/LLNL at: image.l
 Plate: LLCW801 row: o column: 11
 High quality sequence stop: 729

FEATURES
 source
 1..828
 Location/Qualifiers

/organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:3944674"
 /tissue_type="small cell carcinoma"
 /cell_line="MGC3"
 /lab_host="DH10B (phage-resistant)"
 /clone_lib="NIH MGC 7"
 /note="Organ: lung; Vector: pOTB7; Site 1: XhoI
 EcoRI; cDNA made by oligo-dT priming. Directly
 cloned into EcoRI/XhoI sites using the followir
 adaptor: GGCACGAG(G). Size-selected >500bp for
 insert size 1.8kb. Library constructed by Ling
 the laboratory of Gerald M. Rubin (University of
 California, Berkeley) using ZAP-cDNA synthesis
 (Stratagene) and Superscript II RT (Life Technic

ORIGIN

Alignment Scores:
 Pred. No.: 3,36e-27 Length: 828
 Score: 1241.50 Matches: 251
 Percent Similarity: 95.49% Conservatives: 3
 Best Local Similarity: 94.36% Mismatches: 9
 Query Match: 43.56% Indels: 5
 DB: 10 Gaps: 2

US-09-976-740-43 (1-538) x BE794500 (1-828)

QY 261 SerGlyGlyAlaGlyArgLeuThrArgGlyArgValGlnGlyLeuGlu
 DB 3 AGCGCGCGCGCGCGGTGCGCTAACCGCGCGCGTGCAC---GGCGTGTGGA
 QY 281 AlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuPrc
 DB 60 GCGCGGGCTCGAGGCGCTCTGAGAGCGACCCCGTCTCGAGAGCGCTTGGCTGGCC
 QY 301 AspArgProGlyArgAlaProProAlaAlaSerAlaAlaArgProSerArgSerIys
 DB 120 GACAGCGCGGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGAGCAAC
 QY 321 GlyGluGluArgValLeuGluLysGluGluGluGluGluAspAspGluAspGlu
 DB 180 GGAGAGAGCGAGTACTTGGAGAAAGAGAGAGAGATGATGATGAAGATGA
 QY 341 GluAspAspValSerGlySerGluValProGluSerAspArgProAlaGly
 DB 240 GAAATGATGTCTGAGAGGCTCTGAAGTCCCGGAGAGTACCGTCTCTGAGGT
 QY 361 HisHisGlnLeuAsnGlyGluArgGlyProGlnSerAlaLysGluArgValLys
 DB 300 CACCACGAGTTACGGCGAGCGGGGACCTCAGAGTGCCAGAGAGGGGTCAAG
 QY 381 ThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaProGly

```

|||||
CCCTGGGACCGACCGACCGGCGAGTGAAGGGGGGGGGCGAGCCCGGGGAGCGGC 419
|||||
ArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyThrAlaSerValAla 420
|||||
CGCCAGGTGTTCTCCATGGCAGCCATGAACAAAGGAAGGGGAAACAGCTTCTGTGGC 479
|||||
GlyProAspSerProSerProValProLeuProProGlyLysProAlaLeuProGly 440
|||||
GGGCCAGACTCCCGCTCCCGCTGCTTTGCTCCCGCAGCAACAGCCCTACCTGGG 539
|||||
AspGlyThrProPheGlyCysProProGlyArgLysGluLysProSerAspProVal 460
|||||
GACGGGACCCCTTTGGCTGCTCTCCCGGGCGCAAGAGAGCCATCTGATCCGTC 599
|||||
TrpThrValMetAspValValGluTyrPheThrGluAlaGlyPheProGluGlnAla 480
|||||
TGGACCGTGATGGATGTCGTGCAATATTTACTGAGGCTGGATTCCTGGAGCAGCG 659
|||||
AlaPheGlnGluGln-GluIleAspGlyLysSerLeuLeuMetGlnArgThrAs 500
|||||
AGTTTTCAAGAGCAGGGAAATTTGATGGCAATCTTTGCTGTC-ATGCAGCGCACAGA 718
|||||
lleuThrGlyLeuSerIleArgLeuGlyProAlaLeuLysIleTyrGluHisHisI 520
|||||
GCTCAGCG--CTTGTCATTCGGCTCGGGCCCGCAGCTGAAATTAAGACACACAT-- 774
|||||
sValLeuGlnGln 525
|||||
GGTGCTTCAGCAG 789

```

805 1109 bp mRNA linear EST 13-JUL-2000
3804F1 NIH_MGC_8 Homo sapiens cDNA clone IMAGE:2966449 5',
sequence.

805
805.1 GI:9144449

sapiens (human)

yota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
lia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

ases 1 to 1109)

Mc http://mgs.nci.nih.gov/.

mal Institutes of Health, Mammalian Gene Collection (MGC)

lished (1999)

ct: Robert Strausberg, Ph.D.

: cgapbs-remail.nih.gov

ie procurement: Louis M. Staudt, M.D., Ph.D.

Library Preparation: Ling Hong/Rubin Laboratory

Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

Sequencing by: Incyte Genomics, Inc.

ie distribution: MGC clone distribution information can be

i through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov

: LNC69 row: h column: 02

quality sequence stop: 749.

Location/Qualifiers

1. .1109

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:2966449"

/tissue_type="Burkitt lymphoma"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH MGC 8"

/note="organ: lymph; Vector: pOTB7; Site 1: XhoI; Site 2:

EcoRI; cDNA made by oligo-dT priming. Directionally

cloned into EcoRI/XhoI sites using the following 5'

adaptor: GGCACAG(G). Size-selected >500bp for average

insert size 1.8kb. Library constructed by Ling Hong in

the laboratory of Gerald M. Rubin (University of

California, Berkeley) using ZAP-cDNA synthesis kit

(Stratagene) and Superscript II RT (Life Technol

ORIGIN

Alignment Scores:

Pred. No.: 9,81e-27 Length: 1109

Score: 1229.00 Matches: 229

Percent Similarity: 100.00% Conservative: 0

Best Local Similarity: 100.00% Mismatches: 0

Query Match: 43.12% Indels: 0

DB: 10 Gaps: 0

US-09-976-740-43 (1-538) x BE270805 (1-1109)

QY 310 AlaSerAlaArgProSerArgSerLysArgGlyGlyGluArgValLeuGlu

Db 3 GCCAGGCCCGCCGCTCTCCAGCAGAGAGGTGGAGAGCGAGTACTTGAG

QY 330 GluGluGluAspAspAspGluAspGluAspGluAspValSerGluGly

Db 63 GAGGAGAGATGATGATGAAGATGAAGATGAGAGATGATGTCTCAGAGGC

QY 350 ValProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuAsnGlyGlu

Db 123 GTCCCCAGAGTACCGTCTCTGAGGTGCCAGCACCAGCTTAAACGGCGAG

QY 370 ProGlnSerAlaLysGluArgValLysGluTyrThrProCysGlyProHisGln

Db 183 CCTCAGAGTCCCAAGAGAGAGGTCAAGAGTGGACCCCTCGGACCGCACCA

QY 390 AspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValPheSerMet

Db 243 GATGAAGGGGGGGGGCCAGCCCGGGCAGCGGACCCCGCAGGTGTCTCCATC

QY 410 MetAsnLysGluGlyGlyThrAlaSerValAlaThrGlyProAspSerProSer

Db 303 ATGAACAAGGAAGGGGAAACAGCTTCTGTGGCCACCGGGCCAGACTCCCGCTCC

QY 430 ProLeuProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheGly

Db 363 CCTTTGCCCGGCAACCCAGCCCTTACTGGGGCCGCGGACCCCTTTGGC

QY 450 ProGlyArgLysGluLysProSerAspProValGluTyrThrValMetAspVal

Db 423 CCCGGGCGCAAGAGAGCCATCTGATCCCGTCCAGTGGACCCGTGATGGATGTC

QY 470 TyrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnGluGln

Db 483 TATTTTACTGAGGCTGGATTCCCGGAGCAGCGCAGCTTTCGAAGAGCAGGAA

QY 490 GlyLysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGlyLeuSerIle

Db 543 GGCAAACTTTGCTGCTCATGCAGCGCACAGATGTGCTCACCGGCTGTCCATC

QY 510 GlyProAlaLeuLysIleTyrGluHisHisIleLysValLeuGlnGlnGlyHis

Db 603 GGGCAGCCCTGAAATCTACGAGCACCACATCAAGGTGCTTCAGCAAGGCCAC

QY 530 AspAspAspProAspGlyPheLeuGly 538

Db 663 GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT

RESULT 5

BF058975

LOCUS

DEFINITION

BF058975

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eute

BF058975 704 bp mRNA linear EST

7K36f08.x1 NCI CGAP Ov18 Homo sapiens cDNA clone IMAGE:3;

similar to FR:076866 076866 EG:100G10.6 PROTEIN. [1]; con

element MER22 repetitive element ; mRNA sequence.

BF058975

BF058975.1 GI:10812871

EST.

Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eute

alia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 bases 1 to 704)
 CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 onal Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 r Gene Index
 blished (1997)
 act: Robert Strausberg, Ph.D.
 l: cgaps-r@mail.nih.gov
 ue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael
 mert-Buck, M.D., Ph.D. cDNA Library Preparation: M. Bento
 es, Ph.D. cDNA Library Arrayed by: Christa Prange, The
 A.G.E. Consortium DNA Sequencing by: Washington University
 me Sequencing Center
 ne distribution: NCI-CGAP clone distribution information can be
 d through the I.M.A.G.E. Consortium/LLNL, send email to:
 @image.llnl.gov
 primer: -40UP from Gibco
 quality sequence stop: 495.
 Location/Qualifiers
 1. 704
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:3477639"
 /tissue_type="fibrotheoma"
 /lab_host="DH10B (phage-resistant)"
 /clone_lib="NCI CGAP Ov18"
 /notes="Organ: ovary; Vector: pT73D-Pac (Pharmacia) with a
 modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
 strand cDNA was primed with a Not I - oligo(dT) primer [5'
 TGTTACCAATCTGAGTGGAGCGCGCGGCACATTTTTTTTTTTTTT 3'];
 double-stranded cDNA was ligated to Eco RI adaptors
 (Pharmacia), digested with Not I and cloned into the Not
 I and Eco RI sites of the modified pT73 vector. Library
 went through one round of normalization, and was
 constructed by Bento Soares and M. Fatima Bonaldo."
 (1-538) x BF058975 (1-704)
 YArgValGlnGlyLeuLeuGluGluAlaAlaAlaArgGlyArgLeuGluArgThr 290
 :CCGCTGCAGGGCTGCTGGAGGAGGAGCGCGCGCTCGAGCGCGCCACC 62
 gLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaProAlaAla 310
 :TCTCGAGCGCTTGGCTGCCCCCGGGGAGCAGCGCCGAGCGCGCGCGCGCC 122
 :AlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuGluLysGluGlu 330
 :CGCCCGCCCGCTCTCGCAGCAGAGAGGTGGAGAGCGAGTACTTGAAGAAGAG 182
 uGluAspAspGluAspGluAspGluAspValSerGluGlySerGluVal 350
 :AGAAGATGATGATGAAGATGAAGATGAAGATGAAGATGATGTCAGAGGGCTCTGAAGT 242
 :GluSerAspArgProAlaGlyAlaGlnHisGlnLeuAsnGlyGluArgGlyPro 370
 :CAGAGATGACCTCTGAGGTGCGCAGCCAGCCAGCTTTAACCGCGAGCGGGACCT 302
 nSerAlaLysGluArgValLysGluTrpThrProCysGlyProHisGlnGlyGlnAsp 390
 :GAGTCCAGAGAGAGGGTCAAGAGTGGACCCCTTCGCGAGCGCAGCCAGGAT 362
 uGlyArgGlyProAlaProGlySerGlyThrArgGlnValPheSerMetAlaMet 410

Db 363 GAAGGGCGGGGGCGAGCCCGGGCAGCGGCACCGCGAGGTGTCTCCATGGC
 QY 411 ASnlysluGlyGlyThrAlaSerValAlaThrGlyProAspSerProSerPn
 Db 423 AACAGGAGAGGGGAAACAGCTTCTGTTCACCGGGCCAGACTCCCGTCCCC
 QY 431 LeuProProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheGlyCY
 Db 483 TTGCACCCAGGCAAAACAGCCCTACCTGGGGCCGAGGGACCCCTTGTGGCTG
 QY 451 GlyArgLysGluLysProSerAspProValGluTrpThrValMetAspValva
 Db 543 GGCGCGAAAGAGAGCATCTGATCCCGTCGAGTGGACCGTGGATGTCGT
 QY 471 PheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnGluGlnGlu
 Db 603 TWTACTGATGCTGGATTCCCGGAGCAGCGACTGCTTCCAGAGCAGGAAT
 QY 491 LysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGly 504
 Db 663 AAATCTTGTCTGCTCATGCAGCGCAGAGTGTGTCACCGGG 704
 RESULT 6
 BE746961
 LOCUS
 DEFINITION
 mRNA sequence.
 BE746961
 BE746961.1 GI:10160953
 EST.
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eut.
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Ho
 REFERENCE
 1 (bases 1 to 707)
 NIH-MGC <http://mgi.nci.nih.gov/>.
 National Institutes of Health, Mammalian Gene Collection
 Unpublished (1999)
 COMMENT
 Contact: Robert Strausberg, Ph.D.
 Email: cgaps-r@mail.nih.gov
 Tissue Procurement: DCTD/DTF
 CDNA Library Preparation: Ling Hong/Rubin Laboratory
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LL
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone distribution: MGC clone distribution information
 found through the I.M.A.G.E. Consortium/LLNL at: image.
 Plate: LLCW762 row: p column: 22
 High quality sequence stop: 671.
 Location/Qualifiers
 1. 707
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:3929733"
 /tissue_type="adenocarcinoma cell line"
 /lab_host="DH10B (phage-resistant)"
 /clone_lib="NIH MGC 9"
 /notes="Organ: ovary; Vector: pOTB7; Site 1: Xh
 EcoRI, cDNA made by oligo-dT priming. Directi
 cloned into EcoRI/XhoI sites using the followi
 adaptor: GGCACGAG(G). Size-selected >500bp fo
 insert size 1.8kb. Library constructed by Ling
 the laboratory of Gerald M. Rubin (University o
 California, Berkeley) using ZAP-cDNA synthesis;
 (Stratagene) and Superscript II RT (Life techn
 Alignment Scores:
 Pred. No.: 1,48e-26 Length: 707
 Score: 1217.00 Matches: 229
 Percent Similarity: 99.14% Conservatives: 2
 Best Local Similarity: 98.28% Mismatches: 2

42.70% Indels: 0
10 Gaps: 0
(1-538) x BE746961 (1-707)
GlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGlu 280
GG 62
AlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuProArgGly 300
GG 122
ArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArgSerLysArgGly 320
AGGG 182
GluGluArgValLeuGluLysGluGluGluGluArgAspAspGluAspGlu 340
GAAGAGCGGAGTACTTGAGAAAGAGAGAGAGAGATGATGATGATGATGATGAA 242
AspAspValSerGluGlySerGluValProGluSerAspArgProAlaGlyAlaGln 360
GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 302
HisGlnLeuAsnGlyGluArgGlyProGlnSerAlaLysGluArgValLysGluTrp 380
CACCAAGCTTACCGGGGAGGGGGACCTCAGAGTCCCAAGAGAGAGGTCAAGAGTGG 362
ProCysGlyProHisGlnGlnAspGluGlyArgGlyProAlaProGlySerGly 400
CCCTGGGAGCCGACCCAGGAGGATGATGAGGGGGGGGGGGGGGGGGGGGGGG 422
ArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyGlyThrAlaSerValAla 420
CGCCAGGTGTCTCCATGCGAGCCATGAACAGGAAGGGGGGAACAGCTTCTGTGCC 482
GlyProAspSerProValProLeuProGlyLysProGlyLysProAlaLeuProGly 440
GGGGCAGACTCCCGGTCCTCCCGTCTTTGGCCCCCAGGCAACAGCCCTACCTGGG 542
AspGlyThrProPheGlyCysProProGlyArgLysGluLysProSerAspProVal 460
AGCGGAGACCCCTTTGGTGTCTCCCGGGGCAAGAGAGGATCTGATCCCGTC 602
TrpThrValMetAspValValGluTrpPheThrGluAlaGlyPheProGluGlnAla 480
GTGACCGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 662
AlaPheGlnGluGluLeuLeuAspGlyLysSerLeu 493
GCTTTCCAAAGCAGAAATCGATTGGCAATTCCTT 701

743 bp mRNA linear EST 16-OCT-2000
12.x1 NCI CGAP Ovl8 Homo sapiens cDNA clone IMAGE:3477623 3'
ar to TR:076865 076865 EG:100G10.6 PROTEIN. [1] ; contains
nt TARI repetitive element 1; mRNA sequence.

118
118.1 GI:10812014

sapiens (human)

sapiens

Yota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
ilia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

ases 1 to 743)

CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.

nal Cancer Institute, Cancer Genome Anatomy Project (CGAP),

: Gene Index

lished (1997)

act: Robert Strausberg, Ph.D.

[; cgapbs-remail.nih.gov

Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D.,
R. Emmert-Buck, M.D., Ph.D. cDNA Library Preparation: M.
Soares, Ph.D. cDNA Library Arrayed by: Christa Prange, Ph.D.
I.M.A.G.E. Consortium DNA Sequencing by: Washington Univ
Genome Sequencing Center

Clone distribution: NCI-CGAP clone distribution informa
found through the I.M.A.G.E. Consortium/LLNL, send email
infoimage.llnl.gov

Seq primer: -40UP from Gibco

High quality sequence stop: 495.

Location/Qualifiers

1. .743

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:3477623"

/tissue_type="fibrotheoma"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NCI CGAP Ovl8"

/notes="Organ: ovary; Vector: pT7T3D-Pac (Pharma
modified polylinker; Site 1: Not I; Site 2: Eco
strand cDNA was primed with a Not I oligo (dT)
TGTACCAATCTGAAGTGGAGCGCGCGACATTTTITTTT

double-stranded cDNA was ligated to Eco RI adapt
(Pharmacia), digested with Not I and cloned int
I and Eco RI sites of the modified pT7T3 vecto
went through one round of normalization, and wa
constructed by Bento Soares and M. Fatima Bonal

ORIGIN

Alignment Scores:
Pred. No.: 2,3e-26 Length: 743
Score: 1211.00 Matches: 232
Percent Similarity: 94.74% Conservative: 2
Best Local Similarity: 93.93% Mismatches: 13
Query Match: 42.49% Indels: 0
DB: 10 Gaps: 0

US-09-976-740-43 (1-538) x BF058118 (1-743)

Qy 271 GlyArgValGlnGlyLeuLeuGluGluGluAlaAlaAlaArgGlyArgLeuGlu
Db 3 GGCGCGTGCAGGGCGTGTGGAGAGAGCGCGCTCGAGCGCGTCTGAGG
Qy 291 ArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaProPro
Db 63 CGCTCGAGCGCTTGGCTGCCCGGGGACAGGCCGCGGCGCGCGCGCG
Qy 311 SerAlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuLys
Db 123 AGCGCGCGCGCTCTCGAGCAGAGAGGTGGAGAGCGGAGTACTTGAGAA
Qy 331 GluGluAspAspAspGluAspGluAspGluAspAspValSerGluGlySer
Db 183 GAAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG
Qy 351 ProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuAenGlyGluArg
Db 243 CCCGAGAGTGACCGCTCTCGAGGTGCCAGCACCAGCTTAACCGGAGCGG
Qy 371 GlnSerAlaLysGluArgValLysGluTrpThrProCysGlyProHisGlnGly
Db 303 CAGAGTCCCAAGGAGAGGGTCAAGGAGTGGACCCCTCGGACCGCACCGAGG
Qy 391 GluGlyArgGlyProAlaProGlySerGlyThrArgGlnValPheSerMetAla
Db 363 GAAGGG
Qy 411 AsnLysGluGlyGlyThrAlaSerValAlaThrGlyProAspSerProSerPro
Db 423 AACAGGAAGGGGAAACAGCTTCTGTGGCACCAGGGGCGAGCTCCCGTCC
Qy 431 LeuProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheGlyCys

Contact: Robert Strausberg, Ph.D.

cgapbs-@mail.nih.gov
 clone is available royalty-free through LLNL ; contact the
 Consortium (info@image.llnl.gov) for further information.
 rimer: -40UP from Gibco
 quality sequence stop: 454.
 Location/Qualifiers
 1..683
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:3300286"
 /lab_host="DH10B"
 /clone_lib="Soares NSF F8 9W OT PA P S1"
 /note="Organ: pooled; Vector: pT7E3-Pac (Pharmacia) with
 a modified polylinker; Site_1: Not 1; Site_2: Eco RI;
 Equal amounts of plasmid DNA from five normalized
 libraries were mixed, and ss circles were made in vitro.
 Following HAP purification, this DNA was used as tracer in
 a subtractive hybridization reaction. The driver was
 PCR-amplified cDNAs from pools of 5,000 clones made from
 the same 5 libraries. The pools consisted of the following
 libraries and clones: Soares NBSF pool 1:
 309384-310919, 323208-325895 Soares NB2HP pool 1:
 145032-147335, 147720-148103, 148872-149255, 15002 -
 150407, 151176-152327 Soares NB2HP8-9W pool 1:
 758280-760583, 772104-774407 Soares NBHPA pool 1:
 304776-306311, 320136-322823, 326280-326663 Soares NBHOT
 pool 1: 723720-726407, 739080-740999 Subtraction by Bento
 Soares and M. Fatima Bonaldo."

9,15e-26 Length: 683
 1189.00 Matches: 224
 Y: 99.56% Conservativity: 1
 99.12% Mismatches: 1
 41.72% Indels: 0
 1.0 Gaps: 0
 (1-538) x BB857956 (1-683)

gLuGluAlaAlaAArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAla 296
 xGAGGAGGAGGCGCGCTCGAGCGCTCGAGCGCACCCGCTCGAGCGCTTCGC 62
 pProGlyAspArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArg 316
 xCCCCGCGGGACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCTCGC 122
 yAsArgGlyGlyGluArgValLeuGluGlyGluGluGluGluGluGluGluGlu 336
 xAGAGAGGTGGAGAGAGCGAGTACTTGAGAGAGAGAGAGAGAGAGATGATGAA 182
 xGluGluGluGluGluGluGluGluGluGluGluGluGluGluGluGluGluGlu 356
 xGAAGATGAAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 242
 yAlaAlaGlnHisGlnLeuGluGluGluGluGluGluGluGluGluGluGluGlu 376
 xGTGTCACAGCACCCAGCTTAACCGCGAGCGCGCGCGCGCGCGCGCGCGCGCG 302
 yLysGluThrThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAla 396
 xAGAGAGTGAACCCCTCGGACCGGACCGGACCGGACCGGACCGGACCGGACCG 362
 yGlySerGlyThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyThr 416
 xGCGAGCGGACCCCGCAGGTGTTCTCATGTCAGGCGATGAAACAAGAGAGGGAACA 422
 ySerValAlaThrGlyProAspSerProSerProValProLeuProProGlyLysPro 436
 xTCTGTGTCACCGGCGAGACTCCCGCTCCCGCTTCGCTTCGCTTCGCTTCGCTTC 482

QY 437 AlaLeuProGlyAlaAspGlyThrProPheGlyCysProProGlyArgLysGlu
 Db 483 GCCTTACCTGGGCGGACGGGACCCCTTGGCTGCTCCTCCGCGGCGCAGAG#
 QY 457 SerAspProValGluTrpThrValMetAspValValGluThrGluAlaC
 Db 543 TCTGATCCCGTCGATGGACCGTGGATGATGTCGATATATTTTACTGAGGCT
 QY 477 ProGluGlnAlaThrAlaPheGlnGluGlnGluGluLeuAspGlyLysSerLeuLeu
 Db 603 CCGAGCAGCGGACAGCTTTCCAGAGCAGGAAATTGATGGAGAGTCTTTGCTC
 QY 497 GlnArgThrAspValLeu 502
 Db 663 CAGCGCACAGATGTGCTC 680
 RESULT 10
 BI226646 785 bp mRNA linear EST
 LOCUS 602951660P1 NIH_MGC_8 Homo sapiens cDNA clone IMAGE:5095
 DEFINITION mRNA sequence.
 ACCESSION BI226646 GI:14680090
 VERSION BI226646
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eute;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Hom
 REFERENCE 1 (bases 1 to 785)
 AUTHORS NIH-MGC http://mgi.nci.nih.gov/
 TITLE National Institutes of Health, Mammalian Gene Collection
 JOURNAL Unpublished (1999)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-@mail.nih.gov
 Tissue Procurement: Louis M. Staudt, M.D., Ph.D.
 cDNA Library Preparation: Ling Hong/Rubin Laboratory
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone distribution: MGC clone distribution information
 found through the I.M.A.G.E. Consortium/LLNL at:
 http://image.llnl.gov
 Plate: LHCMI866 row: h column: 15
 High quality sequence stop: 785.
 Location/Qualifiers
 1..785
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:5095742"
 /tissue_type="Burkitt lymphoma"
 /lab_host="DH10B (phage-resistant)"
 /clone_lib="NIH MGC 8"
 /note="Organ: lymph; Vector: pOTB7; Site 1: Xho;
 EcoRI; cDNA made by oligo-dT priming. Direction
 cloned into EcoRI/XhoI sites using the following
 adaptor: GGCACGAG(G). Size-selected >500bp for
 insert size 1.8kb. Library constructed by Ling
 the laboratory of Gerald M. Rubin (University of
 California, Berkeley) using ZAP-cDNA synthesis
 (Stratagene) and Superscript II RT (Life Techno.
 ORIGIN
 Alignment Scores:
 Pred. No.: 1.74e-25 Length: 785
 Score: 1181.00 Matches: 233
 Percent Similarity: 98.73% Conservativity: 0
 Best Local Similarity: 98.73% Mismatches: 3
 Query Match: 41.44% Indels: 3
 DB: 12 Gaps: 0
 US-09-976-740-43 (1-538) x BI226646 (1-785)
 QY 303 ProGlyArgAlaProProAlaAlaSerAlaArgProSerArgSerLysArgGly

LOCUS BG116718 906 bp mRNA linear EST
DEFINITION 602317440F1 NIH_MGC_88 Homo sapiens cDNA clone IMAGE:44
mRNA sequence.

KEYWORDS	EST.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Vertebrata; Eut
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Hc
REFERENCE	1 (bases 1 to 906)

JOURNAL COMMENT
Unpublished (1957)
Contact: Robert Strausberg, Ph.D.

Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.

DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information
found through the IMA G.E. Consortium/LLNL at:

http://image.llnl.gov
plate: LLAMI0150 row: p column: 09

FEATURES	Location/Qualifiers
source	1. .906

```

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

```

```

/culture_medium="DMEM"
/culture_type="duodenal adenocarcinoma, cell 1"
/lab_host="DH10B (phage-resistant)"

```

```

/clone_id="NH_MGC_88
/note="Organ: small_intestine; Vector: pCW-S
Site 1: NotI; Site 2: SalI; Cloned unidirecti

```

oligo-dT primed. Average insert size 1.7 kb. Enriched for full-length clones and construct Technologies. Note: this is a NIH MGC Library

ORIGIN	Alignment Scores:
1	100
2	100
3	100
4	100
5	100
6	100
7	100
8	100
9	100
10	100
11	100
12	100
13	100
14	100
15	100
16	100
17	100
18	100
19	100
20	100
21	100
22	100
23	100
24	100
25	100
26	100
27	100
28	100
29	100
30	100
31	100
32	100
33	100
34	100
35	100
36	100
37	100
38	100
39	100
40	100
41	100
42	100
43	100
44	100
45	100
46	100
47	100
48	100
49	100
50	100
51	100
52	100
53	100
54	100
55	100
56	100
57	100
58	100
59	100
60	100
61	100
62	100
63	100
64	100
65	100
66	100
67	100
68	100
69	100
70	100
71	100
72	100
73	100
74	100
75	100
76	100
77	100
78	100
79	100
80	100
81	100
82	100
83	100
84	100
85	100
86	100
87	100
88	100
89	100
90	100
91	100
92	100
93	100
94	100
95	100
96	100
97	100
98	100
99	100
100	100

Length:	3.29e-23	906
Pred. No.:		230
Matches:	1103.50	
Score:	90.23%	1
Conservative:		

Percent Similarity:	89.84%	Mismatches:	13
Best Local Similarity:	38.72%	Indels:	14
Query Match:	12	Gaps:	2

US-09-976-740-43 (1-538) x BG116718 (1-906)

Qy 266 GlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGluGluAlaAla

DB 12 GGTCGACCCACACCCG

QV 286 ArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArg!

Db
45 CGTCTGGAGCGCACCCGTCTCGGAGCGCTTGGCTGCCCGCGGGGACAGG

Qy 306 ALAPPTPTQALAAALASEALAAALGFLCCCLAAAGGAA
rh 105 GGCCCGCCGGCCGCCAGCGCCCGCCCTCTCCAGCAAGAGAGGTGGAGAA

Qy 326 LeuGluLysGluGluGluGluAspAspAspGluAspGluAspGluGluAsp.

[illegible]

225 GAGGGCTCTGAAGTGCCACGAGAGTGACCGTCTTCAGGTGCCCCAGCACCA

Qy
365 nGlyGluArgGlyProGlnSerAlaLysGluArgValLysGluTrpThrPr

/note=organ; lymph; Vector: pOT87; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dr priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZIP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Search completed: March 13, 2004, 04:01:57
Job time : 8144.53 secs

Search completed: March 13, 2004, 04:01:57
Job time : 8144.53 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

leic search, using frame_plus_p2n model

March 12, 2004, 19:49:56 ; Search time 8171.41 Seconds
(without alignments)

2853.675 Million cell updates/sec

US-09-976-740-43

2850
1 MAGPPALPPPTAAATAA.....HIKVLQCHFEDDPDGFLG 538

BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

3470272 seqs, 21671516995 residues

hits satisfying chosen parameters: 6940544

length: 0
length: 2000000000

Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

ameters:
n.model -DEV=xlp
spool_p/US09976740/runat_10032004_094548_19540/app_query.faeta_1.1898
T=faastp -SUFFIX=rge -MINMATCH=0.1 -LOOPEXT=0 -LOOPEXT=0
RT=1 -END=-1 -MATRIX=biolum2 -TRANS=human40.cdi -LIST=45
HR_SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
M=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
@CGN 1 1 9705 @runat_10032004_094548_19540 -NCPU=6 -ICPU=3
VERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
OP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

GenEmbl:*
1: gb.ba:*
2: gb.htg:*
3: gb.in:*
4: gb.cm:*
5: gb.ov:*
6: gb.pat:*
7: gb.ph:*
8: gb.pl:*
9: gb.pr:*
10: gb.ro:*
11: gb.sts:*
12: gb.sy:*
13: gb.un:*
14: gb.vi:*
15: em.ba:*
16: em.fun:*
17: em.hum:*
18: em.in:*
19: em.mu:*
20: em.or:*
21: em.ov:*
22: em.pat:*
23: em.ph:*
24: em.pl:*
25: em.ro:*
26: em.ste:*
27: em.un:*
28: em.un:*

29: em.vi:*
30: em.htg_hum:*
31: em.htg_inv:*
32: em.htg_other:*
33: em.htg_mus:*
34: em.htg_pln:*
35: em.htg_rod:*
36: em.htg_mam:*
37: em.htg_vrt:*
38: em.sy:*
39: em.htgo_hum:*
40: em.htgo_mus:*
41: em.htgo_other:*

Pred. No. is the number of results predicted by chance to have
score greater than or equal to the score of the result being
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query			DB	ID	Descript:
	Score	Match	Length			
1	2850	100.0	1614	6	AR409337	AR409337
2	2850	100.0	1614	6	AX239602	AX239602
3	2850	100.0	1617	9	AY453840	AY453840
4	2616.5	91.8	12425	6	AR409341	AR409341
5	2616.5	91.8	12425	6	AX239607	AX239607
6	2594	91.0	2560	4	AY453841	AY453841
7	2594	91.0	2561	6	AR409339	AR409339
8	2594	91.0	2561	6	AX239605	AX239605
9	1983.5	69.6	237931	9	AC022098	AC022098
10	1560	54.7	1470	9	BC030129	BC030129
11	1455.5	51.1	1617	6	AR199530	AR199530
12	1455.5	51.1	1617	6	AR374682	AR374682
13	1455.5	51.1	1617	6	AR409317	AR409317
14	1455.5	51.1	1617	6	AX239568	AX239568
15	1455.5	51.1	1617	6	BD056444	BD056444
16	1269	44.5	982	9	BC007384	BC007384
17	1256.5	44.1	140795	2	AC079562	AC079562
18	1224.5	43.0	279020	2	AC133803	AC133803
19	1191.5	41.8	1422	6	AR199532	AR199532
20	1191.5	41.8	1422	6	AR374684	AR374684
21	1191.5	41.8	1422	6	AR409319	AR409319
22	1191.5	41.8	1422	6	AX239570	AX239570
23	1191.5	41.8	1422	6	BD056446	BD056446
24	1170	41.1	1208	6	AR199535	AR199535
25	1170	41.1	1208	6	AR374687	AR374687
26	1170	41.1	1208	6	AR409322	AR409322
27	1170	41.1	1208	6	AX239573	AX239573
28	1170	41.1	1208	6	BD056449	BD056449
29	1087	38.1	218687	2	AC079501	AC079501
30	1086.5	38.1	1362	6	AR199531	AR199531
31	1086.5	38.1	1362	6	AR374683	AR374683
32	1086.5	38.1	1362	6	AR409318	AR409318
33	1086.5	38.1	1362	6	AX239569	AX239569
34	1086.5	38.1	1362	6	BD056445	BD056445
35	997.5	35.0	215265	2	AC134005	AC134005
36	902.5	31.7	263957	2	AC120697	AC120697
37	811	28.5	1134	6	BD275342	BD275342
38	418.5	14.7	316050	1	BX248346	BX248346
39	417	14.6	349606	15	BX842583	BX842583
40	411.5	14.4	15348	1	AE007163	AE007163
41	410	14.4	8113	14	HSBICP4A	LI4320 E
42	410	14.4	135301	14	BHV1GEN	AJ004801
43	410	14.4	135301	14	BHV1GEN	AJ004801
44	406.5	14.3	126712	9	AL137077	AL137077
45	404	14.2	15382	1	AE006974	AE006974

ALIGNMENTS


```

sapiens
ryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
alia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

A.M., Lees, R.S., Law, S.W. and Arjona, A.A.
density lipoprotein binding proteins and their use in diagnosing
treating atherosclerosis
nt: WO 0164874-A 45 07-SEP-2001;
on Heart Foundation, Inc. (US)
Location/Qualifiers
1..1614
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..>1614
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAC88299.1"
/db_xref="GI:15797276"
/translation="MAGPPALPPPTAAATTAASSSAASPHYOEIWDITDLSRS
RKAPDLERICMVRHRRHGPETRAELEKLIQORAVLRVSFKYSISVNRARVQPP
RGATPAPPRAPRGAPAAATAAAPTTPAPPAPVAAAPAPRAAATAAP
SGPAPGPRAGAAALAAPAPPAAPVAPAGPRAPPAPVAAAREPLPPPPPP
APPQQPPPPPPQPPPEGGVAGGAAPVSLREVVYLGSGGAGRLTRRVQGL
LBEAARGLERLRLGALALPRGDRPAPPAASAPSRKRKRGEEVLEKEEEDD
DEDEDEDVSESGSEVPESDRPAGAQHQLNGPQSAKRWKWTGCGHQQDGG
RGAPSGTGRVPSMAAMKGGTASVATGSPSPVPLPGKPALAGADGTPRGCP
GRKEKPSDVEVMTDVFVTEANGPEQATAFQBEIDGKSLMLMQRTDLTGLSIR
LGPALKIYEHKIVLQOQHFEDEDDPDGFLG"

:      3,26e-44      Length:      1614
      2850.00      Matches:      538
ty:      100.00%      Conservative:      0
arity:      100.00%      Mismatches:      0
      100.00%      Indels:      0
      6      Gaps:      0

(1-538) x AX239602 (1-1614)

tAlaGlyProProAlaLeuProProGluThrAlaAlaAlaThrThrAlaAla 20
GCGGGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
aAlaSerSerSerAlaAlaSerProHisTyTGlnGluTyrIleLeuAspThrIleAsp 40
CGCTCTGTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
rLeuArgSerArgLysAlaAlaArgProAspLeuGluArgLysCysArgMetValArgArg 60
GCTGCGCTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
gHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGlnArg 80
GCACGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
aValLeuArgValSerTyryLysGlySerIleSerTyArgAsnAlaAlaAlaArgValGln 100
CGTCTCCGGGTACGTACAGGGGAGGATCTCTGTACCGAACCGCGCGCGCGCGCG
oProArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaProAla 120
GCCCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
aAlaAlaAlaAlaProProProThrProAlaProProProProProProAlaProVal 140
CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
aAlaAlaAlaProAlaAlaProArgAlaAlaAlaAlaAlaAlaAlaAlaAlaProPro 160
CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG

```

```

161 SerProGlyProAlaGlnProGlyProArgGlnAlaGlnAlaAlaProLeuAla
481 TGGCTTGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
181 ProProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgArg
541 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
201 ProProAlaValAlaAlaArgGluProProLeuProProProProProProPro
601 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
221 ProGlnGlnGlnGlnProProProProGlnProGlnProProProGluGlyGly
661 CCACAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC
241 ArgAlaGlyGlyAlaAlaAlaArgProValSerLeuArgGluValValArgTyrIle
721 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
261 SerGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGly
781 AGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
281 AlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaAlaAlaLeuPro
841 GCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
301 AspArgProGlyArgAlaProProAlaAlaSerAlaAlaArgProSerArgSerLys
901 GACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
321 GlyGluGluArgValLeuGluGlyGluGluGluGluGluGluGluGluGluGlu
961 GGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
341 GluAspAspValSerGluGlySerGluValProGluSerAspArgProAlaGly
1021 GAAGATGATGTCAGAGGGGCTCTGAAGTGCAGAGAGTACCGTCTCTGAGG
361 HisHisGlnLeuAsnGlyGluArgGlyProGlnSerAlaGlyGluArgValLys
1081 CACCACCACTTAACGGCGAGCGCGGACCTCAGAGTGCCCAAGAGAGGAGTCAAC
381 ThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaProGly
1141 ACCCTCTGCGGACCGCACCGCGCGCGAGGATGAAGGCGCGCGCGCGCGCGCG
401 ThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyGlyThrAlaSer
1201 ACCCGCCAGGTGCTCTCCATGGCAGCCATGAACAAGGAGGAGGAGGAGTCT
421 ThrGlyProAspSerProSerProValProLeuProProGlyLysProAlaLeu
1261 ACCGCGCGCAGACTCCCGCTCCCGCTGCTCCCGCGCGCGCGCGCGCGCGCG
441 AlaAspGlyThrProPheGlyCysProProGlyArgLysGluLysGluLysProSerAsp
1321 GCCGACGGGACCCCCCTTTGGCTGTCCCGCGCGCGCGCGCGCGCGCGCGCG
461 GluTyrThrValMetAspValValGluTyrPheThrGluAlaGlyPheProGlu
1381 GAGTGGACCGTGGATGATGTCGTGCAATATTTACTAGGCTGGATTCGCCGAG
481 ThrAlaPheGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGln
1441 ACAGCTTTTCAAGAGCAGGAAATTCATGCAAAATCTTTGCTGCTCTATGAGCGC
501 ValLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuLysIleTyrGluHis
1501 GTGCTCACCGGCTGTCCATCCGCTCGCGCGCGCGCGCGCGCGCGCGCGCGCG

```


ValLeuGlnGlnGlyHisPheGluAspAspProAspGlyPheLeuGly 538
 |||||
 GTGCTTCAGCAAGCCACTTTGAGGATGATACCCCGATGCTTCTTAGGC 1614
 |||||

840 1617 bp mRNA linear PRI 03-DEC-2003
 sapiens atherin mRNA, complete cds.
 840
 840.1 GI:38565528
 sapiens (human)
 sapiens
 yota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 lia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 ases 1 to 1617
 A.M., Deconinck, A.E., Campbell, B.D. and Lees, R.S.
 in, a newly identified LDL-binding protein in human
 osclerotic lesions
 lished
 ases 1 to 1617
 inck, A.E., Law, S.W., Lees, R.S. and Lees, A.M.
 t Submission
 tted (30-OCT-2003) Harvard-MIT Division of Health Sciences and
 ology, Boston Heart Foundation, 139 Main Street, Cambridge, MA
 , USA
 Location/Qualifiers
 1..1617
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /chromosome="19"
 /map="19p13.12"
 /tissue_type="aorta; liver; fetal brain"
 1..1617
 /note="LDL-binding protein; co-localizes with LDL in very
 early human atherosclerotic lesions"
 /codon_start=1
 /product="atherin"
 /protein_id="AAR24087.1"
 /db_xref="GI:38565529"
 /translation="MAGPPALPPPTAAATTAASSAASPHYQEWILDTIDSURS
 RKAPDIERCMVRRHSGPEPTRAELKIQRAVLRVYKGSISYRNAARVQPP
 RRGATPPAPRAAPAAAAAAPPPTAPPAPPAVAAAAPARAAPAAAAATAPP
 SPQAPQPPRAAPAAAPPAAPPAVAPAGPRAPPAVAAAPPLPPPPOPP
 APPQOQPQPPQPPGGAVRGAARPVSLREVVRVYLGSGGAGRLTRGRVQGL
 LEEAARARGLERELGALALPGCDRGRAPPAASAPSPSKGGEFVLEKEEDD
 DEDEDEDDVSGSEVPESDRPAGAHQLNGERGPQSAKERVKEWTPCGPHQCDRG
 RGPAPSGTRQVFSMAWNKEGTVATGDPSPVPLPPKPAALPGADGTPFGCPP
 GRKEKPDVETVMDYVEFTFAGFPEQATFQEQEIDGKSLMLMORTDLTGLSIR
 LGPALKIYEHIIKVLQGHFEDDDPDGFLG"

3.26e-44 Length: 1617
 2850.00 Matches: 538
 Y: 100.00% Conservativity: 0
 rity: 100.00% Mismatches: 0
 100.00% Indels: 0
 9 Gaps: 0
 (1-538) x AY453840 (1-1617)
 AlaGlyProAlaLeuProGluThrAlaAlaAlaAlaThrThrAlaAla 20
 |||||
 AGCGAGCGCGCGCTTACCCCGCGAGACGGCGCGCGCGCCACCAACCGCGGCC 60
 |||||
 AlaSerSerAlaAlaSerProHisGlnGlnGluTrpIleLeuAspThrIleAsp 40
 |||||
 GCCTCGTCGTCGCGCGCTTCCCGCACTACCAAGAGTGATCTCTGGACACCATGCAC 120
 |||||
 LeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
 |||||

Db 121 TCCTGCTGCTCGCGCAAGCGCGCGCGCGCATCTCGAGCGCATCTCGCGGATGGTG<
 QY 61 ArgHisGlyProGluProGluArgThrArgAlaGluLeuGlyLeuIleGln<
 Db 181 CGGACCGGCGCGGAGCGCGGAGCGCACCGCGCGCGAGCTCGAGAACTGATCCAG<
 QY 81 AlaValLeuArgValSerTyrLysGlySerIleSerTyrArgAenAlaAlaArg<
 Db 241 GCCGTGCTCGCGGTACAGTACAAAGGGGAGCATCTCGTACCGCAACGCGCGCG<
 QY 101 ProProArgArgGlyAlaThrProProAlaProProAlaProProArgGlyAla<
 Db 301 CCGCCCGCGCGGAGCCACCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG<
 QY 121 AlaAlaAlaAlaAlaProProProThrProAlaProProProProProAla<
 Db 361 GCCCG<
 QY 141 AlaAlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaAlaThrAla<
 Db 421 GCCCG<
 QY 161 SerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAla<
 Db 481 TCGCCTGGCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG<
 QY 181 ProProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgArg<
 Db 541 CCGCCCGCGCGCGCGCTCCCGCGCGGTGGCGCGCGCGCGCGCGCGCGCG<
 QY 201 ProProAlaValAlaAlaArgGluProProLeuProProProProProProPro<
 Db 601 CCGCGCGCGCTCGCGCGCGCGGAGCGCGCGCGCGCGCGCGCGCGCGCGCG<
 QY 221 ProGlnGlnGlnProProProProGlnProGlnProProProGlnGlyGly<
 Db 661 CCACAGCAGCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG<
 QY 241 ArgAlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeu<
 Db 721 CGGCG<
 QY 261 SerGlyGlyAlaGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGlu<
 Db 781 AGCGCGCGCGCGCGCGCTCGCTTAAACCGCGCGCGCGCGCGCGCGCGCG<
 QY 281 AlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaAlaLeuLeuPro<
 Db 841 CGCGCGCGCTCGAGCGCGCTCTGGAGCGCGCGCGCGCGCGCGCGCGCGCG<
 QY 301 AspArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArgSerLys<
 Db 901 GACAGCG<
 QY 321 GlyGluGluArgValLeuGluLysGluGluGluGluGluGluGluGluGluGlu<
 Db 961 GGAGAAAGAGCGAGTACTTGAAGAAAGAGAGAGAGAGAGATGATGATGAAGTGAAG<
 QY 341 GluAspAspValSerGluGlySerGluValProGluSerAspArgProAlaGly<
 Db 1021 GAAGATGATGTGTGAGAGGGCTCTGAAGTGCCCGGAGGTGACCGTCTGAGGGTG<
 QY 361 HisHisGlnLeuAsnGlyGluArgGlyProGlnSerAlaLysGluArgValLys<
 Db 1081 CACCACAGCTTAACCGCGAGCGGGACCTCAGAGTGCACAGAGAGAGGGTCAAG<
 QY 381 ThrProCysGlyProHisGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGln<
 Db 1141 ACCCGCTGCGGACCGCACCGAGGCGGAGTGAAGGCGGGGCGCGCGCGCGCG<
 QY 401 ThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyGlyThrAlaSer<
 Db 1201 ACCCGCGAGGTGTCTTCCATGGCAGCCATGAACAAAGAGAGGGGGAACAGCTTCT<

rGlyProAspSerProSerProValProLeuProProGlyLysProAlaLeuProGly 440
 CGGGGACACTCCCGCTCCCGCTTGGCCCGAGCAACACGACCTACCTGGG 1320
 aAspGlyThrProPheGlyCysProProGlyArgLysGluLysProSerAspProVal 460
 CGACGGGACCCCTTTGGCTGTCCCGCGGGCGCAAGAGAGCCATCTGATCCCGTC 1380
 uTrpThrValMetAspValValGluTyrPheThrGluAlaGlyPheProGluGlnAla 480
 GTGGACCGTGATGGATGCTGCGAATATTTTACTGAGGCTGGATTCCTCCGGAGCAGCG 1440
 rAlaPheGlnGlnGlnGluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAsp 500
 AGCTTTCAGAGCAGGAGAAATGGATGGCAATCTTTGCTGCTCATGACGCGCACAGAT 1500
 lLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuLysIleTyrGluHisHisIle 520
 GCTCACCGGCTGTCCATCCGCTCGGGCCAGCCCTGAAATCTACGAGCACCACATC 1560
 sValLeuGlnGlnGlyHisPheGluAspAspProAspGlyPheLeuGly 538
 GGTGCTTCAGCAAGCCACTTTGAGGATGATGACCCCGATGGCTTCTTAGGC 1614

9341 12425 bp DNA linear PAT 18-DEC-2003
 ence 50 from patent US 6632923.
 9341
 9341.1 GI:40160129

own.

assified.

bases 1 to 12425)

A.M., Lees, R.S., Law, S.W. and Arjona, A.A.

density lipoprotein binding proteins and their use in

nosing and treating atherosclerosis

nt: US 6632923-A 50 14-OCT-2003;

Location/Qualifiers

1. 12425

/organism="unknown"

/mol_type="genomic DNA"

1.69e-39 Length: 12425
 2616.50 Matches: 536
 ty: 69.16% Conservative: 0
 arity: 69.16% Mismatches: 2
 91.81% Indels: 239
 6 Gaps: 4

(1-538) x AR409341 (1-12425)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThrAlaAla 20
 CGGGGGCCCGCCCTTACCCCGCGGAGACGGCGCGCGCCACACCGCGGCC 2891
 aAlaSerSerAlaAlaSerProHisTyrGlnGluTyrIleLeuAspThrIleAsp 40
 CGCTCGCTGTCGCGCCCTTCCCGGCACTACCAAGATGGATCTTGACACCATCGAC 2951
 rLeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
 CTGCGCTCGGCAAGCGCGCGGACCTTGGAGCGCATCTGCCGATGGTGGCGGG 3011
 fHisGlyProGluProGluArgThrArgAlaGluLeuLysLeuIleGlnArg 80
 ACACGGCCCGAGCGAGCGACGCGCGCGAGCTCGAGAACTGATCCAGCAGCGC 3071
 aValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln 100

3072 GCCTGCTCCGGTCACTACAAGGGAGCATCTCGTACCGCAACCGCGGCGG
 101 ProProArgArgGlyAlaThrProProAlaProProArgAlaProProArgGlyAl
 3132 CCGCCCGCGCGGAGCACCCCGCGGCCCGCGCGCGCGCGCGCGCGCGCGG
 121 AlaAlaAlaAlaAlaProProProThrProAlaProProProProProAl.
 3192 GCG
 141 AlaAlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaThrAl.
 3252 GCG
 161 SerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAl.
 3312 TCGCTTGGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 181 ProProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgAr
 3372 CCG
 201 ProProAlaValAlaAlaArgGluProProLeuProProProProProProPr
 3432 CCG
 221 ProGlnGlnGlnProProProProGlnProGlnProProProGlnGlyGly
 3492 CCACAGCAGCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
 241 ArgAlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeu
 3552 CCG
 261 SerGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuGlu
 3612 AGCG
 281 AlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaAlaAlaLeuPrc
 3672 GCGCGCGCTCGAGGCGCGCTTGGAGCGCACCCCGCTCTCGAGCGCGCTTGC
 301 AspArgProGlyArgAlaProProAlaAlaSerAlaAlaArgProSerArg
 3732 GACAGCGCGGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 316
 3792 GCGCGCGGAGCG
 316
 3852 GCGAGTCCCGGAGGAACCTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTTC
 316
 3912 CTCGGTGGGTGGTGACCTTGGCAAGTGAATTGAATCTCCCGGAGCGCTCAGTTTC
 316
 3972 GTAAACGGGTTTAAACAGTAGCGACCCCTTGGGGTTGTTGAGCGAGTTTAG
 316
 4032 TTGGTTGCGAGGGCTTTAGTTAAACAGAGCCTGGCAGCGAGTGAATGCGGTAA
 316
 4092 GTCCGATTGTTCTTAAAGGTGAATCGGTTCTCTCCCGACCGCGCGGAGCGC
 317
 Ser
 |||

```

3GTCTGGATTAGAACAGCTACTAAATTTTCATGCTTCTCTCTCGGCTCCAG-AGA 4210
3lyGluGluArgValLeuGluLysGluGluGluGluAspAspGluAspGluAsp 339
3AGAGAGCGAGTACTTGAAGAAGAGAGAGATGATGATGATGATGATGATGATGAT 4270
3luAspAspValSerGluGluSerGluValProGluSerAspArgProAlaGlyAla 359
3AAGATGATGTCTCAGAGGCTCTGAAGTCCCGAGAGTACCGTCTCGAGGTGCC 4330
3HisGlnLeuGluGluArgGlyProGlnSerAlaLysGluArgValLysGlu 379
3ACACACAGCTTAAACGGCGAGCGGGACCTCAGATGCCAAGAGAGGGTCAAGGAG 4390
3ThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaProGlySer 399
3ACCCCTTGGCGACCGCACCGGCGAGGATGAAGGGCGGGGCGAGCCCGGGGCGAGC 4450
3ThrArgGlnValPheSerMetAlaAlaMetAenLysGluGlyGlyThr----- 416
3ACCGCGCAGGTGTTCTCATGGCAGCATGAACAAGGAGGGGGAACAGGTAAGGAT 4510
----- 416
3CTGGGTGGGAAGAGTGCTAGTGGAGAGGAAGTACGCCCGGAAGAACAGCCAAAG 4570
-----AlaSerValAlaThrGlyProAspSerProSerProVa 429
3GTGTTTTTTTCTTCCAGCTTCTGTGTGCCACCGGGCGAGACTCCCGGTCCCGCT 4630
3LeuProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheGlyCysPr 449
3TTTGGCCCCAGGCAACAGCCCTACCTGGGGCGGAGCCCGCTTTGGCTGTCC----- 4690
----- 449
3GTTGGGTATTGGAGACATGGGGTGCTGCTCAGGTGTGTGTACAGCCAGAGAGA 4750
-----ProGlyArgLysGluLysProS 457
3CGTGTTCACCTGGTGCTGTTGTTTGTATGTCAGTCCCGGGCGCAAGAGAGCCAT 4810
3ProValGluTrpThrValMetAspValValGluTrpPheThrGluAlaGlyPheP 477
3ATCCGTCGAGTGGACCGTGATGGATGCTCGAATATTTTACTGAGGCTGGATTCC 4870
3luGlnAlaThrAlaPheGlnGlu----- 485
3ACAGGCGACAGCTTCCACAGA-CCAGGTGAGTTTCCAGCCAGGACTACACTGA 4929
----- 485
3ACACAGGGGCTCCCTGGGATGTGCCTGATCCCGGCTTCTCTGTTCTGTCTCCCA 4989
3lnGluLeuAspGlyLysSerLeuLeuMetGlnArgThrAspValLeuThrGlyL 505
3AGAAATGATGGAATATCTTGTGCTATGACAGCGACAGATGTGCTCACCGGCC 5049
3erileArgLeuGlyProAlaLeuLysIleTyrlGluHisHisIleLysValLeuGln 525
3CCATCCGCTCGGGCAGCCCTGAAATCTACGAGCACCAATCAAGTGTCTTTCAGC 5109
3lyHisPheGluAspAspProAspGlyPheLeuGly 538
3GCCACTTTGAGGATGATGACCCCGATGGCTTCTTAGGC 5150

```

607 12425 bp DNA linear PAT 26-SEP-2001
 nce 50 from Patent WO0164874.
 607
 607.1 GI:15797282

```

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lees, A.M., Lees, R.S., Law, S.W. and Arjona, A.A.
TITLE Low density lipoprotein binding proteins and their use in d
JOURNAL Patent: WO 0164874-A 50 07-SEP-2001;
FEATURES Boston Heart Foundation, Inc. (US)
source 1..12425
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/mb_xref="taxon:9606"
ORIGIN
Alignment Scores:
Pred. No.: 1.69e-39 Length: 12425
Score: 2616.50 Matches: 536
Percent Similarity: 69.16% Conservative: 0
Best Local Similarity: 69.16% Mismatches: 2
Query Match: 91.81% Indels: 239
DB: 6 Gaps: 4
US-09-976-740-43 (1-538) x AX239607 (1-12425)
QY 1 MetAlaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThrA
Db 2832 ATGGCGGGGCCCCCGGCCCTACCCCGCGGAGACGGCGGCGCGCCACCGG
QY 21 AlaAlaSerSerSerAlaAlaSerProHisTyrGlnGluTrpIleLeuAspThrI
Db 2892 GCGCGCTGCTGCTCGCGCTTCCCGCACTACCAAGAGTGGATCTCTGACACCA
QY 41 SerLeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetVala
Db 2952 TCGTGTGCTGCGCAAGCGCGCGGACCTGGAGCGCATCTGCCGGAATGTGTC
QY 61 ArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnG
Db 3012 CGGACGCGCGCGGAGCGGAGCGCGCGCGAGCTCGAGAACTGTATCCAGC
QY 81 AlaValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgV
Db 3072 GCGGTGCTCGGCTCAGCTACCAAGGGGAGCATCTCGTACCGCAACGCGCGCGG
QY 101 ProProArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaP
Db 3132 CGGCGCGCGCGGAGCGCACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
QY 121 AlaAlaAlaAlaAlaAlaProProProProProProAlaProProProProAlaP
Db 3192 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
QY 141 AlaAlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaAlaThrAlaP
Db 3252 GCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
QY 161 SerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaA
Db 3312 TGCTGTGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
QY 181 ProProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgArgA
Db 3372 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
QY 201 ProProAlaValAlaAlaArgGluProProLeuProProProProGlnProProA
Db 3432 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG
QY 221 ProGlnGlnGlnProProProProGlnProGlnProProProGlnGlyGlyA

```


SRKAPDLERICMVRHHPETRAELEKLIQRAVLRSYKGSISYRNAARVQP
 PRGATPPAPRPGCPAAAAAPPPTTAPPPAPPAAPAAAPAAAPAAAPAAATA
 PPSGPAPGPRAPRAAPLAAPPAAPAAAPAAAPAAAPAAAPAAAPAAAPAA
 POPAPPOQQOQPPPPPOQPOPPPEGGAAGAGPARPVSLREVYLVGSSGAGRV
 LTRGRVQGLLEEAARGLERLRLGALALPRGDRPRAPPAASARAARXKAGERV
 LEKEEEEEDEDDDDDDVVSGSEVPSDRPAGAHQHLNGERGERGPOTAKERAKBW
 SLCPHPFGPEGRGAAGSTGRQVFFMAALSKEGSSASTTGPDSFSPVLPFGKPAL
 PGADGTFPGCFARKEKPADPVETWMDVVEYFEAGFPFEQATAFQEQIDGKSLILM
 QRTDVLTLGLSIRLGPALKIYEHKI KVLQQHFEDDDDEGFLG"

1.68e-39 Length: 2560
 2594.00 Matches: 503
 Y: 94.20% Conservative: 17
 rity: 91.12% Mismatches: 16
 91.02% Indels: 16
 4 Gaps: 8

(1-538) x AY453841 (1-2560)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThr---Ala 19
 3CGGGGCCCCCGGCTTACCCCGCGGACCGCGCGCGCCGCCACCGCGCGG 305
 AlaAlaSerSerAlaAlaSerProHisTyrglnGlnuTrpIleLeuAspThrIle 39
 3CGGCTCGTCTCGCGCGCTTCCCGCACTACCAAGAGTGGATTCTGGACACCATC 365
 SerLeuArgSerArgIysAlaArgProAspLeuGluArgIleCysArgMetValArg 59
 TCGCTGGCTCGCGCAAGCGCGCGCGGACCTCGAGCGCATCTGCGGATGGTGGCG 425
 ArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGln 79
 TGGACCGGCGGAGCGGAGCGGACCGCGCGCGGAGCTCGAGAACTGATCGAGCAG 485
 AlaValLeuArgValSerTyrglySerIleSerTyrglnAsnAlaAlaArgVal 99
 TCGGTCTCGCGGTGAGTACAGGGGAGCATCTCGTACCGCAACGCGCGCGCGTCC 545
 ProProArgArgGlyAlaThrProProAlaProProAlaProArgGlyAlaPro 119
 TCGCGCGCGCGCGAGCACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 605
 AlaAlaAlaAlaAlaProProProThrProAlaProProProProAlaPro 139
 ---GCCG 659
 ---AlaAlaAlaAlaProAlaArgAlaProArg-----AlaAlaAlaAlaAla 156
 TCG 719
 AlaProProSerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaPro 176
 TCG 779
 AlaAlaProProProAlaProAlaProProAlaProAlaProProAlaGlyPro 196
 TCG 839
 ArgAlaProProPro-----AlaValAlaAlaArgGluProProLeuProProPro 214
 TCG 899
 GlnProProAlaProProGlnGlnGlnGln-----ProProProProPro 229
 CAGCG 959
 ProGlnProProProGluGlyGlyAlaValArgAlaGlyGlyAlaAlaArgProVal 249
 CCACAGCGCGCGCGGAGGGGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1019

250 SerLeuArgGluValValArgTyrluGlySerGlyGlyValalaGlyGlyArgL
 1020 AGCCTCGCGGAAAGTCTGCGCTACCTCGCGGGGTAGCAGCGCGCTGCGCGCGCC
 270 ArgGlyArgValGlnGlyLeuLeuGluGluAlaAlaAlaArgGlyArgLeuG
 1080 CCGCGCGCGCTGCGAGGTCTGCTGGAAGAGAGGCGCGCGCGCGCGCGCGCTGG
 290 ThrArgLeuGlyAlaAlaLeuProArgGlyAspArgProGlyArgAlaProp
 1140 ACCGCTCTCGAGCGCTTGGCTGCGCGCGCGGAGCAGCGCGCGCGCGCGCGC
 310 AlaSerAlaArgProSerArgSerIysArgGlyGlyGluGluArgValLeuGluL
 1200 GCCAGCGCGCGCGCGCGGAAACAAGAGAGCTGGCGAGGAGCGAGTGTGTA
 330 GluGluGluAspAspAspGluAspGluAspGluGluAspAsp-----ValSerG
 1260 GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
 348 SerGluValProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuAsn-
 1320 TCGGAGGTGCGCGAGAGCGATCTGTCGCGGGGTGCGCAGCATCACCGAGCTGATG
 367 GluArgGlyProGlnSerAlaLysGluArgValLysGluTrpThrProCysGlyP
 1380 GAGCGCGCGCGCGCAGACCGCGCAAGGAGCGCGCGCGCGCGCGCGCGCGCG
 387 GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValP
 1440 CTGCGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
 407 MetAlaAlaMetAsnLysGluGlyThrAlaSerValAlaThrGlyProAsps
 1500 ATGCGCGCTTGAAGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
 427 SerProValProLeuProProGlyLysProAlaLeuProGlyAlaAlaAspGlyThrP
 1560 TCCCGCGTGCCTTTCGCGCGCGGAAAGCGCGCGCGCGCGCGCGCGCGCGCG
 447 GlyCysProProGlyArgLysGluLysProSerAspProValGluTrpThrValM
 1620 GGTGCTGCTGCGCGCGCGGAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
 467 ValValGluTyrrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnG
 1680 GTCTGGAGTACTTCCCGCGCGCGGCTTCCCTGAGCAAGCAGCGCGCTTCCAGG
 487 GluIleAspGlyLysSerLeuLeuMetGlnArgThrAspValLeuThrGlyL
 1740 GAGATCGAGCGCAAGTCCCTGCTGCTGATGAGCGCGCGCGCGCGCGCGCGCG
 507 IleArgLeuGlyProAlaLeuLysIleTyrrGluHisHisIleLysValLeuGlnG
 1800 ATCCGCTGCGCGCGCGCGGTTGAAATCTATGAGCACCATTATCAAGGTGTGCGAG
 527 HisPheGluAspAspProAspGlyPheLeuGly 538
 1860 CACTTCGAGGAGTACGATCCCGCGAGGCTTCTCTGGGA 1895

RESULT 7

AR409339 LOCUS 2561 bp DNA linear PAT 1
 DEFINITION Sequence 48 from patent US 6632923.
 AR409339 ACCESSION
 AR409339.1 GI:40160127
 AR409339.1 VERSION
 AR409339.1 SOURCE
 AR409339.1 ORGANISM
 AR409339.1 Unclassified.
 AR409339.1 Unknown.
 AR409339.1 (bases 1 to 2561)
 AR409339.1 Authors Lees, R.S., Law, S.W. and Arjona, A.A.
 AR409339.1 Title Low density lipoprotein binding proteins and their use in

```
/mol_type="genomic DNA"
```

[illegible]

```

Location/Qualifiers
1. .2561
/organism="Oryctolagus cuniculus"
/mol_type="unassigned DNA"
/db_xref="taxon:9986"
246_1898
/codon="unnamed protein product"
/note="start=1"
/protein_id="CAC88301.1"
/db_xref="GI:15797280"
/db_xref="REMBEL:PCB88301"
/db_translation="WAGPDLPPPTAAATTTAAASASSAASPHYQEWLITDLSLR
SRKARPDLIERICMVRHRHGPPESTRAELEKLIQRAVLRVSYKSGISYRNARVQP
PRRGTPAPPRPGGPAAPAAAPPTPAPPPPAAPAAAPAGPRAPPPAAVAARSPPLPP
PSPGPAQGPAPRAAPAAAPPAAPAAAPAGPRAPPPAAVAARSPPLPP
FQPPAPQQQQPPPPPPPPPPGGAAGGAPRVPVLSREVVYLGSGGAGRV
LTRGVQQLLEEEAARGLERLICALALPRGDRGPAPPAASARAANKKAGAGRV
LEKEEEEEDEDDDDVVSGESVSPEDSPAGAQHQLNGRGPGPTAKERAKEW
SLCGPHPGQEEGDEGPAAGSGTRQVSMALKEGGSASSTTGPDSFSPVPLPPGXKAL
PGADTGPCCGAGRKADPAWETVMDVVEVTFEAGFPEQATFQEQEIDGKSLILM
QRTDVLTLGSLIRLPALKIYEHHKVLOQGHFDDDDPEGFGLG"
Length: 2561
1_68e-39 Matches: 503
Identity: 94.20% Conservative: 17
Mismatches: 16
Indels: 16
Gaps: 8
(1-538) x AY239605 (1-2561)
AlaGlyProProAlaLeuProProProGluThrAlaAlaAlaAlaThrThr---Ala 19
FCGGGGCCCCCGGCCCTACCCCGCGGAGCGCGCGCGGCCACCAACGGCGCG 305
AlaAlaSerSerSerAlaAlaSerProHisTyrGlnGluTrpIleLeuAspThrIle 39
FCGGCGCTCGTGTGTCGCGCGCTCCCGCGCACTACCAAGATGGGATTCGGACACCATC 365
SerLeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArg 59
TCGTCTCGCTCGCGCAAGCGCGCGCGCGACTGGAGCGCATCTGCCGATGTGTGGCG 425
ArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGln 79
CGCACGGCGCGGAGCGGAGCGCACGCGCGCGAGCTCGAGAAATGATCCAGCAG 485
AlaValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgVal 99
FCGCTGCTCGGGTACGTCACAGGGGAGCATCTCTGATCCAGCAACGGCGCGCGCTC 545
ProProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaPro 119
CGCGCCCGCGCGGAGCCACCCCGCGGCCCGCGCGCGCGCGCGCGCGCGCGCGCC 605
AlaAlaAlaAlaAlaProProProThrProAlaProProProProProAlaPro 139
---GCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCC 659
----AlaAlaAlaAlaProAlaArgAlaProArg-----AlaAlaAlaAlaAla 156
GCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 719
AlaProProSerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaPro 176
GCCGCCCTCTGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCC 779
AlaAlaProProProAlaProAlaAlaProProAlaValAlaProProAlaGlyPro 196
CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 819

```


KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Eutele Eumalia; Eutele; Primates; Catarrhini; Hominoidea; Homi
REFERENCE	1 (bases 1 to 1470)
AUTHORS	Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Scott, Altschul, S.F., Zeeberg, B., Moore, T., Max, S.I., Wang, J., Hsi Hopkins, R.F., Jordan, H., Moore, T., Khat, S.I., Wang, J., Hsi Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Carninci, T.E., Brownstein, M.J., Ustin, T.B., Toshikiyuki, S., Carnici, P., Prange, C., Raha, S.S., Loquellano, N.A., Peter, Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, J., Fahey, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., My, Butterfield, J.S., Krzywinski, M.I., Skalska, U., Smal, A., Schnerker, A., Schein, J.E., Jones, S.J., and Marra, M.A.
TITLE	Generation and initial analysis of more than 15,000 full- length and mouse cDNA sequences
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16999-16993 (2002)
MEDLINE	22388257
PUBMED	12477932
REFERENCE	2 (bases 1 to 1470)
AUTHORS	Strausberg, R.
TITLE	Direct Submission
JOURNAL	Submitted (07-MAY-2002) National Institutes of Health, Ma Gene Collection (MGC), Cancer Genomics Office, National C Institute, 31 Center Drive, Room 11A03, Bethesda, MD 2089 USA
REMARK	NIH-MGC Project URL: http://mgc.nci.nih.gov On Aug 19, 2003 this sequence version replaced gi:2253961 Contact: MGC help desk Email: cgapbs-r@mail.nih.gov
COMMENT	Tissue Procurement: DCTD/DT CDNA Library Preparation: Rubin Laboratory CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: National Institutes of Health Intramur Sequencing Center (NISC), Gaithersburg, Maryland Web site: http://www.nisc.nih.gov/ Contact: nisc.mcg@nih.gov Ahter, N., Ayale, K., Beckstrom-Sternberg, S.M., Benjamin, E. Blakesley, R.W., Bouffard, G.G., Green, K., Brinkley, C., Br Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghghighi, P. Hansen, N., Ho, S.-L., Karlins, E., Kwong, P., Laric, P., Lega Maduro, Q.L., Masiello, C., Maskeri, B., Mastriani, S.D., McCic McDowell, J., Pearson, R., Stantirip, S., Thomas, P.J., Touc Turgeon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wigg Young, A., Zhang, L.-H. and Green, E.D.
FEATURES	Clone distribution: MGC clone distribution information ca through the I.M.A.G.E. Consortium/LLNL at: http://image.lln Series: IRAL Plate: 15 Row: m Column: 17 This clone was selected for full length sequencing becaus passed the following selection criteria: Hexamer frequenc analysis, GenomeScan gene prediction. Location/Qualifiers 1. 1470 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="IMAGE:3943601" /tissue_type="Lung, small cell carcinoma" /clone_lib="NIH MGC 7" /lab_host="DH10B-R" /note="Vector: pDOTB7"
source	

```

<1..1470
/genes="LOC90378"
/db_xref="LOCusID:90378"
<1..890
/genes="LOC90378"
/codon_start=3
/product="LOC90378 protein"
/protein_id="AAH30129.1"
/db_xref="GI:33871479"
/db_xref="LOCusID:90378"
/translation="GAARFVSLREVVYRGSGGAGRLTRGVQGLLEEAARGRL
ETRLGALPRGDRPAPRASAPRSKGGSERVLEKKEBEDDDDEEDDVS
EGSEVPESRPAGAHQHLNGERGPQSAKRVKSWTPCGHOGDGRGPAPSGTRQ
VFSMAANKGGTASVATGDPSPVPLFPKALPGADGTPFCGPKRKPSPDE
WTVMVDVVEFTAGFPPEQATFQEQIBDGKSLLMQRTDLVLTGLSLRGLKIVYEH
IKVLOQHPFEDDDPDGFLG"
648..848
/genes="LOC90378"
/notes="SAM; Region: Sterile alpha motif. Widespread domain
in signalling and nuclear proteins. In Eph-related
tyrosine kinases, appears to mediate cell-cell initiated
signal transduction via the binding of SH2-containing
proteins to a conserved tyrosine that is phosphorylated.
In many cases mediates homodimerisation"
/db_xref="CDD:smart00454"

```

```

: 4..37e-21 Length: 1470
1560.00 Matches: 295
ty: 100.00% Conservative: 0
arity: 100.00% Mismatches: 0
54.74% Indels: 0
9 Gaps: 0
(1-538) x BC030129 (1-1470)

```

```

yAlaAArgProValSerLeuArgGluValValArgTyrLeuGlyGlySerGly 263
CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
aGlyValArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGluAlaAla 283
CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
fGlyArgLeuGluThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArg 303
AGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
yArgAlaProProAlaAlaSerAlaArgProSerArgSerLeuArgGlyGlu 323
ACGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
fValLeuGluLysGluGluGluAspAspAspGluAspGluAspGluAsp 343
AGTACTTGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAT 302
lSerGlyLysGluValProGluSerAspArgProAlaGlyAlaGlnHisGln 363
fTCAGAGGGCTCTGAAGTCCCGAGAGTACCGTCTGCGAGGTGCCAGACAC 362
uAnGlyGluArgGlyProGlnSerAlaLysGluArgValLysGluTrpThr 383
fAACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 422
yProHisGlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThr 403
ACCGCACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 482
lPheSerMetAlaAlaMetAsnLysGluGlyGlyThrAlaSerValAlaThr 423
fTTCCTCATGCGAGCCATGAACAGGAGAGAGAGAGAGAGAGAGAGAGAG 542

```

```

QY 424 AspSerProSerProValProLeuProProGlyLysProAlaLeuProGlyVal:
Db 543 GACTCCCGCTGCCCGCTGCTTTCGCCCGCAGGCAACACCGCCCTACTGGGGC
QY 444 ThrProPheGlyCysProProGlyArgLysGluLysPheSerAspProValGln:
Db 603 ACCCCCTTTGGCTGCTCCTCCGGCGCAAAAGAGAGCCATCTGATCCCGTCGA
QY 464 ValMetAspValValGluTyrPheThrGluAlaGlyPheProGluGlnAlaTh:
Db 663 GTGATGGATGTCTGCAATATTTTACTGAGGCTGGATTCCTCCGAGCAGCGC
QY 484 GlnGluGlnGluLeuLeuAspGlyLysSerLeuLeuMetGlnArgThrAspVa:
Db 723 CAAGAGCAGAAATTCATGGCAATCTTTGCTGCTCATCAGCGCACAGATGY
QY 504 GlyLeuSerLeuArgLeuGlyProAlaLeuLysIleTyrGluHisIleLys:
Db 783 GGCCTGTCCATCCGCTCGGGCCAGCCCTGAAATCTACGAGCACCACATCAA
QY 524 GlnGlnGlyHisPheGluAspAspProAspGlyPheLeuGly 538
Db 843 CAGCAGGCGCACTTTGAGGATGATGACCCCGATGGCTTCTTAGGC 887

RESULT 11
AR199530
LOCUS AR199530 1617 bp DNA linear PAT
DEFINITION Sequence 11 from patent US 6355451.
ACCESSION AR199530
VERSION AR199530.1 GI:20249604
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1617)
AUTHORS Lees,A.M., Lees,R.S., Law,S.W. and Arjona,A.A.
TITLE Low density lipoprotein binding proteins and their use i
JOURNAL Patent: US 6355451-A 11 12-MAR-2002;
FEATURES Location/Qualifiers
source 1..1617
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Alignment Scores:
Pred. No.: 3,47e-19 Length: 1617
Score: 1455.50 Matches: 281
Percent Similarity: 92.86% Conservative: 18
Best Local Similarity: 87.27% Mismatches: 13
Query Match: 51.07% Indels: 10
DB: 6 Gaps: 3

US-09-976-740-43 (1-538) x AR199530 (1-1617)
QY 221 ProGlnGlnGlnGlnProProProGlnProGlnProPro-ProGluGlyGly
Db 6 CGCGAGCAGCAGCAA-----CAACCGTAGCCGAGGGGTGG
QY 240 lArgAlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLe
Db 48 GCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCT
QY 260 ySerGlyGlyAlaGlyArgLeuThrArgGlyArgValGlnGlyLeuGly
Db 108 TAGCAGCGCGCGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCTGCTG
QY 280 uAlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuPr
Db 168 GCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCTG
QY 300 yAspArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArgSerLy

```


Qy	417	aSerValAlaThrGlyProAspSerProSerProValProLeuProProGlyL	
Db	588	CTCTCGACACCGGGCCCTGACTCCCGCTCCCGGTGCCTTTGCCGCCCGGGGA	
Qy	437	aLeuProGlyAlaAspGlyThrProPheGlyCysProProGlyArgLysGluL	
Db	648	CTCCCGAGGAGCGATGGAGACCCCTTTGGCTGCCCTGCCGGGCGCAAGAGA	
Qy	457	rAspProValGluTyrThrValMetAspValValGluTyrPheThrGluAlaG:	
Db	708	AGACCCCGTGGAGTGACAGTCAATGACACTCGTGGAGTACTTCACCGAGCGCG	
Qy	477	oGluGlnAlaThrAlaPheGlnGluGlnLeuAspGlyLysSerLeuLeuL	
Db	768	TGAGCAAGCCACGGCTTTCCAGGAGCAGGAGATCGACGCAAGTCCCTCGTGC	
Qy	497	nArgThrAspValLeuThrGlyLeuSerLeuArgLeuGlyProAlaLeuLysI	
Db	828	GGCACCGATGCTCTACCGGCTGTTCATTCGCCCTGGGGGCGAGCGGTGAAAA	
Qy	517	uHisHisIleLysValLeuGlnGlnGlyHisPheGluAspAspAspProAspG	
Db	888	GCACCATATCAAGGTCTCCAGCAGGTCACTTCAGGACGATGACCCCGAAC	

9317.1 GI:40160105

own.
assified.

, A.M., Lees, R. S.

nt: US 6632923-A 11 14-OCT-2003;

1. .1617

/mot_type="genomic DNA"

:	3.47e-19	Length:	1617
	1455.50	Matches:	281
ty:	92.8%	Conservative:	18
arity:	87.2%	Mismatches:	13
	51.0%	Indels:	10
	6	Gaps:	3

oGlnGlnGlnProProProGlnProGlnProPro-GluGlyGlyAlaVala 240
|||||
3CAGCAGCAGCAA-----CAACCGCTAGCCGAAGGGTGGCGCGGC 47

rgAlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeuGlyGly 260
366CCGCGCGGCCCGCGCGGCCCGCGTGGAGCCCTCGCGGAGTGTGTCGCTACTCGGGGG 107

serGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGluGlu 280
 30ACGCGCGCGTGGCGGCGCGCTTACCGCGCGCCGCGTGCAGGGTCTCTCTGAGAGAGA 167

laalaalaargGlyArgLeuGluArgThrArgIeuGlyAlaLeuAlaLeuProArgG1 300
VGGCGGCGGGGCGCGCTTGGAGCGACCCGCTTCGGAGCGCTTGGCGCTGCCCGCGG 227

spArgProGlyArgAlaProProAlaSerAlaArgProSerArgSerLysArgGl 320
:::|:::
ACAGGCCCGSAGCGGGCGCCACCAGCAGCCCGCGGGCGCGGAACAAGAGAGC 287

Protein

IYGluClnArgValLeuGluLysGluClnAspAspGluAaspGluAaspCl	340
: : : : : : : : : : : : : : : :	
SCAGACGACGATGTCTTGAAAGAAGAGGAGGAGCGAGGAGGAACA	347

ValSerGluGlySerGluValProGluSerAspArgProAlaG 358
:::|
ACGACGACGCAGCTCGTGTTCGAGGGCTCGAGAGTGCCCGAGACGGATCGTTCGCCCGGG 407

IaGlnHisHisGlnLeuAsn---GlyCyluArgGlyProGlnSerAlaLysGluArgVa 377
GCAGCATCACACGTCTGAATGGCGGGGTCAGCGCGCCGCCGACACCGCCACGAGCGCGGC 467

36LUTrpThrProCysGlyProHisGlnGlnAspGluGlyArgGlyProAlaPr 397
 |||||:::|||||:::|||||:::|||||:::|||||:::|||||:::|||||:::
 46GAGTGTGTGTGTGTGTGCGCCGCCAACCCTGGCAGAGAGAGGCGCGCGCGCG 527

lySerGlyThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyThrAl 417
:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
ICAGTGGCACCCGCCACAGGTGTTTCATCGCGCCTTGATGATAGAGAGGGGGATCAGC 587

Qy	417	aSerValAlaThrGlyProAspSerProSerProValProLeuProProGlyL	
Db	588	CTCTCGACACCGGGCCCTGACTCCCGCTCCCGGTGCCTTTGCCGCCCGGGGA	
Qy	437	aLeuProGlyAlaAspGlyThrProPheGlyCysProProGlyArgLysGluL	
Db	648	CTCCCGAGGAGCGATGGAGACCCCTTTGGCTGCCCTGCCGGGCGCAAGAGA	
Qy	457	rAspProValGluTyrThrValMetAspValValGluTyrPheThrGluAlaG:	
Db	708	AGACCCCGTGGAGTGACAGTCAATGACACTCGTGGAGTACTTCACCGAGCGCG	
Qy	477	oGluGlnAlaThrAlaPheGlnGluGlnLeuAspGlyLysSerLeuLeuL	
Db	768	TGAGCAAGCCACGGCTTTCCAGGAGCAGGAGATCGACGCAAGTCCCTCGTGC	
Qy	497	nArgThrAspValLeuThrGlyLeuSerLeuArgLeuGlyProAlaLeuLysI	
Db	828	GGCACCGATGCTCTACCGGCTGTTCATTCGCCCTGGGGGCGAGCGGTGAAAA	
Qy	517	uHisHisIleLysValLeuGlnGlnGlyHisPheGluAspAspAspProAspG	
Db	888	GCACCATATCAAGGTCTCCAGCAGGTCACTTCAGGACGATGACCCCGAAC	

AX239568

DEFINITION

VERSION
KEYWORDS

SOURCE ORGANISMS

AUTHORS

JOURNAL

FEATURES

OBJET

Alignment

Score:

Best Local

DB:

2
-
n
n
2
2
2

©

אמר

Oy

CAGCGCGCTGGCGCCCTGACCCCGCGCGCGCTGCGAGGGTCTGCTGGAAGAGGA 167
 aAlaAaArgGlyArgLeuGluAaArgThrArgLeuGlyAlaLeuAlaLeuProArgG 300
 GCGCGCGCGCGCGCTGGAGCGACCCGCTCGAGCGCTTGCGCTGCCCGCGG 227
 pArgProGlyArgAlaProProAlaAlaSerAlaAaArgProSerArgSerLyArgG 320
 CAGCG 287
 yGluGluArgValLeuGluLyGluGluGluGluGluGluGluGluGluGluGluGlu 340
 CGAGGAGCGAGTGTGTTGAAGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 347
 uAspAsp-----ValSerGluGlySerGluValProGluSerAspArgProAlaG 358
 CGAGCAGCAGCTGCTGTCGAGGGCTCGAGGTGCCGAGAGCGATCGTCCCGCGG 407
 aGlnHisGlnLeuAsn---GlyGluArgGlyProGlnSerAlaLyGluArgVa 377
 GCAGCATCACCGAGCTGAATGCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCG 467
 sGluTrpThrProCysGlyProHisGlnGlnAspGluGlyArgGlyProAlaPr 397
 GGAGTGTGCTGCTGTGGCCCGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCG 527
 ySerGlyThrArgGlnValPheSerMetAlaAlaMetAsnLyGluGlyThrAl 417
 CAGTGGCACCGCGCGAGGTGTTCTCCATGCGCGCGCTTGAGTAAGAGAGGGGATCAGC 587
 rValAlaThrGlyProAspSerProSerProValProLeuProGlyLyProAl 437
 TTCAGCACCGCGCGCTGACTCCCGCTCCCGCGCGCGCGCGCGCGCGCGCGCG 647
 uProGlyAlaAspGlyThrProPheGlyCysProProGlyArgLyGluLyProSe 457
 CCCAGAGCGCGATGGGACCCCTTTGGCTGCGCTGCCGCGCGCGCGCGCGCGCG 707
 pProValGluTrpThrValMetAspValValGluTrpPheThrGluAlaGlyPhePr 477
 CCGCGTGGAGTGGACAGTCATGAGCGTGTGAGTACTTTCACCGAGCGCGGCTTCCC 767
 uGlnAlaThrAlaPheGlnGluGlnGluGluGluGluGluGluGluGluGluGlu 497
 GCAAGCACCGCGCTTTCAGGAGCAGAGATCGACGCGAAGTCCCTGTGCTCATGA 827
 gThrAspValLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuLyIleTyG 517
 CACCGATGTCTTACCGCGCTGTCCATCCGCTGGGCGCGCGCGCGCGCGCGCG 887
 sHisIleLyGluValLeuGlnGlyHisPheGluAspAspProAspGlyPheLe 537
 CCATATCAAGGTGTGCGAGCAGGCTCACTTCGAGACGATGACCGCGGAAGGCTTCT 947
 Y 538
 A 951

444 1617 bp DNA linear PAT 27-AUG-2002
 low density lipoprotein binding proteins and their use in
 osing and treating atherosclerosis,,

444
 444.1 GI:22602050
 01506983-A/2.
 rea victoria
 rea victoria
 yota; Metazoa; Cnidaria; Hydrozoa; Hydroids; Leptomedusae;
 reidae; Aequorea.
 ases 1 to 1617)
 A.M., Lees, R.S., Law, S.W. and Arjona, A.A.
 low density lipoprotein binding proteins and their use in

diagnosing and treating atherosclerosis
 Patent: JP 2001506983-A 2 29-MAY-2001;
 BOSTON HEART FOUNDATION INC
 PN JP 2001506983-A/2
 PD 29-MAY-2001
 PF 26-NOV-1997 JP 1998524870
 PR 27-NOV-1996 US 60/031930, 03-JUN-1997 US 60/044
 ANN M LEES, ROBERT S LEES, SIMON W LAW, ANIBAL A ARJONA PC
 A61K38/04, A61K38/17, A61K39/00, A61K48/00, A61K49/00, A61K51/
 C07H21/00,
 PC C07K7/00, C07K14/705, C12N15/12, C12Q1/02, C12Q1/68, G01P
 Strandedness: Single;
 CC Topology: Linear;
 FH Key Location/Qualifiers.
 FEATURES
 source
 1. .1617
 /organism="Aequorea victoria"
 /mol_type="genomic DNA"
 /db_xref="taxon:6100"
 ORIGIN
 Alignment Scores:
 Pred. No.: 3,47e-19 Length: 1617
 Score: 1455.50 Matches: 281
 Percent Similarity: 92.86% Conservative: 18
 Best Local Similarity: 87.27% Mismatches: 13
 Query Match: 51.07% Indels: 10
 DB: 6 Gaps: 3
 US-09-976-740-43 (1-538) x BD056444 (1-1617)
 QY 221 ProGlnGlnGlnGlnProProProGlnProGlnProPro-ProGluGlyGly
 DB 6 CGCGCAGCAGCAGCAA-----CAACCGCTAGCCGAGGCGTGGC
 QY 240 lArgAlaGlyGlyAlaAlaAaArgProValSerLeuArgGluValValArgTyLeu
 DB 48 GCGGCG
 QY 260 ySerGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGlu
 DB 108 TAGCAGCGCGCGCTGGCGCGCGCGCTGACCCCGCGCGCGCGCGCGCGCGCG
 QY 280 uAlaAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuPrc
 DB 168 GCGGCG
 QY 300 yAspArgProGlyArgAlaProProAlaAlaSerAlaAaArgProSerArgSerLy
 DB 228 GACAGCG
 QY 320 yGlyGluGluArgValLeuGluLyGluGluGluGluGluGluGluGluGluGlu
 DB 288 TGCGGAGGAGCGAGTGTGTTGAAGAAGAGAGAGAGAGAGAGAGAGAGAGAG
 QY 340 uGluAspAsp-----ValSerGluGlySerGluValProGluSerAspArgPrc
 DB 348 CGACGACGACGACGCTGCTGTCGAGGGCTCGAGGGTGCCTCGAGAGCGATCGTCCC
 QY 358 yAlaGlnHisGlnLeuAsn---GlyGluArgGlyProGlnSerAlaLyGlu
 DB 408 TGCGCAGCATCACCGAGTGAATGGCGCGAGCGCGCGCGCGCGCGCGCGCGCG
 QY 377 lLyGluTrpThrProCysGlyProHisGlnGlnGlyGlnGlyGluGlyArgGlyPro
 DB 468 CAAGGAGTGTGCTGTGTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 QY 397 oGlySerGlyThrArgGlnValPheSerMetAlaAlaMetAsnLyGluGlyGly
 DB 528 GGGCAGTGGCACCGCGCAGGTGTTCTCCATGCGCGCGCTTGTAGTAAAGAGAGG
 QY 417 aSerValAlaThrGlyProAspSerProSerProValProLeuProProGlyLy

09:28:15 2004

us-09-976-740-43.rge

CTTCGACCACCGGCGCTGACTCCCGGTCCCGGTGCTTTCCTCCCGGGAAGCCAGC 647
euProGlyAlaAspGlyThrProPheGlyCysProGlyArgLysGluLysProSe 457
TCCGAGGAGCGGATGGGACCCCTTTGGCTGCTCCCTGCGGGCGCAAGAGAGCCGGC 707
spProValGluTyrThrValMetAspValValGluTyrPheThrGluAlaGlyPhePr 477
ACCCGCTGGAGTGACAGTCAATGACGTCGTGGAGTACTTCACCGAGCGGGCTTCCC 767
luGlnAlaThrAlaPheGlnGluGlnGluLeuAspGlyLysSerLeuLeuMetGl 497
AGCAAGCCACCGCTTCCAGGAGCAGGAGATCGACGGCAAGTCCCTGCTGCTCATGCA 827
rgThrAspValLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuLysIleTyrGl 517
GCACCGATGTCTCACCGGCTGTCCATCCGCTGGGGCCAGCGTTCGAAATCTATCA 887
iHisIleLysValLeuGlnGlnGlyHisPheGluAspAspProAspGlyPheLe 537
ACCATATCAAGGTGCTGACGAGGGTCACTTCGAGGACGATGACCCGGAAGGCTTCT 947
LY 538
3A 951

: March 13, 2004, 00:37:50
41 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

leic search, using frame_plus_p2n model

March 12, 2004, 19:48:14 ; Search time 852.766 Seconds
(without alignments)
2680.137 Million cell updates/sec

US-09-976-740-43

1 MAGPPALPPETAAATAA.....HIKVLQQGHFEDDDPGFLG 538

BLOSUM62

Xgapop 10.0 , Xgapext 0.5

Ygapop 10.0 , Ygapext 0.5

Fgapop 6.0 , Fgapext 7.0

Delop 6.0 , Delext 7.0

3373863 seqs, 2124099041 residues

hits satisfying chosen parameters: 6747726

length: 0

length: 2000000000

Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

ameters:

model -DEV=xlp

Jan04 -QFMT=fastap -SUPFI=ring -MINMATCH=0.1 -LOOPCL=0

S-bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi

3N-200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15

FMT=ptc -NORW=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000

@CGN 1 1 1596 @runat 10032004 094547 19532 -NCPU=6 -ICPU=3

JERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG

-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6

DP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Geneseq 29Jan04:*

1: geneseqn1980s:*

2: geneseqn1990s:*

3: geneseqn2000s:*

4: geneseqn2001as:*

5: geneseqn2001bs:*

6: geneseqn2002s:*

7: geneseqn2003as:*

8: geneseqn2003bs:*

9: geneseqn2003cs:*

10: geneseqn2004s:*

is the number of results predicted by chance to have a
per than or equal to the score of the result being printed,
lived by analysis of the total score distribution.

SUMMARIES

Query	Match	Length	DB	ID	Description
100.0	1614	5	AAH26499		Aah26499 Human low
91.8	12425	5	AAH26495		Aah26495 Human low
91.0	2561	5	AAH26500		Aah26500 Rabbit lo
51.1	1617	5	AAH26488		Aah26488 Rabbit lo
50.9	1617	2	AAV32835		Aav32835 Rabbit lo
44.2	1336	3	AAF21860		Aaf21860 Human bre
41.8	1422	5	AAH26490		Aah26490 Rabbit lo
41.1	1208	2	AAV32838		Aav32838 Human low

9	1170	41.1	1208	5	AAH26494	Aah26494
10	1086.5	38.1	1362	5	AAH26489	Aah26489
C 11	811	28.5	1134	3	AAH26495	Aah26495
C 12	451	15.8	460	9	ADB49888	Adb49888
C 13	417	14.6	110000	4	AAI99682_39	Continuat
C 14	415	14.6	533	6	ABQ49733	Abq49733
C 15	415	14.6	533	6	ABQ49732	Abq49732
C 16	411.5	14.4	110000	4	AAI99683_39	Continuat
C 17	404	14.2	110000	4	AAI99683_09	Continuat
C 18	403.5	14.2	4650	9	ADC32422	Adc32422
C 19	402	14.1	2307	6	ABK32842	Abk32842
C 20	400	14.0	110000	4	AAI99682_09	Continuat
C 21	394.5	13.8	110000	4	AAI99682_09	Continuat
C 22	394.5	13.8	110000	4	AAI99683_09	Continuat
C 23	391	13.7	2214	2	AAV22682	Aav22682
C 24	391	13.7	3331	2	AAV22683	Aav22683
C 25	391	13.7	3331	2	AAZ32021	Aaz32021
C 26	391	13.7	3331	5	AAC90078	Aac90078
C 27	389	13.6	8438	2	AAQ73500	Aaq73500
C 28	388	13.6	110000	4	AAI99682_14	Continuat
C 29	388	13.6	110000	4	AAI99683_14	Continuat
C 30	386	13.5	1926	3	AAH50254	Aah50254
C 31	386	13.5	1926	4	AAF82902	Aaf82902
C 32	386	13.5	2580	3	AAH75454	Aah75454
C 33	386	13.5	2580	6	AAI64275	Aai64275
C 34	386	13.5	5452	2	AAH90923	Aah90923
C 35	386	13.5	8705	2	AAZ23778	Aaz23778
C 36	386	13.5	9600	2	AAV21683	Aav21683
C 37	386	13.5	10285	6	ABS71027	AbS71027
C 38	386	13.5	10285	6	ABS66453	AbS66453
C 39	386	13.5	10380	2	AAZ22248	Aaz22248
C 40	386	13.5	10596	2	AAQ51731	Aaq51731
C 41	386	13.5	10596	2	AAH15650	Aah15650
C 42	386	13.5	10596	2	AAH40348	Aat40348
C 43	386	13.5	16080	3	AAH59553	Aah59553
C 44	386	13.5	82746	7	AAH61224	Aah61224
C 45	380	13.3	110000	4	AAI99682_08	Continuat

ALIGNMENTS

RESULT 1

AAH26499

ID AAH26499 standard; DNA; 1614 BP.

XX

AC AAH26499;

XX

DT 12-NOV-2001 (first entry)

XX

DE Human low density lipoprotein binding protein 2 (LBP-2) DNA.

XX

KW Low density lipoprotein binding protein 2; LBP-2; LDL; human;

KW atherosclerosis; antiarteriosclerotic; gene therapy; diagnosis;

KW ds.

XX

OS Homo sapiens.

XX

PN WO200164874-A2.

XX

PD 07-SEP-2001.

XX

PF 28-FEB-2001; 2001WO-US006356.

XX

PR 02-MAR-2000; 2000US-00517849.

XX

PR 14-JUL-2000; 2000US-00616289.

XX

(BOST-) BOSTON HEART FOUND INC.

 XX |

PI Lees AM, Lees RS, Law SW, Arjona AA;

 XX |

DR WPI; 2001-565505/63.

 XX |

P-PSDB; AAB82806.

low density lipoprotein binding polypeptide for treating, d/or identifying therapeutic agents for atherosclerosis.

7A; 143pp; English.

sequence is that of the coding region of the human gene (see () encoding novel human low density lipoprotein binding p-2, see AAB82806). The gene was isolated from a genomic DNA LBP-2 cDNA as probe. The LBP-2 protein predicted from the sequence differs from that predicted from a cDNA clone (see that it contains an additional 321 amino acids at its N-terminus). LBP-2 nucleic acids are among the nucleotides of the invention that encode novel polypeptides corresponding to native and methylated LDL. Also claimed are polypeptides, and biologically active fragments and derivatives thereof, as well as expression vectors, cells and methods of using them. Methods of determining if an animal is at risk for LBP-2 related diseases, methods for evaluating an agent for use in treating LBP-2 related diseases, and methods for treating a cell having an abnormality in the metabolism of LBP are claimed. Pharmaceutical compositions containing LBP polypeptide or nucleic acid, and vaccine compositions, and methods of using them are also claimed.

BP; 243 A; 638 C; 564 G; 169 T; 0 U; 0 Other;

```

2.04e-69      1614
2850.00      538
:             0
ity:          0
100.00%      0
100.00%      0
100.00%      0
5             0

```

1-538) x AAH26499 (1-1614)

laGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThrAlaAla 20
CGGGGCCCCGGGCCCTACCCCGCGGAGACGGCGCGCGCCACCAACGGCGGC 60
laSerSerAlaAlaSerProHisTyrGlnGluTrpIleLeuAspThrIleAsp 40
CCTCGTCGTCGGCGGCTTCCCGCGCATCTACAGAGTGGATCTGGACACCATCGAC 120
euArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
TGCGCTCGGCCAAGCGCGACCTGAGCGCATCTGCCGATGTTGGCGCG 180
isGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnArg 80
ACGGCCGGAGCCGAGCGGACCGCGCGGAGCTCGAGAACTGATCGACGAGCG 240
allieuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln 100
TGCTCCGGGTCACTACAAGGGAGCATCTCGTACCGCAACGCGCGCGCTCCAG 300
roArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaProAla 120
CCGGCGCGGAGCACCCCGCGGCCCGCGCGGCCCGCCCGCGGGCGCCCGCGC 360
laAlaAlaAlaProProThrProAlaProProProProProAlaProVal 140
CCGCGCGCGCGCGCGCGCCACGCGCGCCCGCGCGCACCGCCCGCGCCCGTC 420
laAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaAlaThrAlaProPro 160
CCGCGCGCCCGC 480
roGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaPro 180
CTGCCCCGGCGAGCGGGCCCCCGCGCGAGCGGGCCCGCGCCCTTGGCGCGCG 540
roAlaProAlaAlaProProAlaValaProProAlaGlyProArgArgAlaPro 200

RESULT 2

RESUL 2
AAH26495AAH26493
ID AAH26495 standard: DNA: 12425 BP.

425 BP; 2563 A; 3702 C; 3566 G; 2594 T; 0 U; 0 Other;

[illegible]

Qy	477	roGluGlnAlaThrAlaPheGlnGlu-
Db	4871	CGGAGCAGCGCGACAGCTTTTCCAAGA-GCAGGTGAGTTTCCAGCCAGCACTACAC
Qy	485	-----
Db	4930	CAGACACAGAGGGCCCTCCCTGGGATGTGCTGATCCCGGCTTTCTCTGTGTTCTCTC
Qy	486	--GlnGluileAspGlyLyvsSerLeuLeuLeuMetGlnArgThrAspValLeuTr
Db	4990	CCCAGGAAATTCATGGCAAACTTTTGTCTGCTCATGCGCGCACAGATGTGCTCAC
Qy	505	euSerlleArgLeuGlyProAlaLeuLyslleTyrGluHisHislleLysValLeu
Db	5050	TGTCACATCCGCTCGGGCCAGCCCTGAAATCTACGAGCACCATCAAGGTGCT
Qy	525	lGlyHisPheGluAspAspProAspGlyPheLeuGly 538
Db	5110	AAGGCCACTTGGAGATGATGACCCCGATGGCTTCTTAGGC 5150
	RESULT 3	
	AAH26500	
ID	AAH26500	standard; cDNA; 2561 BP.
XX	AC	AAH26500;
XX		
DT	12-NOV-2001	(first entry)
XX		
DE		Rabbit low density lipoprotein binding protein 2 (LBP-2) cDNA.
KW		Low density lipoprotein binding protein 2; LBP-2; LDL; rabbit;
KW		atherosclerosis; antiarteriosclerotic; gene therapy; diagnosis;
KW		ss.
OS		Oryctolagus cuniculus.
XX		
PH		Key Location/Qualifiers
FT	CDS	246..1328
FT		/*tag= a
XX		
PN	WO200164874-A2.	
XX		
PD	07-SRP-2001.	
XX		
PF	28-FEB-2001; 2301WO-US006356.	
XX		
PR	02-MAR-2000; 2000US-00517849.	
PR	14-JUL-2000; 2000US-00616289.	
XX		
PA	(BOST-) BOSTON HEART FOUND INC.	
XX		
FI	Lees AM, Lees RS, Law SW, Arjona AA;	
XX		
DR	WPI; 2001-565505/63.	
DR	P-PSDB; AAB82807.	
XX		
FT	New isolated low density lipoprotein binding polypeptide for tre	
FT	diagnosing and/or identifying therapeutic agents for atheroscler	
XX		
PS	Claim 4; Fig 2A; 143pp; English.	
XX		
CC	The present sequence is that of cDNA encoding novel rabbit low d	
CC	lipoprotein binding protein 1 (LBP-2, see AAB82807). The cDNA wa	
CC	isolated following screening of a rabbit cDNA library for clones	
CC	LBPs that bound to both native low density lipoprotein (LDL) and	
CC	LDL. The invention provides claimed polynucleotides encoding nov	
CC	polypeptides which are capable of binding to native and methylat	
CC	the isolated polypeptides, termed LBPs, and biologically active	
CC	and analogues of them, as well as expression vectors, cells and	
CC	of producing the LBPs. Also claimed are methods of determining i	
CC	animal is at risk for atherosclerosis, methods for evaluating an	
CC	for use in treating atherosclerosis, and methods for treating a	

normality in structure or metabolism of LBP. Pharmaceutical
s comprising an LBP polypeptide or nucleic acid, and vaccine
s, are also claimed

61 BP; 372 A; 937 C; 879 G; 373 T; 0 U; 0 Other;

2.13e-62 Length: 2561
2594.00 Matches: 503
Conservative: 17
arity: 91.12% Mismatches: 16
91.02% Indels: 16
5 Gaps: 8

(1-538) x AAH26500 (1-2561)

taLaGlyProProAlaLeuProProGluThrAlaAlaAlaThrThr---Ala 19
GGGGGGCCCCCGACCTACCCCGCGGAGAGCGCGCGGCCGCCACCGCGCGCG 305
aAlaSerSerSerAlaAlaSerProHisTyrGlnGluTrpIleLeuAspThrIle 39
CGCGCGCTCGTCTGCTCGCGCTTCCCGCACTACCAAGAGTGGATTCTGGACACCATC 365
oSerLeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArg 59
CTGCTCGCTCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 425
3ArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLeuLeuGlnGln 79
3CGGCACCGCGCGGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 485
3AlaValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaVal 99
3CGCGTGTCTCGCGTACAGTACAGGCGGAGCATCTGCTACCGCAACCGCGCGCG 545
3ProProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaPro 119
3CG 605
3AlaAlaAlaAlaAlaProProProThrProAlaProProProProAlaPro 139
-----GCCG 659
3AlaAlaAlaAlaAlaProAlaArgAlaProArg-----AlaAlaAlaAlaAla 156
3CG 719
3AlaProProSerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaPro 176
3CG 779
3AlaAlaProProAlaProAlaAlaProProAlaValAlaAlaProProAlaGlyPro 196
3CG 839
3ArgAlaProProPro-----AlaValAlaAlaArgGluProProProProPro 214
3CG 899
3GlnProProAlaProGlnGlnGlnGln-----ProProProProPro 229
3CG 959
3ProGlnProProProGluGlyAlaValArgAlaGlyGlyAlaAlaArgProVal 249
3CGACAGCG 1019
3LeuArgGluValValArgTyrLeuGlyGlySerGlyAlaGlyGlyArgLeuThr 269
3CTGCGGGAAGTCTGCTGCTACCTCGCGGTAGCAGCGCGCTGGCGCGCGCTGACC 1079
3GlyArgValGlnGlyLeuLeuGluGluAlaAlaAlaArgGlyArgGluArg 289

1080 CGCGCGCGCGTGCAGGCTCTGCTGGAAGAGAGAGCGCGCGCGCGCGCGCGCTK
290 ThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaPro
1140 ACCGCTCTCGAGCGCTTGCCTGCCCCCGGGGACAGGCGCGCGCGCGCGCGC
310 AlaSerAlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuGlu
1200 GCCAGCG
330 GluGluGluAspAspGluAspGluAspGluAspGluAspGluAspGluAsp
1260 GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
348 SerGluValProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuSer
1320 TCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
367 GluArgGlyProGlnSerAlaLysGluArgValLysGluTyrThrProCysGly
1380 GAGCG
387 GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnVal
1440 CCTGCG
407 MetAlaAlaMetAsnLysGluGlyGlyThrAlaSerValAlaThrGlyProSer
1500 ATGCGCGCGCTTGAGTAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
427 SerProValProLeuProGlyLysProAlaLeuProGlyAlaAspGlyThr
1560 TCCCGCGTGCCTTTGCCCGCGCGGAGCGCGCGCGCGCGCGCGCGCGCG
447 GlyCysProProGlyArgGlyGlyLysProSerAspProValGluTyrThrVal
1620 GCTGCTGCTGCG
467 ValValGluTyrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGln
1680 GTCTGGAGTACTTCCCGAGCGCGCTTCCCTGAGCAAGCGCGCGCGCTTTCAG
487 GluIleAspGlyLysSerLeuLeuMetGlnArgThrAspValLeuThrGly
1740 GAGATCGAGCGCAAGTCTCTGCTCATGCGCGCGCGCGCGCGCGCGCGCG
507 IleArgLeuGlyProAlaLeuLysIleTyrGluHisHisIleLysValLeuGln
1800 ATCCGCTTGGCG
527 HisPheGluAspAspProAspGlyPheLeuGly 538
1860 CACTTCGAGGAGCATGATGACCGCGAGGCTTCTCTGGGA 1895

RESULT 4

AAH26488
ID AAH26488 standard; cDNA; 1617 BP.
XX AAH26488;
AC AAH26488;
DT 12-NOV-2001 (first entry)
DE Rabbit low density lipoprotein binding protein 2 (LBP-2) cDNA.
KW Low density lipoprotein binding protein 2; LBP-2; LDL; rabbit;
KW atherosclerosis; antiarteriosclerotic; gene therapy; diagnosis;
KW ss.
OS Oryctolagus cuniculus.
FH Key Location/Qualifiers
FT CDS 1..955

```

/tag= a
/partial
/note= "includes in-frame stop codon at nucleotides
28..30"

12.
2001WO-US006356.
2000US-00517849.
2000US-00616289.
DN HEART FOUND INC.
as RS, Law SW, Arjona AA;
5505/63.
2798.
low density lipoprotein binding polypeptide for treating,
nd/or identifying therapeutic agents for atherosclerosis.
ig 11; 143pp; English.
sequence is that of cDNA encoding a portion (see AAB82798) of
low density lipoprotein binding protein 2 (LBP-2). The cDNA
following screening of a rabbit cDNA library for clones
that bound to both native low density lipoprotein (LDL) and
a full-length sequence for LBP-2 is given in AAB26500. The
ovides claimed polynucleotides encoding novel polypeptides
able of binding to native and methylated LDL, the isolated
termed LBPs, and biologically active fragments and
them, as well as expression vectors, cells and methods of
LBPs. Also claimed are methods of determining if an animal
or atherosclerosis, methods for evaluating an agent for use
atherosclerosis, and methods for treating a cell having an
in structure or metabolism of LBP. Pharmaceutical
comprising an LBP polypeptide or nucleic acid, and vaccine
are also claimed
7 BP; 289 A; 513 C; 530 G; 285 T; 0 U; 0 Other;
7.73e-32 Length: 1617
1455.50 Matches: 281
92.86% Conservative: 18
87.27% Mismatches: 13
51.07% Indels: 10
5 Gaps: 3
(1-538) x AAB26488 (1-1617)
lnGlnGlnGlnProProProGlnProGlnProPro-ProdLgLyGlyAlaVa 240
AGACAGACAA-----CAACGGCTAGCGAAGGTTGGCGCGCG 47
AlaGlyGlyAlaAlaAArgProValSerIeArgLgValValArgTyrLeuGly 260
EGCGGCGCGCGCGCGCGCGCGCTGAGCGCTCGCGGAAATCGTGCCTACCTCGGGGG 107
rGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGlnGly 280
CAGCGCGCTTGGCGGCGCGCTGACCCGCGCGCGCTGCGAGGCTTCTGTGGAAGAGA 167
aAlaAaArgGlyArgLeuGluArgThrArgLeuGlyAlaAlaLeuProArgG 300
EGCGGCGCGCGCGCGCGCTGAGCGCACCGCTCGAGAGCTTGGCGTGCCTCGCGGG 227
oArgProGlyArgAlaProProAlaAaSerAlaAArgProSerArgIysArg 320
CAGCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 287

```


121 GAAGATGAAGAAGATGATGTCTCAGAGGCTCTGAAGTCCCGAGAGTGACCGTC
358 GlyAlaGlnHisGlnLeuAsnGlyuArgGlyProGlnSerAlaLysGluA
181 GGTGCCCAGCACCCAGCTTAACGCGAGCGGGACCTCAGAGTGCCCAAGGAGA

Z41 AAAGGAGTGGACCCCTGCTGGACCGCACCAAGGGCCAGGAAGAGGGCCAGGGGCCCCAG

301 GGCAGCGGCACCGCCAGGGTCTCTCAIAGGAGGCCAIGHACAHGGAHGGGGAH

418 SelvaValaAlaInnIGLyFI0A8SpSelfFI0SelfFI0ValFI0LeuFI0FI0GLyTySe

36T TCTATGCCCCACCGGGCCAGACATCCCCTGTGCCCTTTGGCCCCCAGGCATAAC

438 LEUFIQGIYATAASpelyinIFIOFHEGIVCYBFIOFIOGIYAlGtYSGIULYSF

421 C T A C C C T G G G G C C C G A C G G G A C C C C C C T T T G G C T G T C C C C C G G G C G C A T A A G A G A A G C

458 AspprovalGluTrpThrValMetAspValValGluTyrPheThrGluAlaGlyP

481 GATCCGTCGAGTSGACCGTCGATGGATGCTCGAATATTTTACTGAGCGTGGAT
478 GluGlnAlaThrAlaPheGlnGluGlnGluLeuAspGlyLysSerLeuLeuLeuM

THE

458 HisGluHisLeuValLeuGlnGlnGlyHisPheGluAspAspProAspGlyP
459 HisGluHisLeuValLeuGlnGlnGlyHisPheGluAspAspProAspGlyP
601 CGCACAGATGTGCTACCGGCGCTGTCCATCCGCTCGGGCCAGCCCTGAAAAATCT
518 HisHisIleLysValLeuGlnGlnGlyHisPheGluAspAspProAspGlyP
661 CACCACATCAAGGTGCTTCAGCAGGCCACTTTGAGGATGATGACCCCGATGGCT
538 Gly 538
721 GGC 723
1490 standard; cDNA; 1422 BP.
1490;
OV-2001 (first entry)

at low density tripropylene blending process 3 (LBF-3) CDA.

Location/Qualifiers
1.955

$\partial \text{Lag} = \alpha$
/partial

164874-A2.
BP-2001.

98B-2001; 2001WO-US006356.
98R-2000; 2000US-00517849.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

5490 standard; cDNA; 1422 BP.

5490;

PV-2001 (first entry)

at low density lipoprotein binding protein 3 (LBP-3) cDNA.

density lipoprotein binding protein 3; LBP-3; LDL; rabbit; atherosclerosis; antiarteriosclerotic; gene therapy; diagnosis;

Colagus cuniculus.

Location/Qualifiers

1. .955

/*tag= a

$$\frac{\partial}{\partial \text{partial}}$$

0164874-A2.

EP-2001.

EB-2001; 2001WO-US006356.

BR-2000: 2000US-00517849.

UK-2000: 2000US-00317849.
IL-2000: 2000US-00616289.

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

ees RS, Law SW, Arizona AA;

82800.

Fig 13; 143pp; English.

22 BP: 265 A: 447 C: 442 G: 268 T: 0 U: 0 Other:

(1-538) x AAH26490 (1-1422)

rArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaProProAla 309
CGTCTCCGAGCGCTTTGCGTGTCCCGCGGGGACAGCGCCGGACCGCGGCACCGGGC 60
aSerAlaArgProSerArgSerIysArgGlyGlyGluGluArgValLeuGluLysGlu 329
TAGCGCCCGCGCGCGGACCAAGAGACTGGGAGGACGAGTGTCTGAAGAAGGAG 120
gGluGluAspAspAspGluAspGluAspGluAspGluAspAsp-----ValSerGluGly 347
GAGAGGAGGAGGAGGAGGAGACACACGAGGACGACGACGACGCTGTGTCCGAGGGC 180
rGluValProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuAsn--Gly 366
GAGAGTGTCCCGAGAGCGATCGTCCCGGGGTGGCAGCATCACAGCTGAATGGCGGC 240
rArgGlyProGlnSerAlaLysGluArgValLysGluTyrThrProCysGlyProHis 386
GCGCGCGCCGCGACCGCCAAAGAGCGGGCCAAAGGAGTGTGTGTGGCCCCCAC 300
rGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValPheSer 406
TGCCAGAGAGAAAGGCGGGGGCGCGCGCGCGCATGTGGACCCCGCAGGTGTCTCC 360
rAlaAlaMetAsnLysGluGlyGlyThrAlaSerValAlaThrGlyProAspSerPro 426
GCGCGGCTTGAGTAAGGAGGGGGGATCAGCTCTTCGACCAACCGGGGCTGACTCCCG 420
rProValProLeuProProGlyLysProAlaLeuProGlyAlaAspGlyThrProPhe 446
CCGGTGGCTTTTGCCCCCGGGGAAGCAGCGCTCCGAGGAGCGGATGGGACCCCTTT 480
rCysProProGlyArgLysGluLysProSerAspProValGluTyrThrValMetAsp 466

ATCGAGCGCAAGTCCCTGCTGCTCATGACGCGACCGATGCTCTCCACCGCCTGTGCC 600
 ArgLeuGlyProAlaLeuLysIleTyrGluHisIleLysValLeuGlnGlnGly 526
 CGCTGGGCGCCAGCGTTGAAATCTATGACCAATATCAAGTGTCTGACGAGGT 560
 pheGluAspAspAspProGlyPheLeuGly 538
 CTCGAGGACGATGACCGCGAAGGCTTCTCTGGGA 696

idard; cDNA; 1134 BP.

(first entry)

ad protein gene 9 SEQ ID NO:19.

ed protein; diagnosis; neuroprotective; cytotatic;
 imunomodulatory; muscular active general; vulnerary;
 inal; nephrotropic; antiinfective; synaecological;
 rial; gene therapy; detection; cancer; chromosome marker;
 lentification; neural disorder; immune disorder;
 order; reproductive disorder; gastrointestinal disorder;
 order; cardiovascular disorder; renal disorder;
 disorder; wound healing; infectious disease; preservative;
 ; 88.

1.

2000WO-US006822.

99US-0126054P.
 99US-0169916P.

GENOME SCI INC.

iben SM, Komatsoulis G;
 7666/55.
 1307.

ad proteins and gene sequences encoding them, useful for
 reventing, and treating disorders such as cancer,
 disorders and immune system disorders.

344; 429pp; English.

sotide sequences given in AAC59566 to AAC59614 encode the
 ad proteins given in AAB34299 to AAB34347. AAB34348 to
 resent human secreted polypeptide sequences and proteins
 them, which are given in the exemplification of the present
 man secreted proteins have activities based on the tissues
 genes are expressed in. Example of activities include:
 ive; cytostatic; cardioactive; immunomodulatory; muscular
 al; vulnerary; gastrointestinal; nephrotropic; antiinfective;
 al; and antibacterial. The polynucleotides can be used for
 n of various disorders such as cancer, chromosome
 on, as chromosome markers, and for numerous other diagnostic
 purposes. The secreted proteins can be used to treat
 ch as neural, immune, muscular, reproductive,
 inal, pulmonary, cardiovascular, renal, and proliferative
 und healing, and infectious diseases. The proteins can also
 food additive or preservative to increase or decrease
 bilities. AAC59557 to AAC59565 and AAB34298 represent
 ed in the exemplification of the present invention

SQ Sequence 1134 BP; 248 A; 294 C; 366 G; 225 T; 0 U; 1 Other;

Alignment Scores:
 Pred. No.: 1,46e-14 Length: 1134
 Score: 811.00 Matches: 151
 Percent Similarity: 100.00% Conservative: 1
 Best Local Similarity: 99.34% Mismatches: 0
 Query Match: 28.46% Indels: 0
 DB: 3 Gaps: 0

US-09-976-740-43 (1-538) x AAC59574 (1-1134)

QY 387 GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValp
 Db 921 CAGGCGCAGGATGAAGGGCGGGGCGAGCCCGGGGCGAGCGGACCGCGCAGGTGT
 QY 407 MetAlaAlaMetAsnLysGluGlyThrAlaSerValAlaThrGlyProAsps
 Db 861 ATGGCAGCCATGAACAAGGAAGGGGGAACAGCTTCTTGTGCCACCGGGCCAGACT
 QY 427 SerProValProLeuProGlyLysProAlaLeuProGlyValaAspGlyThrp
 Db 801 TCCCGCGTGCCTTGGCCCGCCAGGCAACAGCCCTACTTGGGGCGCAGCGGTCCC
 QY 447 GlyCysProProGlyArgLysGluLysProSerAspProValGluTrpThrValM
 Db 741 GGCTGTCTCTCCCGGCGCAAGAGAGCCATCGATCCCGTGGAGTGAGCCGTGA
 QY 467 ValValGluTyrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnG
 Db 681 GTCTGCGAATATTTTACTGAGGCTGGATTCCCGGAGCAGCGGACAGCTTTCGAG
 QY 487 GluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGlyL
 Db 621 GAAATTGATGCAANTCTTTGCTGCTCATGACGCGCACAGATGTGCTCACCAGCC
 QY 507 IleArgLeuGlyProAlaLeuLysIleTyrGluHisIleLysValLeuGlnG
 Db 561 ATCCGCTCGGGCCAGCCCTGAAATCTACGAACACCAACATCAAGGTGCTTCAGC
 QY 527 HisPheGluAspAspProGlyPheLeuGly 538
 Db 501 CACTTGTAGGATGATGACCCCGATGCTTCTTAGGC 466

RESULT 12
 ADB49888/c
 ID ADB49888 standard; DNA; 460 BP.
 XX
 AC ADB49888;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Primary rat hepatocyte toxicity modelling related gene SEQ ID NO
 XX
 KW toxic effect; gene expression profile; hepatotoxicity; diagnosti
 KW toxicity marker; toxicity progression; drug screening;
 KW Primary rat hepatocyte toxicity modelling; gene; ds.
 OS Rattus norvegicus.
 XX
 PN WO2003065993-A2.
 XX
 PD 14-AUG-2003.
 XX
 PF 04-FEB-2003; 2003WO-US003482.
 XX
 PR 04-FEB-2002; 2002US-0353171P.
 PR 13-MAR-2002; 2002US-0363534P.
 PR 08-APR-2002; 2002US-0370248P.
 PR 10-APR-2002; 2002US-0371134P.
 PR 10-APR-2002; 2002US-0371135P.
 PR 10-APR-2002; 2002US-0371150P.
 PR 11-APR-2002; 2002US-0371413P.

uTrpThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaProGly 398
 : : : : :
 STGGTCGCCCTGTGGACCTTTCAGGCGCCAGGATGAAGGCGCGGGACCAGCACTGC 400

 rGlyThrArgGlnValPheSerMetAlaIleMetAsnLysGluGlyValThrAlaSer 418
 : : : : :
 CTCACACACCAGTGTTCTTCGATGACAGCTATGAAATAAGAGGGGGATCGCCTGTG 340

 lAlaThrGlyProAspSerProSerProValProLeuProProGlyLysProAlaLeu 438
 : : : : :
 TACAGCTGCTGCCAGATTCTCCATTCTCGTGCCTTTGCTCCAGGAAAACAGCCCTTA 280

 oGlyAlaAspGlyThrProPheGlyCysProProGlyArgLysGluLysProSerAsp 458
 : : : : :
 TGSGGCTGATGGACACCATTTGGCTGTCTCTCTGGCGGCAGAGAGCACCAAGCAC 220

 oValGluThrTrpValMetAspValvalGluTyrrPheThrGluAlaGlyPheProGlu 478
 AGTGGAGTGGACAGTCATGGATGTGGT-----TTTCCTGT 178
 -----TTTCCTGT

[illegible]

[illegible][illegible]

09:28:16 2004

us-09-976-740-43.rng

CGACCTACCCCGCGGAAACGACGACGACCGCCACACGACGACCGCGCGCTCG 343
SerAlaIaSerProHisTyrGlnGluTyrIleLeuAspThrIleAspSerLeuArg 43
TCGCGCGCTTCGCGGCACTACCAAAATAATCTAAACACCATCGACTCGCTACGC 283
ArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArgArgHisGly 63
TCGAAACGCGGACCGAACCTAAACGCTCTACCGATATATACGACGACGACGAC 223
GluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGlnArgAlaValLeu 83
AAACCGAAACGCGACGCGCGGCACTCGAAAACTAATCCAACAAACGCGCGTACTC 163
ValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGlnProProArg 103
ATCAACTACAAAAAAACATCTGTACCGAACGCGACGCGCGTCCAAACCGCCCGA 103
GlyAlaThrPro-ProAlaProPro 112
GAACACCGCGCTCCGAATCCACCG 75

March 12, 2004, 21:10:03
6 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

leic search, using frame_plus_p2n model

March 12, 2004, 20:05:17 ; Search time 182.406 Seconds
(without alignments)
1636.805 Million cell updates/sec

US-09-976-740-43

2850
1 MAGPPALPPETAAATTA.....HIKVLQQHFDDDPDGLG 538

BLOSUM62

Xgapop 10.0 , Xgapext 0.5

Ygapop 10.0 , Ygapext 0.5

Fgapop 6.0 , Fgapext 7.0

Delop 6.0 , Delext 7.0

682709 seqs, 277475446 residues

hits satisfying chosen parameters: 1365418

ength: 0

ength: 2000000000

Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

ameters:

n.model -DEV=xlp
spool p/US09976740/runat 10032004 094549 19564/app query.fasta_1.1898
ts NA -QFMT=fastap -SUFFIX=rni -MINMATCH=0.1 -LOPCL=0
S=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human0.cdi
SN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15
FMT=pto -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
@CGN 1 1 235 @runat 10032004 094549 19564 -NCPU=6 -ICPU=3
JERY -NEG_SCORES=0 -WAIT -DSPLOCK=100 -LONGLOG
-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
CP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Issued Patents NA:*

- 1: /cgn2_6/ptodata/2/ina/5A_COMB.seq:*
- 2: /cgn2_6/ptodata/2/ina/5B_COMB.seq:*
- 3: /cgn2_6/ptodata/2/ina/6A_COMB.seq:*
- 4: /cgn2_6/ptodata/2/ina/6B_COMB.seq:*
- 5: /cgn2_6/ptodata/2/ina/ptus_COMB.seq:*
- 6: /cgn2_6/ptodata/2/ina/backfiles1.seq:*

is the number of results predicted by chance to have a
ter than or equal to the score of the result being printed,
ived by analysis of the total score distribution.

SUMMARIES

Query	Match	Length	DB	ID	Description
100.0	1614	4	US-09-616-289-45		Sequence 45, Appl
91.8	12425	4	US-09-616-289-50		Sequence 50, Appl
91.0	2561	4	US-09-616-289-48		Sequence 48, Appl
51.1	1617	4	US-08-979-608A-11		Sequence 11, Appl
51.1	1617	4	US-09-517-849-11		Sequence 11, Appl
51.1	1617	4	US-09-616-289-11		Sequence 11, Appl
41.8	1422	4	US-08-979-608A-13		Sequence 13, Appl
41.8	1422	4	US-09-517-849-13		Sequence 13, Appl
41.8	1422	4	US-09-616-289-13		Sequence 13, Appl
41.1	1208	4	US-08-979-608A-16		Sequence 16, Appl
41.1	1208	4	US-09-517-849-16		Sequence 16, Appl
41.1	1208	4	US-09-616-289-16		Sequence 16, Appl

13	1086.5	38.1	1362	4	US-08-979-608A-12	Sequenc
14	1086.5	38.1	1362	4	US-09-517-849-12	Sequenc
15	1086.5	38.1	1362	4	US-09-616-289-12	Sequenc
C 16	417	14.6	4411529	3	US-09-103-840A-1	Sequenc
C 17	411.5	14.4	4403765	3	US-09-103-840A-2	Sequenc
C 18	394.5	13.8	4403765	3	US-09-103-840A-2	Sequenc
C 19	394.5	13.8	4411529	3	US-09-103-840A-1	Sequenc
C 20	391	13.7	2214	3	US-08-864-038A-1	Sequenc
C 21	391	13.7	3331	3	US-08-864-038A-2	Sequenc
C 22	391	13.7	3331	3	US-08-864-038A-4	Sequenc
C 23	390	13.7	425	4	US-09-621-976-9791	Sequenc
C 24	389	13.6	8438	1	US-07-945-283-1	Sequenc
C 25	386	13.5	1926	4	US-09-249-585A-2	Sequenc
C 26	386	13.5	1926	4	US-09-410-399-3	Sequenc
C 27	386	13.5	2580	3	US-09-050-863-2	Sequenc
C 28	386	13.5	2580	3	US-09-359-081-2	Sequenc
C 29	386	13.5	5452	2	US-09-130-114-1	Sequenc
C 30	386	13.5	8705	4	US-09-647-344A-14	Sequenc
C 31	386	13.5	9600	3	US-08-910-647-1	Sequenc
C 32	386	13.5	9600	4	US-09-620-925-1	Sequenc
C 33	386	13.5	10596	1	US-07-884-811-15	Sequenc
C 34	386	13.5	10596	1	US-07-885-971-15	Sequenc
C 35	386	13.5	10596	1	US-08-087-783A-15	Sequenc
C 36	386	13.5	10596	1	US-08-194-088B-15	Sequenc
C 37	386	13.5	10596	2	US-08-194-088B-15	Sequenc
C 38	386	13.5	10596	5	PCT-US93-04648-15	Sequenc
C 39	386	13.5	16080	4	US-09-724-566A-48	Sequenc
C 40	372.5	13.1	2481	4	US-09-894-998A-35	Sequenc
C 41	360	12.6	2793	1	US-08-209-747-1	Sequenc
C 42	360	12.6	2793	1	US-08-458-298-1	Sequenc
C 43	357	12.5	71989	3	US-09-443-501A-2	Sequenc
C 44	352	12.4	33529	3	US-09-144-085-3	Sequenc
C 45	351.5	12.3	12001	1	US-08-458-568A-11	Sequenc

ALIGNMENTS

RESULT 1
US-09-616-289-45
; Sequence 45, Application US/09616289
; Patent No. 6632923
; GENERAL INFORMATION:
; APPLICANT: Lees, Ann M.
; APPLICANT: Lees, Robert S.
; APPLICANT: Law, Simon W.
; APPLICANT: Arjona, Anibal A.
; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
; TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TRE
; TITLE OF INVENTION: ATHEROSCLEROSIS
; FILE REFERENCE: 10797-004001
; CURRENT APPLICATION NUMBER: US/09/616,289
; CURRENT FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 09/517,849
; PRIOR FILING DATE: 2000-03-02
; PRIOR APPLICATION NUMBER: US 08/979,608
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: US 60/031,930
; PRIOR FILING DATE: 1996-11-27
; PRIOR APPLICATION NUMBER: US 60/048,547
; PRIOR FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 45
; LENGTH: 1614
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)...(1614)
US-09-616-289-45
Alignment Scores: 7.45e-100 Length: 1614
Pred. No.:

	2850.00	Matches:	538
Identity:	100.00%	Conservative:	0
Similarity:	100.00%	Mismatches:	0
Indels:	0	Indels:	0
Gaps:	0	Gaps:	0
(1-538) x US-09-616-289-45 (1-1614)			
AlaGlyProProAlaLeuProProGluThrAlaAlaAlaThrThrAlaAla	20		
CGCGGCGCCCGCGCTTACCCCGCGAGACGGCGCGGCCACACGCGCGCC	60		
AlaSerSerSerAlaAlaSerProHisTyrGlnGluTrpLleLeuAspThrIleAsp	40		
GCCTCGTCGTCCGCGCGCTTCCCGCACTTACCAGAGTGGATCTCTGGACACCATCGAC	120		
LeuArgSerArgLysAlaArgProAspLeuGluArgLleCysArgMetValArgArg	60		
CTCGCGCTCGCGCAAGGCGCGCGCGACCTGGAGCGCATCTCCCGATGGTGTGGCGGG	180		
HisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGlnArg	80		
CACGCGCGGAGCGGAGCGCACGCGCGCGAGCTCGAGAAATGTATCCAGCAGCGC	240		
ValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln	100		
GTGCTCGGGTCACTACAGGGGAGCATCTCTGATCCGCAACGCGCGCGGTCCAG	300		
ProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyValaProAla	120		
CCCGCGCGGAGGCCACCCGCGCGCCCGCGCGCGCCCGCGCGCGCGCGCGCGCC	360		
AlaAlaAlaAlaProProProThrProAlaProProProProProAlaProVal	140		
CGCGCGCGCGCGCGCGCGCGCACGCGCGCGCGCGCGCGCGCGCGCGCGCGC	420		
AlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaThrAlaProPro	160		
CGC	480		
ProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaAlaPro	180		
CTTGC	540		
ProAlaProAlaAlaProProAlaAlaProProAlaGlyProArgArgAlaPro	200		
CCCGCGCGCGCGCTCCCGCGCGGTGGCGCGCGCGCGCGCGCGCGCGCGCGC	600		
ProAlaValAlaAlaArgGluProProLeuProProProProGlnProProAlaPro	220		
CCCGCGCTCGCGCGCGGAGCGCGCTGCGCGCGCGCGCGCGCACAGCGCGCGCGCG	660		
GlnGlnGlnGlnProProProProGlnProGlnProProProGluGlyGlyAlaVal	240		
CACACACAGACGCGCGCGCGCGCGCACAGCGCGCGCGCGCGAGGGGGCGCGGTG	720		
AlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeuGlyGly	260		
GC CGCGCGCGCGCGCGCGCGCTGAGCCCTCGGGAGTGTGTGCGTACTCTCGGGGGC	780		
GlyGlyAlaGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGlu	280		
GGCGCGCGCGCGCGCTTACCCCGCGCGCGCGCGCTGAGGGGCTCTGGAGGAGGAG	840		
AlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuProArgGly	300		
GC CGCTCGAGCGCGCTCTGGAGCGCACCCGCTCGGAGCGCTTGTGCGCTGCCCGCGCGG	900		
ArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArgSerLysArgGly	320		
AGGCGCGGAGCGGGC	960		
GluGluArgValLeuGluLysGluGluGluAlaGluAspAspGluAspGluAspGlu	340		

961	Db	GGAGAAGAGCCGAGTACTTTGAGAAAGAGAGAGAAAGATGATGAAGATGAAG	
341	QY	GluAspAspValSerGluGlySerGluValProGluSerAspArgProAlaGlyA	
1021	Db	GAAGATGATGTGTACAGAGGGCTCTGAAGTGCCCGAGAGTGACCGTCTCTG	CAGGTG
361	QY	HisHisGlnLeuAsnGlyClnArgGlyProGlnSerAlaIysGluArgValIysG	
1081	Db	CACCACCAGCTTAAACGGCGAGCGGGAGCCTCAGAGTGCCCAAGGAGAGGGTCA	AGG
381	QY	ThrProCysGlyProHisGlnGlyClnAspGluGlyArgGlyProAlaProGlyS	
1141	Db	ACCCCTCTGGGACCGCACACAGGGCCAGGATGAAGGCGGGGGCCAGCCCCGG	GGCA
401	QY	ThrArgGlnValPheSerMetAlaAlaMetAsnIysGluGlyThrAlaSerV	
1201	Db	ACCCGCCAGGTGTCTTCATGCGACCATGAACAAAGAAAGGGGGAAACAGCT	TCCTG
421	QY	ThrGlyProAspSerProSerProValProLeuProGlyLysProAlaLeuP	
1261	Db	ACCGGGCCAGACTCCCGCTCCCGCTTGCTTGGCCCCCAGGCAAAACAGCCCT	TAC
441	QY	AlaAspGlyThrProPheGlyCysProProGlyArgIysGluIysProSerAspF	
1321	Db	GCCGACGGGACCCCTTTGGCTGTCCGCGCGGGCGCAAGAGAGACCATCTG	ATCTG
461	QY	GluTrpThrValMetAspValValGluTyrPheThrGluAlaGlyPheProGluG	
1381	Db	GAGTGGACGGTGATGGATGCTCGAATATATTTTACTGAGGCTGATTTCCCG	GGAGC
481	QY	ThrAlaPheGlnGluGlnGluIleAspGlyLysSerLeuLeuLeuMetGlnArgT	
1441	Db	ACAGCTTTCCAAAGACAGCAAAATGATGGCAAAATCTTTGCTGCTCATGCA	CGCGCA
501	QY	ValLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuIysIleTyrGluHisH	
1501	Db	GRGCTACCGGCGCTGCTCATCCGCTCGGGCCAGCCCTGAAATATCTACGAG	CAACC
521	QY	LysValLeuGlnGlnGlyHisPheGluAspAspProAspGlyPheLeuGly	
1561	Db	AAAGTGTCTTACGACGACCATTTTGAGATGATCAACCCCGATGGCTCTTAG	CGC

RESULT 2

```

RESULT 2
US-09-616-289-50
; Sequence 50, Application US/09616289
; Patent No. 6632923
; GENERAL INFORMATION:
; APPLICANT: Lees, Ann M.
; APPLICANT: Lees, Robert S.
; APPLICANT: Law, Simon W.
; APPLICANT: Arjona, Anibal A.
; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
; TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREA
; TITLE OF INVENTION: ATHEROSCLEROSIS
; FILE REFERENCE: 10797-004001
; CURRENT APPLICATION NUMBER: US/09/616,289
; CURRENT FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 09/517,849
; PRIOR FILING DATE: 2000-03-02
; PRIOR APPLICATION NUMBER: US 08/979,608
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: US 60/031,930
; PRIOR FILING DATE: 1996-11-27
; PRIOR APPLICATION NUMBER: US 60/048,547
; PRIOR FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 12425
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-616-289-50

```


1:	2.16e-90	Length:	12425
	2616.50	Matches:	536
ty:	69.16%	Conservative:	0
arity:	69.16%	Mismatches:	2
	91.81%	Indels:	239
	4	Gaps:	4

(1-538) x US-09-616-289-50 (1-12425)

```

tAlaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThrAlaAla 20
'GGCGGGCCCCCGGCCCTACCCCGCCGGAGAGCGCGCGCCACCACCGCGGCC 2891
aAlaSerSerAlaAlaSerProHisTyrGlnGluTrrPileLeuAspThrIleAsp 40
'CGCTCGTTCGTCGCGCGCTTCGCCGCACTACCAAGAGTGGATCTCTGGACACCATCGAC 2951
rLeuArgSerArgLysAlaArgProAspLeuGluArgGleCySArgMetValArgArg 60
'GCTGCGCTCGCGCAAGCGCGCGCGGACCTGGAGCGCATCTGCCCGATGGTGGCGCGG 3011
gHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnArg 80
'GCACGCCCGGAGCGGAGCGCAGCGCGCGCGAGTCGAGAAATGTATCCAGCAGCGC 3071
aValLeuArgValSerTyrIlySglySerIleSerTyrArgAsnAlaAlaArgValGln 100
'CTGTCTCCGGGTAGCTACAAAGGGGAGCATCTCGTACCGCAACCGCGCGCGCTCCAG 3131
oProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaProAla 120
'GCCCGCGCGGAGGCCACCCCGCGCGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCG 3191
aAlaAlaAlaAlaProProProThrProAlaProProProProProAlaProVal 140
'CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGTC 3251
aAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaAlaThrAlaProPro 160
'CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 3311
rProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaAlaPro 180
'GCCTGGCCCCGCGAGCGCGGCCCCCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCG 3371
oProAlaProAlaProProAlaValAlaProProAlaGlyProArgAlaPro 200
'GCCCGCGCGCGCGCTCCCCCGCGGTGGCGCCCCCGCGCGCGCGCGCGCGCGCGCG 3431
oProAlaValAlaAlaArgGluProProLeuProProProProProGlnProProAlaPro 220
'GCCCGCGGTGCGCGCGCGGAGCGCGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 3491
oGlnGlnGlnProProProGlnProGlnProProProGluGlyGlyAlaVal 240
'ACAGCAGCAGCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGGTG 3551
gAlaGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeuGlyGly 260
'GGCGCGCGCGCGCGCGCGCGCGGTGAGCTCGCGGAAGTCGTGCGCTACCTCGGGGCG 3611
rGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGlu 280
'CGCGCGCGCGCGCGGTGCGCTTAACCGCGCGCGCGCGCGCGCGCGCGCGCGCGTCTGAGAGAGAG 3671
aAlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuProArgGly 300
'GGCGGCTCGAGCGCGTCTGAGGCGCACCGCTCTTCGAGCGCGCTTGGCGCTGCCCCCGCG 3731
pArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArg----- 316

```

```

luGlnAlaThrAlaPheGlnGlu----- 485
|||
366 GACTCGTGGCTCGCGCAGCGCGCGCGACCTCGAGCGCATCTGCGCGATGG
|||
QY 60 ArgArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLeuLeuLeuG
|||
Db 426 CGCGCGCACGGCGCGAGCGCGAGCGCACGCGCGCGAGCTCGAGAACTGATCC
|||
QY 80 ArgAlaValLeuArgValSerTyrIysGlySerIleSerTyrArgAsnAlaAla
|||
Db 486 CGCGCGTGTCTCGGTCAGCTACAGGGGAGCATCTCGTACCGCAACGGCGGC
|||
QY 100 GlnProProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyA
|||
Db 546 CAGCGCGCGCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 120 AlaAlaAlaAlaAlaAlaProProProProThrProAlaProProProProProA
|||
Db 606 -----GCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 140 Val---AlaAlaAlaAlaProAlaArgAlaProArg-----AlaAlaAlaAla
|||
Db 660 GTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 157 ThrAlaProProSerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaA
|||
Db 720 ACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 177 LeuAlaAlaProProProAlaProAlaAlaProProAlaValAlaProProAlaG
|||
Db 780 CTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 197 ArgArgAlaProProPro-----AlaValAlaAlaArgGluProProLeuProp
|||
Db 840 CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 215 ProGlnProProAlaProProGlnGlnGln-----ProProp
|||
Db 900 CCACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 230 GlnProGlnProProProGluGlyAlaValArgAlaGlyGlyAlaAlaArgP
|||
Db 960 CAGCCACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 250 SerLeuArgGluValValArgTyrLeuGlyGlySerGlyValAlaGlyGlyArgL
|||
Db 1020 AGCTTGGGGAAAGTCTGTCGCTACCTCGGGGGTAGCAGCGCGCGCGCGCG
|||
QY 270 ArgGlyArgValGlnGlyLeuLeuGluGluAlaAlaAlaArgGlyArgLeuG
|||
Db 1080 CGCGCGCGCGTGCAGGGTCTGCTGGAAGAGAGAGCGCGCGCGCGCGCGCG
|||
QY 290 ThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaProp
|||
Db 1140 ACCCGTCTCGAGCGCTTGCCTGCCCGCGGGGACAGGCCCGGAGCGGGCGCAC
|||
QY 310 AlaSerAlaArgProSerArgSerIysArgGlyGlyGluGluArgValLeuGluL
|||
Db 1200 GCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 330 GluGluGluAspAspGluAspGluAspGluGluGluGluGluGluGluGluG
|||
Db 1260 GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
|||
QY 348 SerGluValProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuAsn-
|||
Db 1320 TCGAGGTGTCGCGAGCGCATCTCGCGCGGTGCGCGCATCACCAGCTGAATG
|||
QY 367 GluArgGlyProGlnSerAlaLysGluArgValLysGluThrProCysGlyP
|||
Db 1380 GAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
|||
QY 387 GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValP

```

```

luGlnAlaThrAlaPheGlnGlu----- 485
|||
ACGAGCGCAGACTTTCACAGA-GCAGGTGAGTTTCCAGGCCAGGACTACACTGA 4929
|||
----- 485
ACACAGAGGGCGCTCCCTCGGATGTCCTGATCCCGGCTTTCCTGTCTCTGTCCTCCCA 4989
|||
lmgIleAspGlyLysSerLeuLeuMetGlnArgThrAspValLeuThrGlyL 505
|||
AGGAAATTGATGGCAATCTTTGCTGCTCATGAGCGCACAGATGTGCTCACCAGGC 5049
|||
erIleArgLeuGlyProAlaLeuLysIleTyrGluHisHisIleLysValLeuGlnG 525
|||
CCATCCGCGCTCGGGCAGCGCTGAAATCTACAGGACACCATCAGAGTCTTTCAGC 5109
|||
lyHisPheGluAspAspProAspGlyPheLeuGly 538
|||
CCACTTTGAGGATGATGACCGCGATGGCTTCTTAGGC 5150

```

Publication US/09616289

323

ION:

3, Ann M.

38, Robert S.

4, Simon W.

iona, Anibal A.

ION: NOVEL LOW DENSITY LIPOPROTEIN BINDING

ION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING

ION: ATHEROSCLEROSIS

: 10797-004001

ATION NUMBER: US/09/616,289

DATE: 2000-07-14

ION NUMBER: US 09/517,849

ATE: 2000-03-02

ION NUMBER: US 08/979,608

ATE: 1997-11-26

ION NUMBER: US 60/031,930

ATE: 1996-11-27

ION NUMBER: US 60/048,547

ATE: 1997-06-03

ID NOS: 53

SEQ for Windows Version 4.0

ctolagus cuniculus

5) ... (1895)

	4,41e-90	Length:	2561
Matches:	2594.00		503
Conservative:	94.20%		17
Mismatches:	91.12%		16
Indels:	91.02%		16
Gaps:	4		8

(1-538) x US-09-616-289-48 (1-2561)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThr---Ala 19

3CGGGGGCGCGCGCGCTTACCGCGCGGACAGCGCGCGCGCGCGCGCGCGCG 305

AlaAlaSerSerAlaAlaSerProHisTyrGlnGluThrIleLeuAspThrIle 39

3CGCGCTGTCGTCGCGCGCTTCCCGCACTACCAAGAGTGGATTCTGGACCATC 365

E: nucleic acid
ANDEDNESS: single
LOGY: linear

E/KEY: Coding Sequence
ATION: 1...756
DESCRIPTION: SEQ ID NO: 13:

1.35e-37 Length: 1422
1191.50 Matches: 223
Y: 95.24% Conservative: 17
ity: 88.49% Mismatches: 9
Indels: 3
4

(1-538) x US-08-979-608A-13 (1-1422)

ArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaProAla 309
CGTCTCGAGGCTTGGCTGCCCGCGGGACAGCCCGCGCGCCACCGGCC 60
SerAlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuGluLysGlu 329
AGCGCCCGCGCGCGCGGACCAAGAGAGCTGGCGAGGAGCGAGTGTGAAAGGAG 120
GluGluAspAspAspGluAspGluAspGluAspGluAspGluAspGluAsp 347
GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 180
GluValProGluSerArgProAlaGlyAlaGlnHisGlnLeuAsn---Gly 366
GAGTGCCCGAGAGCGATCGTCCCGGGGTGGCAGCATCACAGCTGAATGGCGC 240
ArgGlyProGlnSerAlaLysGluArgValLysGluThrProCysGlyProHis 386
CGCGCGCCGACAGCGCCCAAGAGGCGGGCCCAAGGAGTGTGCTGTGGCGCCAC 300
GlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValPheSer 406
GGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 360
AlaAlaMetAsnLysGluGlyThrAlaSerValAlaThrGlyProAspSerPro 426
GCGGCTTTAGTAAGGAGGAGGAGGATCAGCCCTCTTCGACCACCGGCGCTGACTCCCG 420
ProValProLeuProProGlyLysProAlaLeuProGlyAlaAspGlyThrProPhe 446
CCGGTGCTTTTGGCCCGCGGAAAGCAGCCCTCCCGAGGAGCGGATGGGACCCCTTT 480
CysProProGlyArgLysGluLysProSerAspProValGluThrValMetAsp 466
TGCCCTGCGCGCGCGGAAAGAGAGCGCGGACCGCGGAGTGGAGTGCAGTCTGAC 540
ValGluThrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnGluGln 486
GTGGAGTACTTCCAGCGCGGCTTCCCTGAGCAAGCACCGGCTTTCAGAGGAGCAG 600
IleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGlyLeuSer 506
ATCGAGCGCAAGTCTGCTCATGACGCGCACCGGATGCTCCTCAGCGGCTGTGCC 660
ArgLeuGlyProAlaLeuLysLysLysGluHisLysLysLysValLeuGlnGlnGly 526
CCGCTGGGCGCGCGGCTTGAATACTATGACACCATATCAAGTGTCTCAGCAGGGT 720
PheGluAspAspAspProAspGlyPheLeuGly 538
TTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 756

Sequence 13, Application US/09517849
Patent No. 6605588
GENERAL INFORMATION:
APPLICANT: Lees, Ann M.
Law, Simon W.
Arjona, Anibal A.
TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN
BINDING PROTEINS AND THEIR USES IN DIAG
TREATING ATHEROSCLEROSIS

NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/517,849
FILING DATE: 02-Mar-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/979,608
FILING DATE: 26-NOV-1997
ATTORNEY/AGENT INFORMATION:
NAME: Myers, Louis
REGISTRATION NUMBER: 35,965
REFERENCE/DOCKET NUMBER: 10797-003001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906

INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 1422 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 1...756
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-517-849-13

Alignment Scores:
Pred. No.: 1.35e-37 Length: 1422
Score: 1191.50 Matches: 223
Percent Similarity: 95.24% Conservative: 17
Best Local Similarity: 88.49% Mismatches: 9
Query Match: 41.81% Indels: 3
DB: 4 Gaps: 2

US-09-976-740-43 (1-538) x US-09-517-849-13 (1-1422)

Qy 290 ThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaPro
Db 1 ACCGCTCTCGAGCGCTTGGCTGCCCGCGGGACAGCCCGCGGACCGGCGGCCA
Qy 310 AlaSerAlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuGlu
Db 61 GCCAGCGCCCGCGCGCGGAAAGAGAGAGCTGGCGAGGAGCGAGTGTGAA
Qy 330 GluGluAspAspAspGluAspGluAspGluAspGluAspGluAspGluAsp
Db 121 GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
Qy 348 SerGluValProGluSerArgProAlaGlnHisGlnHisGlnLeuAsn
Db 181 TCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG

[illegible]

application US/09616289

2923
ACTION:
es, Ann M.
es, Robert S.
aw, Simon W.
rjona, Arnibal A.
TION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
TION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING
TION: ATHEROSCLEROSIS

3: 10797-004001
 CATION NUMBER: US/09/616,289
 DATE: 2000-07-14
 ION NUMBER: US 09/517,849
 DATE: 2000-03-02
 ION NUMBER: US 08/979,608
 DATE: 1997-11-26
 ION NUMBER: US 60/031,930
 DATE: 1996-11-27
 ION NUMBER: US 60/048,547
 DATE: 1997-06-03

ID NOS: 53
tSEQ for Windows Version 4.0

uctolagus cuniculus

5 } ... (756)

```

::
1.35e-37      Length:      1422

```

Score:	1191.50	Matches:	223
Percent Similarity:	95.24%	Conservative:	17
Best Local Similarity:	88.49%	Mismatches:	9
Query Match:	41.81%	Indels:	3
DB:	4	Gaps:	2

US-09-976-740-43 (1-538) x US-09-616-289-13 (1-1422)

QY	290	ThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaPrC
Dd	1	AACCCTCTCGAGCGCTTGCCTGCCCGGGACAGCCCGGACGGCGCG
QY	310	AlaSerAlaAargProSerArgSerLySArgGlyGluGluArgValLeuGl
Dd	61	GCCAGCGCCCGCGCGCGGNACAAGAGAGCTGCGGAGGACGAGTGCTTG
QY	330	GluGluGluAspAspAspGluAspGluAspGluGluAspAsp-----ValSer
Dd	121	GAGGAGGAGGAGGAGGAGAACACACGACGAGGACGACGACGACTGTGTGC
QY	348	SerGluValProGluSerAspArgProAlaGlyAlaGlnHisHisGlnLeuAr
Dd	181	TCCGAGGTGCCCGAGAGCGATCGTCCC GGCGTGCAGCATCACAGCTGAAT
QY	367	GluArgGlyProGlnSerAlaLysGluArgValLysGluTrpThrProCysGly
Dd	241	GAGCGCGCCCGCACGCCCAAGGAGCGGGCCAAGGAGTGTCGTCTGTGTGC
QY	387	GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnVal
Dd	301	CCTGCCACAGGAGGAGGCGGGCGCGCGCGGCGAGTGGCACCCGCGCAGGTC
QY	407	MetAlaLaMetAsnLysGluGlyThrAlaSerValAlaIatThrGlyProAsf
Dd	361	ATGGCGGCTTTGAGTAAGAGGGGGGATCAGCCTCTTCGACCCACCGGSCCTGAC
QY	427	SerProValProLeuProProGlyLysProAlaLeuProGlyAlaAspGlyThi
Dd	421	TCCCGGTGCCTTTGCCCGCGGAAAGCAGCCCTCCAGGAGCCGATGGGACC
QY	447	GlyCysProProGlyArgGlyAcLulySProSerAspProValGluTrpThrVal
Dd	481	GGCTGCCCTGCCGGCGCAAAGAGAAGCGCGAGACCCCGTGGAGTGACAGTC
QY	467	ValValGluTyPheThrGluAlaGlyPheProGluGlnAlaIatThrAlaPheGr
Dd	541	GTCTGGGAGTACTTCACCGAGCGGGCTTCCTGAGCAAGCCAGCGCTTTCAC
QY	487	GluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGly
Dd	601	GAGATCGACGCGAGTCCCTCGCTCATCAGCGGCACCCGATGTCTCTCACC
QY	507	IleArgLeuGlyProAlaLeuLysIleTyrGluHisHisIleLysValLeuGlr
Dd	661	ATCCGCTGGGGCGAGCGTTGAAATCTATGAGCACCATATCAAGGTGCTGCAC
QY	527	HisPheGluAspAspProAspGlyPheLeuGly 538
Dd	721	CAC TTCGAGGACGATGACCCGGAAGGCTTCTCTGGGA 756

RESULT 10

RESOLUTION
US-08-979-608A-16
; Sequence 16, Application US/08979608A
; Patent No. 6355451

GENERAL INFORMATION:

APPLICANT: Lees, Ann M.
Lees, Robert S.
Law, Simon W.
Arjona, Anibal A.

Aljona, Andai A.
TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN
BINDING PROTEINS AND THEIR USES IN DIAG
TREATING ATHEROSCLEROSIS
NUMBER OF SEQUENCES: 42

09:28:16 2004

us-09-976-740-43.rni

Law, Simon W.
Arjona, Anibal A.
INVENTION: NOVEL LOW DENSITY LIPOPROTEIN
BINDING PROTEINS AND THEIR USES IN DIAGNOSING AND
TREATING ATHEROSCLEROSIS
SEQUENCES: 42
NDENCE ADDRESS:
RESSEE: Fish & Richardson P.C.
SER: 225 Franklin Street
Y: Boston
IE: MA
TRY: USA
: 02110-2804
READABLE FORM:
UM TYPE: Diskette
PUTER: IBM Compatible
ATING SYSTEM: DOS
WARE: FastSeq for Windows Version 2.0
PLICATION DATA:
ING DATE: 26-Nov-1997
PLICATION DATA:
ICATION NUMBER: US 60/048,547
ING DATE: 03-JUN-1997
ICATION NUMBER: US 60/031,930
ING DATE: 27-NOV-1996
AGENT INFORMATION:
E: Myers, Louis
ISTRATION NUMBER: 35,965
ERENCE/DOCKET NUMBER: 10797-002001 (formerly 3983/59818)
INATION INFORMATION:
PHONE: 617/542-5070
EAX: 617/542-8906
R SEQ ID NO: 12:
CHARACTERISTICS:
3T: 1362 base pairs
3: nucleic acid
ANDEDNESS: single
OLOGY: linear
E/KEY: Coding Sequence
ATION: 1...696
DESCRIPTION: SEQ ID NO: 12:

1.15e-33 Length: 1362
1086.50 Matches: 203
94.83% Conservative: 17
city: 87.50% Mismatches: 9
38.12% Indels: 3
4 Gaps: 2

(1-538) x US-08-979-608A-12 (1-1362)

SerAlaArgProSerArgSerLysArgGlyGluGluArgValLeuGluLysGlu 329
|||||
:|||||
AGCGCCGCGCGCGGCGGACACAGAGAGCTGGCGAGGAGGAGTGTGTTGAAGAGG 60
|||||
3luGluAspAspAspGluAspGluAspGluAspAspAspAspAspAspAsp 347
|||||
GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 120
|||||
GluValProGluSerAspArgProAlaGlnHisGlnHisGlnHisGlnHisGln 366
GAGTGTCCGAGAGCGATCGTCCGCGGCGGCGGAGGAGGAGGAGGAGGAGGAG 180
|||||
ArgGlyProGlnSerAlaLysGluArgValLysGluTrpThrProCysGlyProHis 386
|||||
CGCGGCGCGGAGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 240
|||||
GlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnValPheSer 406
|||||

Db 241 CCTGCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTGT
QY 407 MetAlaAlaMetAsnLysGluGlyThrAlaSerValAlaThrGlyProAsps
Db 301 ATGGCGGCGCTTGGTAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTGTACT
QY 427 SerProValProLeuProGlyLysProAlaLeuProGlyValAlaAspGlyThrP
Db 361 TCCCGGCGCTTGGCGGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTGT
QY 447 GlyCysProProGlyArgLysGluLysProSerAspProValGluTrpThrValM
Db 421 GCGTGCCTCGCGGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTGT
QY 467 ValValGluTyrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnG
Db 481 GTCGTGGAGTACTTACCGAGGCGGCGCTTCCCTGAGCAAGGAGGAGGAGGAGTGT
QY 487 GluIleAspGlyLysSerLeuLeuMetGlnArgThrAspValLeuThrGlyL
Db 541 GAGATCGAGCGCAAGTCCCTGCTGCTCATGCGAGCGGAGGAGGAGGAGTGTCTCACC
QY 507 IleArgLeuGlyProAlaLeuLysIleTyrGluHisIleLysValLeuGlnG
Db 601 ATCCGCGCTGGGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTGT
QY 527 HisPheGluAspAspProAspGlyPheLeuGly 538
Db 661 CACTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTGTCTGGGA 696

RESULT 14
US-09-517-849-12
: Sequence 12, Application US/09517849
: Patent No. 6605588
: GENERAL INFORMATION:
: APPLICANT: Lees, Ann M.
: Law, Simon W.
: Arjona, Anibal A.
: TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN
: BINDING PROTEINS AND THEIR USES IN DIAGN
: TREATING ATHEROSCLEROSIS
: NUMBER OF SEQUENCES: 42
: CORRESPONDENCE ADDRESS:
: ADDRESSER: Fish & Richardson P.C.
: STREET: 225 Franklin Street
: CITY: Boston
: STATE: MA
: COUNTRY: USA
: ZIP: 02110-2804
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Diskette
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: DOS
: SOFTWARE: FastSeq for Windows Version 2.0
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/517,849
: FILING DATE: 02-Mar-2000
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/979,608
: FILING DATE: 26-NOV-1997
: ATTORNEY/AGENT INFORMATION:
: NAME: Myers, Louis
: REGISTRATION NUMBER: 35,965
: REFERENCE/DOCKET NUMBER: 10797-003001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617/542-5070
: TELEFAX: 617/542-8906
: INFORMATION FOR SEQ ID NO: 12:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 1362 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single

```

/ APPLICANT: Arjona, Anibal A.
/ TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
/ TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TR
/ TITLE OF INVENTION: ATHEROSCLEROSIS
/ FILE REFERENCE: 10797-004001
/ CURRENT APPLICATION NUMBER: US/09/616,289
/ CURRENT FILING DATE: 2000-07-14
/ PRIOR APPLICATION NUMBER: US 09/517,849
/ PRIOR FILING DATE: 2000-03-02
/ PRIOR APPLICATION NUMBER: US 08/979,608
/ PRIOR FILING DATE: 1997-11-26
/ PRIOR APPLICATION NUMBER: US 60/031,930
/ PRIOR FILING DATE: 1996-11-27
/ PRIOR APPLICATION NUMBER: US 60/048,547
/ PRIOR FILING DATE: 1997-06-03
/ NUMBER OF SEQ ID NOS: 53
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 12
/ LENGTH: 1362
/ TYPE: DNA
/ ORGANISM: Oryctolagus cuniculus
/ FEATURE:
/ NAME/KEY: CDS
/ LOCATION: (1) ... (696)
/ US-09-616-289-12

```

Alignment Scores:	
Pred. No.:	1.15e-33
Score:	1086.50
Percent Similarity:	94.84%
Best Local Similarity:	87.50%
Query Match:	38.12%
DB:	4
Length:	1362
Matches:	203
Conservative:	17
Mismatches:	9
Indels:	3
Gaps:	2

US-09-976-740-43 (1-538) x US-09-616-289-12 (1-1362)

	QY	310 AlaSerAlaArgProSerArgSerIysArgGlyGluGluArgValLeuGI
	DB	1 GCCAGCCGCCGGCGCGGAACAAGAGAGCTGCAGAGCAGCTGTGTTGA
	QY	330 GluGluGluAspAspGluAspGluAspGluAsp-----Valse
	DB	61 GAGGAGGAGGAGGAGGAAGAAGACGACGAGGACGACGACGACGTC
	QY	348 SerGluValProGluSerAspArgProAlaGlyAlaGlnHisGlnLeuAsi
	DB	121 TCGGAGGTGCCGAGAGCGATCGTCCC GGCGGTGCGCAGCATCACCA
	QY	367 GluArgGlyProGlnSerAlaLysGluArgValLysGluTrpThrProCysGL
	DB	181 GAGCGCGGCCCGACAGACCAGGAGCGGCCAAGGAGTGCTGCTGTGTGGI
	QY	387 GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnVa
	DB	241 CCTGCCACAGAGAAAGGGCGGGCGCGCGCGGAGTGGGCACCCGCCAGGT
	QY	407 MetAlaAlaMetAsnLysGluGlyGlyThrAlaSerValAlaThrGlyProAsi
	DB	301 ATGGCGGCTTAGTAAGAGGGGGGATCAGCTCTTCGACCACCGGGGCTGAN
	QY	427 SerProValProLeuProProGlyLysProAlaLeuProGlyAlaAspGlyTh
	DB	361 TCCCCGGTGCTTTGCCCGCGGAAGCCAGCCCTCCCCAGGAGCGATGGGAC
	QY	447 GlyCysProProGlyArgLysGluLysProSerAspProValGluTrpThrVal
	DB	421 GGCTGCGCTTCCGGCGCGAAAAGAGAGCGCGGACGCCCGTGGAGTGGACGT
	QY	467 ValValGluTyrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlr
	DB	481 GTCTGGGAGTACTTCACGAGCGGGCTTCCTCTGAGCAAGCACCGGCTTCCA
	QY	487 GluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGlr

Application US/09616289

CONCLUSION:

ees. Robert

aw, Simon W.

09:28:16 2004

us-09-976-740-43.rni

|||||ATCGACGGCAAGTCCCTGCTGCTCATGCGCGCACCGATGCTCTCACCGGCTGTCC 600
ArgLeuGlyProAlaLeuValIleTyrGluHisIleLysValLeuGlnGlnGly 526
CGCCTGGGGCCAGCGTTGAAAATCTATGAGCACCATATCAAGGTGCTGCACGAGGT 660
PheGluAspAspAspProAspGlyPheLeuGly 538
|||||TTCGAGGACGATGACCCGGAAGGCTTCCTGGGA 696

March 13, 2004, 04:07:02
6 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

leic search, using frame_plus_p2n model

March 12, 2004, 20:46:42 ; Search time 778.355 Seconds
(without alignments)
2544.725 Million cell updates/sec

US-09-976-740-43

2850
1 MAGPPALPPETAAATTAA.....HIKVLQGHFEDDDPGFLG 538

BLOSUM62

Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

2432557 seqs, 1840798884 residues

hits satisfying chosen parameters: 4865114

length: 0
length: 2000000000

Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

ameters:

n.model -DBV=xlp
spool_p/US09976740/runat_10032004_094549_19588/app_query.fasta_1.1898
lications NA_QFWT=fastap_SUFFIX=rnpb_MINMATCH=0.1
xi=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62
di -LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100
N=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0
-NO MAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100
MEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5
XT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Published Applications NA:

1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
13: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
14: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
15: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
16: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq:*
17: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
18: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

is the number of results predicted by chance to have a
ter than or equal to the score of the result being printed,
ived by analysis of the total score distribution.

SUMMARIES

Query	Match	Length	DB	ID	Description

	1	2850	100.0	1614	9	US-09-976-740-45	Sequenc
1	2850	100.0	1614	1614	12	US-10-671-242-45	Sequen
2	2850	100.0	1614	1614	13	US-10-023-529-45	Sequen
3	2850	100.0	1614	1614	13	US-10-023-523-45	Sequen
4	2850	100.0	1614	1614	15	US-10-616-187-45	Sequen
5	2850	100.0	1614	1614	9	US-09-976-740-50	Sequen
6	2616.5	91.8	12425	12425	13	US-10-671-242-50	Sequen
7	2616.5	91.8	12425	12425	13	US-10-023-529-50	Sequen
8	2616.5	91.8	12425	12425	13	US-10-023-523-50	Sequen
9	2616.5	91.8	12425	12425	15	US-10-616-187-50	Sequen
10	2616.5	91.8	12425	12425	15	US-10-616-187-50	Sequen
11	2594	91.0	2561	2561	9	US-09-976-740-48	Sequen
12	2594	91.0	2561	2561	12	US-10-671-242-48	Sequen
13	2594	91.0	2561	2561	13	US-10-023-529-48	Sequen
14	2594	91.0	2561	2561	13	US-10-023-523-48	Sequen
15	2594	91.0	2561	2561	15	US-10-616-187-48	Sequen
16	1470	51.6	1445	1445	10	US-09-945-527-6	Sequen
17	1455.5	51.1	1617	1617	9	US-09-962-055-11	Sequen
18	1455.5	51.1	1617	1617	9	US-09-976-740-11	Sequen
19	1455.5	51.1	1617	1617	12	US-10-671-242-11	Sequen
20	1455.5	51.1	1617	1617	13	US-10-023-529-11	Sequen
21	1455.5	51.1	1617	1617	13	US-10-023-523-11	Sequen
22	1455.5	51.1	1617	1617	15	US-10-616-187-11	Sequen
23	1260	41.2	1336	1336	14	US-10-102-806-247	Sequen
24	1191.5	41.8	1422	1422	9	US-09-962-055-13	Sequen
25	1191.5	41.8	1422	1422	9	US-09-976-740-13	Sequen
26	1191.5	41.8	1422	1422	12	US-10-671-242-13	Sequen
27	1191.5	41.8	1422	1422	13	US-10-023-529-13	Sequen
28	1191.5	41.8	1422	1422	13	US-10-023-523-13	Sequen
29	1191.5	41.8	1422	1422	15	US-10-616-187-13	Sequen
30	1170	41.1	1208	1208	9	US-09-962-055-16	Sequen
31	1170	41.1	1208	1208	9	US-09-976-740-16	Sequen
32	1170	41.1	1208	1208	12	US-10-671-242-16	Sequen
33	1170	41.1	1208	1208	13	US-10-023-529-16	Sequen
34	1170	41.1	1208	1208	13	US-10-023-523-16	Sequen
35	1170	41.1	1208	1208	15	US-10-616-187-16	Sequen
36	1086.5	38.1	1362	1362	9	US-09-962-055-12	Sequen
37	1086.5	38.1	1362	1362	9	US-09-976-740-12	Sequen
38	1086.5	38.1	1362	1362	12	US-10-671-242-12	Sequen
39	1086.5	38.1	1362	1362	12	US-10-023-529-12	Sequen
40	1086.5	38.1	1362	1362	13	US-10-023-523-12	Sequen
41	1086.5	38.1	1362	1362	15	US-10-616-187-12	Sequen
42	402	14.1	2307	2307	10	US-09-893-519A-87	Sequen
C 43	391	13.7	3331	3331	11	US-09-373-658-31	Sequen
C 44	391	13.7	3331	3331	11	US-09-989-687-31	Sequen
C 45	386	13.5	1926	1926	14	US-10-294-804-3	Sequen

ALIGNMENTS

RESULT 1
US-09-976-740-45
; Sequence 45, Application US/09976740
; Publication No. US20020194633A1
; GENERAL INFORMATION:
; APPLICANT: Lees, Ann M.
; APPLICANT: Lees, Robert S.
; APPLICANT: Law, Simon W.
; APPLICANT: Arjona, Anibal A.
; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
; TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TRE
; FILE REFERENCE: 10797-004001
; CURRENT APPLICATION NUMBER: US/09/976,740
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/616,289
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 08/979,608
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: US 60/031,930
; PRIOR FILING DATE: 1996-11-27
; PRIOR APPLICATION NUMBER: US 60/048,547
; PRIOR FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 53

SEQ for Windows Version 4.0

c sapiens

... (1614)

```

5.74e-14      Length:      1614
              Matches:      538
Y:            Conserva:      0
rity:         Mismatches:    0
              Indels:       0
              Gaps:         0

```

(1-538) x US-09-976-740-45 (1-1614)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaThrThrAlaAla 20
3CGGGCGCCCGCGCCCTACCCCGCGGAGACGCGCGCGGCCGACACGCGCGGC 60
AlaSerSerSerAlaAlaSerProHisTyrGlnGluTrpIleLeuAspThrIleAsp 40
3CTCTGCTGTCGCGCTTCCCGGCACATACCAAGAGTGGATCTTGGACACCATTCGAC 120
LeuArgSerArguysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
TTCGCTCGCGCAAGCGCGCGCGACCTGGAGCGCATCTGCCGATGGTGGCGCG 180
HisGlyProGluProGluArgThrArgAlaGluLeuLeuGluLysLeuIleGlnInArg 80
TACGGCCGGAGCCGGAGCGCACGCGCGCCGAGCTCCAGAAACTGATCCACGACGC 240
ValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln 100
TTCCTCCGGTCAAGTACAGGGAGCATCTCTGATCCGCAACGCGCGCGCGCTCCAG 300
ProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaProAla 120
TCCCGCGCGGAGCCACCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 360
AlaAlaAlaAlaAlaProProProThrProAlaProProProProAlaProVal 140
3CGC 420
AlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaThrAlaProPro 160
3CGCGCGCCCGC 480
ProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaAlaPro 180
TCTGGCCCCCGCAGCGCGGCCCGCGCGCGCAGCGGCGCGCGCGCGCGCGCGCG 540
ProAlaProAlaAlaProProAlaAlaAlaProAlaGlyProArgArgAlaPro 200
TCCGCGCCAGCGCTCCCGCGCGGTGCGCGCCCGCGCGCGCGCGCGCGCGCGCG 600
ProAlaValAlaAlaArgGluProProLeuProProProProGlnProProAlaPro 220
TCCGCGCTCGCGCCCGGAGCGCGCTGCGCGCGCGCGCGCACGCGCGCGCGCGCG 660
3InGlnGlnGlnProProProProGlnProGlnProProProGluGlyAlaVal 240
TACGACAGCAGCGCGCGCGCGCGCAGCGCACAGCGCGCGCGCGAGGCGCGCGGT 720
AlaGlyGlyAlaAlaArgProValSerLeuArgGluValValAlaArgTyrLeuGlyGly 260
3CGCGCGCGCGCGCGCGCGCGGTGAGCTCGCGGAAATGTGTGCGCGCTACCTCCGCGGCG 780
3IlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlnGlyLeuLeuGluGlu 280

781	AGCGCGCGCGCGCGGCTGCCTTAACCGCGCGCGCGCTGCAGGGGCTGCCTGGAG	Db
281	AlaAlaAlaArgGlyArgGluArgGluArgGluArgGluAlaLeuAlaLeuProA	Qy
841	GGCGCGGCTCAGAGCGGCTCGAGCGCACCGCTCTCGAGCGCTTGCGCTGCCCC	Db
301	AspArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArgSerLysA	Qy
901	GAAGCCCGGAGCGGCGCGCGCGCGCCAGCGCCCGCTCTCGACGCAAGA	Db
321	GlyGluGluArgValLeuGluLysGluGluGluAspAspGluAspGluA	Qy
961	GGAGAAGACGAGTAGTACTTGAGAAAGAGAGAAAGAGATGATGATGAAGATGAAG	Db
341	GluAspAspValSerGluGlySerGluValProGluSerAspArgProAlaGlyA	Qy
1021	GAAGATGATGTTCAGAGGGCTCTGAAGTGCCCGAGAGTGACCGTCTCTGCGGTG	Db
361	HisHisGlnLeuAsnGlyGluArgGlyProGlnSerAlaLysGluArgValLysG	Qy
1081	CACCACCAAGCTTAAACGGGAGCGGGGACCTCAGAGTGCCCAAGGAGAGGGTCAAAG	Db
381	ThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaProGlyLys	Qy
1141	ACCCCTTCGGAGCCGACACAGGGCGAGATGAAGGGCGGGGGCCAGCCCGCGGCA	Db
401	ThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyGlyThrAlaSerV	Qy
1201	ACCCGCCAGGTGTTCTCCATGCGACCCATGAACAAGGAAGGGGGAAACAGCTTCTG	Db
421	ThrGlyProAspSerProSerProValProLeuProProGlyLysProAlaLeuP	Qy
1261	ACCGGGCCAGACTCCCCGCTCCCGCTGCTTTGCCCCCAGGCAAAACAGCCCTAC	Db
441	AlaAspGlyThrProPheGlyCysProProGlyArgLysGluLysProSerAspP	Qy
1321	GCCGACGGGACCCCTTTGGCTGTGCCCGCGGGCGCAAGAGAAGCCATCTGATC	Db
461	GluTrpThrValMetAspValValGluTyrPheThrGluAlaGlyPheProGluG	Qy
1381	GAGTGGACCGTGATGTGTGCGTAATATTTTACTGAGGCTCGATTTCCCGGAGC	Db
481	ThrAlaPheGlnGluGlnGluAlaAspGlyLysSerLeuLeuLeuMetGlnArgT	Qy
1441	ACAGCTTTCCAAAGACAGCAAAATTTGATGGCAATCTTTTGCTGCTCATGCAGGCA	Db
501	ValLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuLysIleTyrGluHisH	Qy
1501	GTGECTACCGGCTGTCCATCCGCTCTGGGCGAGCCCTGAAATCATCTACGAGCAC	Db
521	LysValLeuGlnGlnGlyHisPheGluAspAspProAspGlyPheLeuGly	Qy
1561	AAAGTGCTTCAGCAAGGCCACTTTGAGCATGATGACCCCGATGGCTTCTTAGGC	Db

RESULT 2

US-10/671-242-45
 ; Application US/10671242
 ; Sequence 45, Application US/10671242
 ; Publication No. US20040040049A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Lees, Ann M.
 ; APPLICANT: Lees, Robert S.
 ; APPLICANT: Law, Simon W.
 ; APPLICANT: Arjona, Anibal A.
 ; TITLE OF INVENTION: PROTEIN LOW DENSITY LIPOPROTEIN BINDING
 ; TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREA
 ; TITLE OF INVENTION: ATHEROSCLEROSIS
 ; FILE REFERENCE: 10797-004001
 ; CURRENT APPLICATION NUMBER: US/10/671,242
 ; CURRENT FILING DATE: 2003-09-24
 ; PRIOR APPLICATION NUMBER: US/09/616,289
 ; PRIOR FILING DATE: 2000-07-14
 ; PRIOR APPLICATION NUMBER: US 09/517,849

tAlaGlyProProAlaLeuProProGluThrAlaAlaAlaThrThrAlaAla 20
GCGGGGGCCCCGGCCCTTACCCCCCGGAGACGGCGCGCGCCACACGCGGGCC 60
aAlaSerSerAlaAlaSerProHisTyrGlnGluTyrIleLeuAspThrIleAsp 40
CGCTCGTGTGTCGCGCGCTTCCCGCACTACCAAGAGTGGATCTCTGGACACCATCGAC 120
rLeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
GCTGCGTCTCGCAAGCGGGCGCGACCTCGAGCGCATCTCGCGATGTTGGTGGCGG 180
gHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGlnArg 80
GCACGCCCCGGAGCCCGAGCGCACCGCGCGAGCTCGAGAACTGATCAGACAGCC 240
aValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln 100
CGTGCTCCGGGTGAGCTACCAAGGGAGCATCTCGTACCGCAACGCGCGCGTCCAG 300
oProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaProAla 120
3CCCCGGCGGAGCCACCCTCGCGCCGCGCGCGCGCCCGCGGGGCGCCCGCGC 360
aAlaAlaAlaAlaProProProThrProAlaProProProProProAlaProVal 140
3GCG 420
aAlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaAlaThrAlaProPro 160
3CG 480
cProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaAlaPro 180
3CGTGGCCCGCGCGACCGCGGCCCGCGCGCGAGCGGGCGCGCCCTTGGCCGCGCG 540
oProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgArgAlaPro 200
3CCCGCGCGCAGCGCGCTCCCGCGCGTGGCGCGCCCGCGCGCGCGCGCGCGCGCC 600
oProAlaValAlaAlaArgGluProProLeuProProProGlnProProAlaPro 220
3CCCGCGGTGCGCGCCCGGGAGCCGCGCTGCGCGCGCGCGCGCGCGCGCGCGCG 660
gGlnGlnGlnGlnProProProGlnProGlnProGlnProProProGluGlyGlyValaVal 240

; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING

GTGGACCGTGTGGATGCTCGAATATTTTACTAGGCTGGATTCCCGGACAGGCG 1440
 rAlaPheGlnGluGlnGluLeuAspGlyLysSerLeuLeuMetGlnArgThrAsp 500
 AGCTTTCCAGAGACGAGAAATGATGGCAATCTTTTGCTGCTCATGCAGGCGCACAGAT 1500
 uLeuThrGlyLeuSerIleArgLeuGlyProAlaLeuLysIleTyrGluHisIle 520
 GCTCACCGGCTGTCTCATCGGCTCTCGGCGCAGCCCTGAAATCTACGAGCACCATC 1560
 sValLeuGlnGlnGlyHisPheGluAspAspProAspGlyPheLeuGly 538
 GGTGCTTCAGCAGGCGCACTTGTAGAGATGATGACCCCGATGCTTCITAGGC 1614

Application US/09976740

US20020194633A1

ATION:

es, Ann M.

es, Robert S.

aw, Simon W.

rjona, Anibal A.

ATION: NOVEL LOW DENSITY LIPOPROTEIN BINDING

NTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING

NTION: ATHEROSCLEROSIS

E: 10797-004001

CATION NUMBER: US/09/976,740

G DATE: 2001-10-12

TION NUMBER: 09/616,289

DATE: 2000-07-14

TION NUMBER: US 08/979,608

DATE: 1997-11-26

TION NUMBER: US 60/031,930

DATE: 1996-11-27

TION NUMBER: US 60/048,547

DATE: 1997-06-03

ID NOS: 53

tSEQ for Windows Version 4.0

5

no sapiens

Length: 12425
 6.82e-131
 2616.50
 Matches: 536
 Y: 69.16%
 Conservative: 0
 Mismatches: 2
 Indels: 239
 Gaps: 4

(1-538) x US-09-976-740-50 (1-12425)

AlaGlyProAlaLeuProProGluThrAlaAlaAlaAlaThrThrAlaAla 20
 XCGGGGCCCCGGCCCTACCCCGCGGAGACGGCGCGCGCGCCACACCGCGGCC 2891
 AlaSerSerAlaAlaSerProHisTyrGlnGluTyrPileLeuAspThrIleAsp 40
 XGCTCGTCCGCGCGCTTCCCGCAGTACCAAGAGTGGATCTGGACACCATCGAC 2951
 LeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
 ICTGCGCTCGCGCAAGCGCGCGCGGACCTGGAGCGCATCTGCCGATGTTGGCGGG 3011
 HisGlyProGluProGluArgThrArgAlaGluLeuLysLeuIleGlnArg 80
 XACGGCCCGGAGCGCGGAGCGCACGCGCGCGAGCTCGAGAACTGATCCAGCAGGCG 3071
 ValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln 100

Db 3072 GCCTGTCTCCGGGTACGTACTAAGGGGAGCATCTCTGTACCGCAACGCGGCGCG
 QY 101 ProProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAl
 Db 3132 CCGCCCCGGCGCGAGGACACCCCGCGCGGCCCGCGCGGCCCGCGCGCGCGCG
 QY 121 AlaAlaAlaAlaAlaProProProThrProAlaProProProProProAl
 Db 3192 GCG
 QY 141 AlaAlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaThrAl
 Db 3252 GCG
 QY 161 SerProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAl
 Db 3312 TCSCCTGGCG
 QY 181 ProProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgAl
 Db 3372 CCG
 QY 201 ProProAlaValAlaAlaArgGluProProLeuProProProProProPro
 Db 3432 CCG
 QY 221 ProGlnGlnGlnProProProProGlnProGlnProProProProGlnGly
 Db 3492 CCACAGCAGCAGCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 QY 241 ArgAlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeu
 Db 3552 CCG
 QY 261 SerGlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGly
 Db 3612 AGCG
 QY 281 AlaAlaAlaArgGlyArgGluArgThrArgLeuGlyAlaLeuAlaLeuPro
 Db 3672 GCG
 QY 301 AspArgProGlyArgAlaProProAlaAlaSerAlaAlaArgProSerArg
 Db 3732 GACAGGCGCGGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 QY 316 -----
 Db 3792 GCGCGCGGAGCGCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 QY 316 -----
 Db 3852 GCGAGTCCCGGGAGAACTGGGTGGCGGGTGGCTGGGGGCTTTTGGCGCGGTTTCC
 QY 316 -----
 Db 3912 CTCGTGGTGGTGCACCTTGGCAAGTGATTAATCTCCCGGAGCCTCAGTTTCC
 QY 316 -----
 Db 3972 GTAAACGCGGTTTAATAACAGTAGCGACCCCTTGGGGTGTGTGAGCGAGTTTAG
 QY 316 -----
 Db 4032 TTGGTTGTGAGGGGCTTTAGTTAAACAGAGCCCTGGCAGCGAGTGAATGCGTAA
 QY 316 -----
 Db 4092 GTCGCTATTGTTCTTAAAGTGGAAATCGGTTCTCTCCCGCGCGCGGAGCGC
 QY 317 -----SerI
 Db 4152 CAGGCTCTGGGATTAGAACAGACTACTAATTTTGTGATCTTCTCTCTCGGCTCC

QY	416	-----	
Db	4511	CCCTCTGGTGGGAAGAGTGCTAGGTGGAGAGGAAC	CTCAGCCGGAAGACAA
QY	417	-----	
Db	4571	ACAGGTGTTTTTCCAGCTCTGTGTGCCACCGGGCCAGACTCC	CCCGGT
QY	429	lProLeuProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheG	
Db	4631	GCCTTTGCCCCAGGCAACACAGCCCTACCTGGGGCCGACGGG	ACCCCTTTG
QY	449	o-----	
Db	4691	GTAA GTGGGGTATTGGAGACATGGGGGTGCTGCTCAGGTGTGTGTG	TACAGCC
QY	450	-----	
Db	4751	CATCCGTGTTCACTGGTGCTGTGTTGTTGTATGCAGTCCC	GGGGCCAAAGAG
QY	457	erAspProValGluTrpThrValMetAspValValGluTyrPheThrGluAla	ac
Db	4811	CTGATCCGTCGAGTGGACCGTGATGATGTCGTGGAATATTTT	ACTGAGGCTC
QY	477	roGluGlnAlaThrAlaPheGlnGlu-----	
Db	4871	CGGAGCAGCGCAGCTTTCCAGA- GCAGGTGAGTTTCCAGCC	CACGAGTACA
QY	485	-----	
Db	4930	CAGACACAGAGGGCCCTCCCTGGGATGTGCCGTATCCCGGCTTT	CTCTGTCTCT
QY	486	--GlnGluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeu	
Db	4990	CCAGGAATATGATGGCAATCTTTGCTGCTCATGCGGCACAGATGTG	CTCA
QY	505	eueSrlEArgLeuGlyProAlaLeuLysIleTyrGluHisIleLysValL	
Db	5050	IGTTCATCCGCTCGGGCAGCCCTGAAATCTACGAGCACCA	CATCAAGGTGC
QY	525	InGlyHisPheGluAspAspProAspGlyPheLeuGly	538
Db	5110	AAGGCCATTTGAGATCATCCCGGATGGCTTCTTAGGC	5150

```

RESULT 8
US-10-023-529-50
; Sequence 50, Application US/10023529
; Publication No. US20020129388A1
; GENERAL INFORMATION:
; APPLICANT: Lees, Ann M.
; APPLICANT: Lees, Robert S.
; APPLICANT: Law, Simon W.
; APPLICANT: Ariona, Anibal A.
; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
; TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TRE
; TITLE OF INVENTION: ATHEROSCLEROSIS
; FILE REFERENCE: 10797-004001
; CURRENT APPLICATION NUMBER: US/10/023,529
; CURRENT FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 09/616,289
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 09/517,849
; PRIOR FILING DATE: 2000-03-02
; PRIOR APPLICATION NUMBER: US 08/979,608
; PRIOR FILING DATE: 1997-11-26
; PRIOR APPLICATION NUMBER: US 60/031,930
; PRIOR FILING DATE: 1996-11-27
; PRIOR APPLICATION NUMBER: US 60/048,547
; PRIOR FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 50

```

o sapiens

```

6.82e-131      Length:      12425
2616.50        Matches:      536
V: 69.16%      Conservative: 0
ity: 69.16%    Mismatches:  2
          91.81% Indels:      239
          13     Gaps:        4

```

(1-538) x US-10-023-529-50 (1-12425)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaThrAlaAla 20
 GCGGGCCCCGGCCCTACCCGCCGAGACGCGCGCGCCACACAGCGCGCC 2891
 AlaSerSerAlaAlaSerProHisTyrGlnGluTrpIleLeuAspThrIleAsp 40
 GCCTGCTGTCGCGCGCTTCCCGCACTACAGAGTGGATCTCTGGACACCATCGAC 2951
 LeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArgArg 60
 CTGCGCTCGCGCAAGCGCGCGACCTTGGAGCGCATCTGCCCGATGGTGTGGCGG 3011
 HisGlyProGluProGluArgThrArgAlaGluLeuGluIleGlnGlnArg 80
 CAGGGCCGGAGCGGAGCGACGCGCGCGAGCTCGAGAACTGTATCCACGACGCGC 3071
 ValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgValGln 100
 TGTCTCGGCTCAGCTACAGGGGAGGCAATCTGTACCGCAACGCGCGCGCTCCAG 3131
 ProArgArgGlyAlaThrProProAlaProProArgAlaProArgGlyAlaProAla 120
 CCGCGCGGAGCACCCCGCGCGCCCGCGCGCGCCCGCGCGCGCGCCCGCC 3191
 AlaAlaAlaAlaAlaProProProThrProAlaProProProProAlaProVal 140
 CGC 3251
 AlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaThrAlaProPro 160
 CGC 3311
 ProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAlaAlaPro 180
 CTGTGCGCGCGCGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGC 3371
 ProAlaProAlaAlaProProAlaValAlaProProAlaGlyProArgArgAlaPro 200
 CCGC 3431
 ProAlaValAlaAlaArgGluProProLeuProProProProGlnProProAlaPro 220
 CCGC 3491
 GlnGlnGlnGlnProProProProGlnProGlnProProProProGluGlyAlaVal 240
 TAGACACAGC 3551
 AlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeuGlyGly 260
 CGC 3611
 GlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGluGlu 280
 CGC 3671
 AlaAlaArgGlyArgLeuGluThrArgLeuGlyAlaLeuAlaLeuProArgGly 300

Db	3672	CGCGCGGCTCGAGCGCGTCTGAGAGCGCACCGCGTCTCGAGAGCGCTTGCGCTGCGCC
Qy	301	AspArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArg-----
Db	3732	GACAGCCCGGACGGGCGCGCGCGCGCGCGCGCGCGCGCGCGCTCTCGAGCAAGC
Qy	316	-----
Db	3792	CGCCCGGAGCGGGGCGCGCGCGTGGCGAGGTGCGGCGAAGTTGTGTGGCGC
Qy	316	-----
Db	3852	GCGAGTCCCGGAGGAACCTGGGTGCGGGTGCGCTGGGCTTTTGC CGCGTTCTCT
Qy	316	-----
Db	3912	CTCGGTGCGTGTGACCTTGGCGAGTGAATTGAATCTCCCGGAGCCTCAGTTTCT
Qy	316	-----
Db	3972	GTAACGCGGTTTAATAACAGTAGCGACCCCTTGCGGTGTGTGAGCGAGTTAGT
Qy	316	-----
Db	4032	TTGGTTGTCGAGGCTTTAGTTAAACAGAGCCTGCGACGAGTGGAATGCGTAA
Qy	316	-----
Db	4092	GTCCGTATTGTTCTTAAAGGTGGAATCGGTCTCTCCCGACCGCCCGGACGCC
Qy	317	-----SerL
Db	4152	CAGGCTCGGATTAGAACAGACTACTAATTTTGATGCTTCTCTCTCGGCTCCA
Qy	320	GlyGlyGluGluArgValIeuGluGlyGluGluGluAspAspAspGluAspG
Db	4211	GGTGGAGAGACGCGAGTACTTTGAGAAAGAGAGAGAGATGATGATGAAGATG
Qy	340	GluGluAspValSerGluGlySerGluValProGluSerAspArgProAlaG
Db	4271	GAAGATGATGTGTGAGAGGCTCTGAAGTCCCGAGAGTACCGTCTCTGCG
Qy	360	GlnHisHisGlnLeuAsnGlyGluArgGlyProGlnSerAlaLysGluArgValL
Db	4331	CAGCACCAACAGCTTAAACGCGAGCGGGACCTCAGAGTGCCAAAGAGAGGGTCA
Qy	380	TrpThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaProG
Db	4391	TGAGCCCCCTCGGACCCGACACGAGGGCCAGATGAAGGGCGGGGGCGAGCCCCGG
Qy	400	GlyThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyGlyThr-----
Db	4451	GGCACCGCGCAGGTGTTCTCCATGGCAGCCATGAACAGGAAGGGGGAAACAGGTA
Qy	416	-----
Db	4511	CCCTCTGGTGGGAAGAGTGCTAGGTGAGAGAGAACTCAGCCCCGAGACAAGC
Qy	417	-----AlaSerValAlaThrGlyProAspSerProSer
Db	4571	ACAGGTGTTTTTTTCTTCCAGGCTTCTGTGTGCCACCGGGCCAGACTCCCCGTC
Qy	429	lProLeuProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheGly
Db	4631	GCCTTTGCCCCAGCAAAACAGGCCCTTACCTGGGGCGGACGGGACCCCCCTTTGGC
Qy	449	o-----
Db	4691	GTAAGTTGGGTATTGGAGACATGGGGGTGCTGCTCAGGTGTGTGTGACAGCCAGI
Qy	450	-----ProGlyArgLysGluLys
Db	4751	CATCGGTGTTCACTGGTGTCTGTTGTTTGTGATGTCAGTCCCGGGCGCAAGAGAA

2
4
4
4
0
4
4
0
0
3
8
9
9
2
1
1
1
1

Db	2892	GC	CGCTCGTCTGTCGCGCGCTTCCCGCACCTACCAAGAGTGTGATCCTCGACACA	
Qy	41	Ser	LeuArgSerArgIysAlaArgProAspLeuGluArgIleCysArgMetVal	
Db	2952	TG	CTGCGCTCGCGCAAGCGCGCGACCTGTGAGCGCATCTGCGGATGGT	
Qy	61	Arg	HisGlyProGluProGluArgThrArgAlaGluLeuGluIysLeuIleG	
Db	3012	CG	GCACGCGCCCGAGCGCGAGCACGCGCGCGAGCTCGAGAACTGATCCA	
Qy	81	Ala	ValLeuArgValSerTyrIysGlySerIleSerTyrArgAsnAlaAlaAr	
Db	3072	GC	GTGTCTCCGGTCAAGGGAGCATCTGTACCGCCACGCGCGCGCG	
Qy	101	Pro	ProArgArgGlyValaThrProProAlaProProAlaProProArgAla	
Db	3132	CG	CCCGCCCGCGCGAGGCCACCCCGCGCGCGCCCGCGCGCGCGCGCG	
Qy	121	Ala	AlaAlaAlaAlaAlaProProProThrProAlaProProProProProAl	
Db	3072	GC	GTGTCTCCGGTCAAGGGAGCATCTGTACCGCCACGCGCGCGCG	
Qy	141	Ala	AlaAlaAlaProAlaArgAlaProArgAlaAlaAlaAlaAlaThrAl	
Db	3252	GC	CG	
Qy	161	Ser	ProGlyProAlaGlnProGlyProArgAlaGlnArgAlaAlaProLeuAl	
Db	3312	TC	GCCTGCGCCCGCGCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCG	
Qy	181	Pro	ProAlaProAlaAlaProProAlaValaAlaProProAlaGlyProArgAr	
Db	3372	CG	CGCCCGCGCGCAGCGCTCCCGCGCGGTGCGCGCGCGCGCGCGCG	
Qy	201	Pro	ProAlaValaAlaArgGluProProLeuProProProProProProProPr	
Db	3432	CG	CGCGCGCGCTGCGCGCCCGGAGCGCGCGCTGCCCGCGCGCGCACG	
Qy	221	Pro	GlnGlnGlnProProProProGlnProGlnProProProGluGlyGly	
Db	3492	CC	ACAGCAGCAGCAGCGCGCGCGCGCGCGCACCGCGCGCGCGCGCGCG	
Qy	241	Arg	AlaGlyGlyAlaAlaArgProValSerLeuArgGluValValArgTyrLeu	
Db	3552	CG	GCG	
Qy	261	Ser	GlyGlyAlaGlyGlyArgLeuThrArgGlyArgValGlnGlyLeuLeuGlu	
Db	3612	AG	CGCGCGCGCGCGCGTGCCTAACCCCGCGCGCGTGCAGGGGCTGCTGAG	
Qy	281	Ala	AlaAlaArgGlyArgLeuGluArgThrArgLeuGlyAlaLeuAlaLeuPro	
Db	3672	GC	CGCGCGCTCGAGCGCGCTCTGAGCGCACCCCTCTCGGAGCGCTTGC	
Qy	301	Asp	ArgProGlyArgAlaProProAlaAlaSerAlaArgProSerArg	
Db	3732	GA	CG	
Qy	316	---	---	
Db	3792	GC	CGCGGAGCGGGGCGCGCGCGGTGGCAGGTGCGGGCGAAGTTGTGGG	
Qy	316	---	---	
Db	3852	GC	AGTCCCGGAGGAATGGTGGCGGGTGGCTGGGGCTTTTGGCGCGTTTC	
Qy	316	---	---	
Db	3912	CT	CGTGGTGGTACCTGGCAAGTGATTGAATCTCCCGGAGCGCTCAGTTTTC	
Qy	316	---	---	

4271	DB	GAAGAAGATGATGTGTACAGAGGCTCTGAAGTGCCTCGACAGTGAACGCTCTCTC	
360	QY	GlnHisHisGlnLeuAsnGlyGluArgGlyProGlnSerAlaLysGluArgVz	
4331	DB	CAGCACCAACAGCTTAAACGGCGAGCGGGACCTCAGATGTGCCAAGAGAGGGGT	
380	QY	ThrThrProCysGlyProHisGlnGlyGlnAspGluGlyArgGlyProAlaPr	
4391	DB	TGGACCCCTCGCGACCGCACCGAGCGCCAGGATGAAGCGCGGGGGCCACGCCCC	
400	QY	GlyThrArgGlnValPheSerMetAlaAlaMetAsnLysGluGlyGlyThr--	
4451	DB	GGCACCCGCCAGGTGTTCTTCATGGCACCATGAACAGGAAGGGGGGAACAGG	
416	QY	-----	
4511	DB	CCCTCTGGGTGGGAAGAGTGTAGTGGAGAGGAACCTCAGCCCGAAGACAA	
417	QY	-----AlaSerValAlaThrGlyProAspSerProS	
4571	DB	ACAGTGTTTTTTCCTTCCAGCTTCTGTGGCACCGGGCCAGACTCCCGT	
429	QY	lProLeuProProGlyLysProAlaLeuProGlyAlaAspGlyThrProPheG	
4631	DB	GCCTTTGCCCCCGAGCAACACCGCCCTACTCTGGGGCCGACGGAGCCCTTTTG	
449	QY	o-----	
4691	DB	GTAAGTTGGGTATTGGAGACATGGGGGTGCTGCTCAGGTGTGTGGTACAGCG	
450	QY	-----ProGlyArgLysGlu	
4751	DB	CATCCGTTTCACCTGGTGCTGTTTGTGATGTCAGTCCCGGGCCAAAGAG	
457	QY	erAspProValGluTrpThrValMetAspValValGluTrpPheThrGluAlaC	
4811	DB	CTGATCCGTCGAGTGGACCGTGTGATGATGTCGTGCAATATTTTACTGAGGCTC	
477	QY	roGluGlnAlaThrAlaPheGlnGlu-----	
4871	DB	CGAGCAGGGCGACAGCTTTTCCAGA--GCAGGTGAGTTTCCAGCCCGAGGACTAC	
485	QY	-----	
4930	DB	CAGACACAGAGGCGCTCCCTGGGATGTGCCCTGATCCCGGCTTTCTGTGTCCT	
486	QY	--GlnGluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeu	
4990	DB	CCAGGAATGATGGCAATCTTTGCTGCTCATGCGCGCACAGATGTGCTCA	
505	QY	euserIleArgLeuGlyProAlaLeuLysIleTrpGluHisIleLysValL	
5050	DB	TGTTCATCCGCTCGGGCCAGCCCTGAAATCTACAGACACACATCAAGGTGC	
525	QY	IleGlyHisPheGluAspAspAspProAspGlyPheLeuGly	538
5110	DB	AAGGCCACTTTGAGATGATGACCCCGATGGCTCTTTAGGC	5150

US-0976-740-48
; Sequence 48, Application US/09976740
; Publication No. US20020194633A1
; GENERAL INFORMATION:
; APPLICANT: Lees, Ann M.
; APPLICANT: Lees, Robert S.
; APPLICANT: Law, Simon W.
; APPLICANT: Arjona, Anibal A.
; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
; TITLE OF INVENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREAT
; TITLE OF INVENTION: ATHEROSCLEROSIS
; FILE REFERENCE: 10797-004001
; CURRENT APPLICATION NUMBER: US/09/976,740
; CURRENT FILING DATE: 2001-10-12

; GENERAL INFORMATION:

ees, Ann M.
 Lees, Robert S.
 Law, Simon W.
 Arjona, Anibal A.
 ENTION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
 ENTION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING
 ENTION: ATHEROSCLEROSIS
 CE: 10797-004001
 ICATION NUMBER: US/10/671,242
 NG DATE: 2003-09-24
 ATION NUMBER: US/09/616,289
 DATE: 2000-07-14
 ATION NUMBER: US 09/517,849
 DATE: 2000-03-02
 ATION NUMBER: US 08/979,608
 DATE: 1997-11-26
 ATION NUMBER: US 60/031,930
 DATE: 1996-11-27
 ATION NUMBER: US 60/048,547
 DATE: 1997-06-03
 ID NOS: 53
 tSEQ for Windows Version 4.0

Yctolagus cuniculus

S
 46)....(1895)

: 3.48e-130 Length: 2561
 2594.00 Matches: 503
 ty: 94.20% Conservative: 17
 arity: 91.12% Mismatches: 16
 91.02% Indels: 16
 12 Gaps: 8

(1-538) x US-10-671-242-48 (1-2561)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThr---Ala 19
 XGGGGGGCCCCCGCCCTACCCCGCGGAGAGCGGGCGGCCGCCACACAGCCCGCG 305
 AlaAlaSerSerAlaAlaAlaSerProHisTyrGlnGluThrPileLeuAspThrIle 39
 XCCGCGCTGTCGTCGCGCGCTTCCCGCCTACCAAGAGTGGATTCTGGACACCATC 365
 SerLeuArgSerArgLysAlaAlaArgProAspLeuGluArgLysCysArgMetValArg 59
 TCGCTGCGCTCGCGCAAGCGCGCGCGGACCTGGAGCGCATCTGCGCGATGTCGCG 425
 ArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGln 79
 CGGCACGCGCGCGAGCGCGAGCGCACGCGCGCGAGCTCGAGAACTGATCCAGCAG 485
 AlaValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAlaArgVal 99
 GCGGTGCTCCGGGTGAGCTACAGGGGAGCATCTCGTACCGCAACGCGCGCGCGGTC 545
 ProProArgArgGlyAlaThrProProAlaProProAlaProProArgGlyAlaPro 119
 CCGCGCGCGCGAGCACCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCC 605
 AlaAlaAlaAlaAlaProProProThrProAlaProProProProProAlaPro 139
 ---GCCCGCC 659
 ---AlaAlaAlaAlaAlaProProProProProProProProProProProPro 156
 3CG 719

157 ThrAlaProProSerProGlyProAlaGlnProGlyProArgAlaGlnArgA
 720 ACAGCGCCCCCTCGCCCGCCCGCGCAGCGCGCCCGCGCGCGCGCGCGCG
 177 LeuAlaAlaProProAlaProAlaAlaProProAlaAlaAlaAlaProProAla
 780 CTGCG
 197 ArgArgAlaProProPro-----AlaValAlaAlaAlaArgGluProProLeuP
 840 CG
 215 ProGlnProProAlaProProGlnGlnGln-----ProPr
 900 CCACAGCG
 230 GlnProGlnProProProGluGlyGlyValAlaAlaAlaAlaAlaAlaAlaA
 960 CAGCCACAGCG
 250 SerLeuArgGluValValArgTyrLeuGlyGlySerGlyGlyAlaGlyGlyAr
 1020 AGCTTCGGGAGTCTGCTGCTACCTCGGGGGTAGCAGCGCGCTGGCGCGCG
 270 ArgGlyArgValGlnGlyLeuLeuGluGluAlaAlaAlaAlaAlaAlaAlaAla
 1080 CGCGCGCGCGTGCAGGGTCTGCTGGAGAGGAGCGCGCGCGCGCGCGCGCGCT
 290 ThrArgLeuGlyAlaAlaAlaLeuProArgGlyVasArgProGlyArgAlaPr
 1140 ACCGCTCTCGAGCGCTTGGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 310 AlaSerAlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuGly
 1200 GCCAGCG
 330 GluGluGluAspAspGluAspGluAspGluGluAspAsp-----ValSer
 1260 GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
 348 SerGluValProGluSerAspArgProAlaGlyAlaGlnHisHisGlnLeuAsn
 1320 TCGGAGGTGCGCGAGCGAGCGATCGTCCCGCGCGCGCGCGCGCGCGCGCGCG
 367 GluArgGlyProGlnSerAlaLysGluArgValLysGluThrThrProCysGly
 1380 GAGCG
 387 GlnGlyGlnAspGluGlyArgGlyProAlaProGlySerGlyThrArgGlnVal
 1440 CCTGGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
 407 MetAlaAlaMetAsnLysGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly
 1500 ATGCGCGCGCTTGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
 427 SerProValProLeuProProGlyLysProAlaLeuProGlyAlaAspGlyThrI
 1560 TCCCGCGCGCTTGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG
 447 GlyCysProProGlyArgLysGluLysProSerAspProValGluThrThrVal
 1620 GGCTGCGCTTGGCG
 467 ValValGluTyrPheThrGluAlaGlyPheProGluGlnAlaThrAlaPheGlnG
 1680 GTGCTGAGTACTTACCGAGCGCGCGCTTCCCTGAGCAAGCAGCGCGCTTTCAGG
 487 GluIleAspGlyLysSerLeuLeuLeuMetGlnArgThrAspValLeuThrGlyL
 1740 GAGATCGAGCGGAGTCCCTGCTGCTCATGCGCGCGCGCGCGCGCGCGCGCGCG
 507 IleArgLeuGlyProAlaLeuLysIleTyrGluHisHisIleLysValLeuGlnG

CGCCCTGGGCGCAGCGTTTGAATAATCATAGACCAATATCAAGGTGCTGCACAGG 1859

sSheGluAspAspProAspGlyPheLeuGly 538
TTCGAGGACGATGACCGCGAAGGCTTCTCTGGGA 1895

Application US/10023529
US20020129388A1
ION:
es, Ann M.
es, Robert S.
w, Simon W.
Jona, Anibal A.
TION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
TION: PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING
TION: ATHEROSCLEROSIS
3: 10797-004001
ATION NUMBER: US/10/023,529
DATE: 2001-12-17
TION NUMBER: 09/616,289
DATE: 2000-07-14
ION NUMBER: US 09/517,849
DATE: 2000-03-02
TION NUMBER: US 08/979,608
DATE: 1997-11-26
TION NUMBER: US 60/031,930
DATE: 1996-11-27
ION NUMBER: US 60/048,547
DATE: 1997-06-03
ID NOS: 53
SEQ for Windows Version 4.0

ctolagus cuniculus

6) ... (1895)

	3 48e-130	Length:	2561
y:	2594.00	Matches:	503
rity:	94.20%	Conservative:	17
	91.12%	Mismatches:	16
	91.02%	Indels:	16
	13	Gaps:	8

(1-538) x US-10-023-529-48 (1-2561)

AlaGlyProProAlaLeuProProGluThrAlaAlaAlaThrThr---Ala 19
FCGGGCCCGCGGCCCTACCCCGCGGAGACGGCGCGCGCACACACGGCGCG 305
AlaAlaserSerSeralalaserProHisTyThrGlnGluTrpIleLeuAspThrIle 39
FCGGCTCTGTGTGCGCGCCCTTCCC CGACTACCAAGAGTGATTTCTGCACACCATC 365
SerLeuArgSerArgLysAlaArgProAspLeuGluArgIleCysArgMetValArg 59
TCGCTCGCTCGCGCAAGCGCGCGGACCTGGAGCGCATCTGCCGANTGTGCGG 425
ArgHisGlyProGluProGluArgThrArgAlaGluLeuGluLysLeuIleGlnGln 79
TCGCACGGCCGCGAGCGCGAGCGCACGGCGCGGAGCTCGAGAACTGATCCAGCAG 485
AlaValLeuArgValSerTyrrylsGlySerIleSerTyrArgAsnAlaAlaArgVal 99
TCGCTGCTCCGGGTGAGCTACAAAGGGAGCATCTGTACCGCAACGCGGCGCGGTC 545

AlaAlaSerSerSerAlaAlaSerProHisTyrGlnGlnTyrTrpIleuAspThr-Ile 39
GC CGCCTCGTGTCTCGCGCGCTTCCCGCACTACCAAGAGTGATTCTTGGACACCATC 365

GGCCAGAGGAGGAGCGGGGGCCCGCGCGGCGAGTGGCACCCCGCAGGTGTTCCTCC	1499
AlaAlaMetAenLysGluGlyGlyThrAlaSerValAlaThrGlyProAspSerPro	426
GCGCCCTTGAGTAGAGGAGGGGGATCAGCCTTCCTGACACCCGGGCGCTGACTCCCG	1559
ProValProLeuProGlyLysProAlaLeuProAlaAspGlyThrProPhe	446
CCGGTGCCTTTGCCCCCGGGAAGCAGCCCTCCACGAGCGGATGGGACCCCTTTT	1619
CysProProGlyArgLysGluLysProSerAspProValGluTrpThrValMetAsp	466
TGCCCTCGCGGGCGCAAGAGAGCCGGCAGCACCCCGCTGGAGTGGACAGTCATGGAC	1679
ValGluTyrPheThrGluAlaGlyPheProGluClnAlaThrAlaPheGlnGluGln	486
GTGGAGTACTTCCACCGAGGGGGGCTTCCTTGAGCAAGCCACGGCTTTCACGAGGACAG	1739
IleAspGlyLysSerLeuLeuLeuMetClnArgThrAspValLeuThrGlyLeuSer	506
ATGCACGGCAAGTCCCTGTCTGTATCGAGGCGCACCGATGTCTTCACCGGCGCTGTCC	1799
ArgLeuGlyProAlaLeuLysIleTyrGluHisIleLysValLeuGlnGlnGly	526
CGCCTGGGGCCAGCGTTGAAATCTATGACGACCATATCAAGGTGTGTCAGCAGGGT	1859
PheClnAspAspAspProAspGlyPheLeuGly	538
TTTCAGAGCATGATACCCCGGAAGGCTTCCTGGGA	1895

Publication US/10616187
US20040013668A1
TITION:
s, Ann M.
es, Robert S.
w, Simon W.
jona, Anibal A.
TION: NOVEL LOW DENSITY LIPOPROTEIN BINDING
TION: PROTEINS AND THEIR USE IN DIAGNOSING AND
TION: ATHEROSCLEROSIS

```

ATTN NUMBER: US/10/616,187
DATE: 2003-07-09
ION NUMBER: US/09/616,289
ATE: 2000-07-14
ION NUMBER: US 09/517,849
ATE: 2000-03-02
ION NUMBER: US 08/979,608
ATE: 1997-11-26
ION NUMBER: US 60/031,930
ATE: 1996-11-27
ION NUMBER: US 60/048,547
ATE: 1997-06-03
ID NOS: 53
SEQ for Windows Version 4.0

```

ctolagus cuniculus

6) ... (1895)

3.48e-130	Length:	2561
2594.00	Matches:	503
94.20%	Conservative:	17
91.12%	Mismatches:	16
91.02%	Indels:	16

DB:	15	Gaps:	8
US-09-376-740-43 (1-538) x US-10-616-187-48 (1-2561)			
QY	1	MetaIaGlyProProAlaLeuProProGluThrAlaAlaAlaAlaThrThr	
Db	246	ATGGGGGGCCCCCGCCCTACCCCGCGGAGACGGCGCGCGCCACCGAC	
QY	20	AlaAlaAlaSerSerAlaAlaSerProHisTyrGlnGluThrIleLeuAsp	
Db	306	GCGCGCGCTCGTCTGTCGCGCTTCCCGGCATCTACAGAGTGGATCTTGAGC	
QY	40	AspSerLeuArgSerArgIyAlaArgProAspLeuGluArgIleCysArgMet	
Db	366	CACTCGCTCGCTCGCGAAGCGCGCGGACCTCGAGGCATCTCGCGGATG	
QY	60	ArgArgHisGlyProGluProGluArgThrArgAlaGluLeuGluIysLeuIle	
Db	426	CGCGCGCACGGCCCCGAGCCGAGCGACGCGCGCCGAGCTCGAGAACTGATC	
QY	80	ArgAlaValLeuArgValSerTyrLysGlySerIleSerTyrArgAsnAlaAla	
Db	486	CGCGCGCTGCTCGGGTCAGTACAAGGGGAGCATCTCGTACCGCAACCGCGCG	
QY	100	GlnProProArgArgGlyAlaThrProProAlaProProArgAlaProArgGly	
Db	546	CAGCGCGCCCGCGCGAGCCACCCCGCGCGCCCGCGCGCGCGCGCGCG	
QY	120	AlaAlaAlaAlaAlaAlaProProProThrProAlaProProProProPro	
Db	606	-----GCCGCGCGCGCGCGCGCGCCGCGCCACGCGCCCGCGCGCGCGCG	
QY	140	Val----AlaAlaAlaAlaProAlaArgAlaProArg-----AlaAlaAlaAla	
Db	660	GTGCGCGCGCGCGCGCCCGCGCCCGGGCGCGCGCGCGCGCGCGCGCTG	
QY	157	ThrAlaProProSerProGlyProAlaGlnProGlyProArgAlaGlnArgAla	
Db	720	ACAGCGCCCCCTCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG	
QY	177	LeuAlaAlaProProAlaProAlaAlaProProAlaValAlaProProAlaG	
Db	780	CTGGCGCGCGCGCGCGCGCGCGCGCTCCCCCGCGCGCGCGCGCGCGCG	
QY	197	ArgArgAlaProProPro-----AlaValAlaAlaArgGluProLeuPro	
Db	840	CGCGCGCGCCCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG	
QY	215	ProGlnProProAlaProProGlnGlnGln-----ProPro	
Db	900	CCACAGCGCGCGCGCGCGCGCACACAGCAGCAGCGCGCGCGCGCGCGCG	
QY	230	GlnProGlnProProProGluGlyGlyAlaValArgAlaGlyAlaAlaArgP	
Db	960	CAGCCACAGCGCGCGCGAGGGGGCGCGCGCGCGCGCGCGCGCGCGCGCG	
QY	250	SerLeuArgGluValValArgTyrLeuGlyGlySerGlyGlyAlaGlyGlyArgL	
Db	1020	AGCTTCGGGAGTCTGTCGCTACCTCGGGGTAGCAGCGCGCGCTGGCGCGCG	
QY	270	ArgGlyArgValGlnGlyLeuLeuGluGluAlaAlaAlaArgGlyArgLeuG	
Db	1080	CGCGCGCGCTGCAGGGTCTGCTGGAAGAGAGAGCGCGCGCGCGCGCGCTGG	
QY	290	ThrArgLeuGlyAlaLeuAlaLeuProArgGlyAspArgProGlyArgAlaPro	
Db	1140	ACCCGCTTCGAGCGCTTGGCGCTGCCCGCGGGGACAGCGCGCGCGCGCAC	
QY	310	AlaSerAlaArgProSerArgSerLysArgGlyGlyGluGluArgValLeuGlu	
Db	1200	CCAGCGCCCGCGCGCGGACACAGAGAGCTGGCGAGAGCGAGTCTTGA	
QY	330	GluGluAlaAspAspAspGluAspGluAspGluAlaAsp-----ValSerG	

us-09-976-740-43.rnpb

: March 13, 2004, 04:27:21
55 secB